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The vascular endothelium plays a vital role in the control of blood flow, haemostasis,
fibrinolysis and inflammation. Impairment of endothelial vasomotor and fibrinolytic
function is implicated in the pathogenesis of ischaemic heart disease. Atherosclerosis
is now widely recognised to be an inflammatory disease process, but the mechanistic
links between inflammation, endothelial dysfunction and endogenous fibrinolysis
remain poorly understood.
In a series of studies, we explored the effects of inflammation on endothelial
vasomotion and fibrinolytic capacity using an in vivo forearm model of systemic and
local inflammation. Systemic inflammation stimulated by typhoid vaccination had no
major effect on vasomotor tone. However, tumour necrosis factor-a induced local
vascular inflammation was associated with impaired resistance vessel endothelium-
dependent vasodilatation, possibly through the development of acute arterial injury.
Both systemic and local inflammation were found to augment the acute release of
endothelial tissue plasminogen activator. In addition, intra-arterial tumour necrosis
factor-a administration resulted in a unique profile of substantial and sustained local
increase in endogenous tissue plasminogen activator.
We extended these investigations and assessed the role of endogenous fibrinolysis
and endothelial dysfunction in the pathogenesis of prothrombotic conditions such as
hyperhomocysteinaemia and coronary stent thrombosis or in-stent restenosis using
this forearm model of endothelial function assessment. In patients with recent
myocardial infarction, elevation of plasma homocysteine concentration was
associated with impaired endothelium-dependent vasodilatation but not endogenous
fibrinolysis. This vasomotor dysfunction was not rectified by vitamin
supplementation. We also assessed three critical aspects of vascular function in
patients who have undergone percutaneous coronary intervention and found no
evidence that endothelial vasomotor, fibrinolytic or platelet function play a major
role in the pathogenesis of acute stent thrombosis or in-stent restenosis.
We conclude that there is complex interaction between inflammation, endothelial
function and endogenous fibrinolysis. We have identified the unique role of systemic
inflammation and specifically, tumour necrosis factor-a. Furthermore, our studies
indicated that there were no significant associations between fibrinolysis and
hyperhomocysteinaemia or coronary stent complications. Therefore modulating
cytokine actions and their interaction with fibrinolysis may be critical in the
prevention of thrombotic coronary occlusion and myocardial ischaemia as well as in
the future development of anti-thrombotic therapies.
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1.1.1 Normal Endothelial Function
The endothelium is a single-cell lining covering the internal surface of the
circulatory system. Initially regarded as a relatively inert semipermeable barrier
between blood and vessel wall, it is now recognised to have an enormous range of
crucial homeostatic functions and participates in metabolic, synthetic and regulatory
pathways [Cines et al 1998]. Strategically located at the interface between tissue
and blood, the vascular endothelium regulates the flow of nutrient substances,
diverse biologically active molecules and blood cells, and plays a key role in the
control of vascular tone, local coagulation and fibrinolysis, inflammation and
vascular proliferative processes. By means of membrane receptor mechanisms, the
endothelium is able to detect and respond to physical and chemical stimuli by the
release of a variety of vasoactive and thromboregulatory molecules, that include
nitric oxide, endothelins, interleukins, plasminogen activators and inhibitors, and von
Willebrand factor.
Under normal conditions, the effects of these endothelial factors maintain normal
vascular tone, blood fluidity and limit vascular inflammation and smooth muscle cell
proliferation. However, in the presence of coronary risk factors, endothelial function
may be impaired and predispose the vasculature to alterations in vascular tone,
leukocyte adherence, platelet activation, vascular inflammation, thrombosis and
atherosclerotic lesion formation [Ross 1999].
1.1.2 Regulation of Vasomotor Tone
Following the seminal work of Furchgott and Zawadski, it has been widely
recognised that an array of mediators can influence vascular tone through
endothelium-dependent actions [Furchgott & Zawadski 1980], Vasodilators such as
nitric oxide and prostacyclin, as well as vasoconstrictors, including endothelin-1 and
platelet activating factor, are secreted by the vascular endothelium to maintain and
regulate tissue perfusion. Endothelial cells may also participate in vasoregulation
following stimulation by circulating vasodilators and constrictors, such as thrombin,
bradykinin and adenosine diphosphate.
1.1.3 Endothelium-dependent Vasodilators
Nitric oxide is a key endothelium-derived relaxing factor. A heterodiatomic free
radical product, nitric oxide is generated through the oxidation of L-arginine to L-
citrulline by nitric oxide synthase [Palmer et al 1988; Stamler et al 1992]. One
isoform, endothelial nitric oxide synthase (eNOS), is constitutively expressed and
active in endothelial cells, but can be upregulated by receptor-dependent agonists.
Nitric oxide tonically relaxes arterial vessels at rest in both the systemic and
pulmonary circulation [Vallance et al 1989; Stamler et al 1994], In addition, nitric
oxide release can be stimulated by a range of agonists including thrombin,
bradykinin, substance P and acetylcholine, as well as by shear and mechanical stress
[Cooke et al 1991]. The increase in eNOS activity evoked by shear stress contributes
to the phenomenon of flow associated or mediated vasodilatation, an important
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autoregulatory mechanism by which blood flow is regulated in response to ischaemia
and hyperaemia [Loscalzo & Vita 1994],
Nitric oxide is released into the abluminal side of the endothelial cells where it
activates smooth muscle cell guanylate cyclase and increases intracellular cyclic
guanosine monophosphate [Arnold et al 1977], This results in a reduction of
intracellular calcium and thereby causes smooth muscle relaxation [Collins et al
1986]. The same pathway is involved in the mechanism of action of exogenous nitric
oxide donors such as sodium nitroprusside and nitroglycerin. Nitric oxide may also
diffuse into vascular lumen where it is predominantly taken up into haemoglobin, but
also enters into platelets and inhibits platelet adhesion, activation, and aggregation
[Mendelsohn et al 1990].
Prostacyclin is another major endothelium-derived vasodilator produced from
arachidonic acid through the enzyme cyclo-oxygenase [Moncada et al 1977]. It is
not constitutively present in endothelial cells, but its rapid synthesis and release is
stimulated by bradykinin and adenosine nucleotides that activate adenylate cyclase
and cause an increase in intracellular cyclic AMP. Prostacyclin also has anti¬
thrombotic and anti-platelet activity [Moncada 1982].
In addition, stimulation of the normal endothelium by acetylcholine produces
hyperpolarisation of the underlying smooth muscle by an endothelium-derived
hyperpolarising factor, which may exert its vascular effects by activating ATP-
sensitive potassium channels or smooth muscle sodium-potassium ATPase, although
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the precise identity and physiologic role of this factor remains uncertain [Feletou &
Vanhoutte 1988].
1.1.4 Endothelium-dependent Vasoconstrictors
Endothelial cells also produce endothelin-1 (ET-1), the most potent vasoconstrictor
identified to date [Levin 1995]. ET-1 is not stored in granules, but is formed after
transcription of the gene encoding its precursor, preproendothelin-1 following
stimulation by hypoxia, shear stress and ischaemia [Boulanger & Luscher 1990].
After removal of a short secretory sequence, preproendothelin-1 undergoes cleavage
by an endoprotease to generate big ET-1, which is subsequently converted by
endothelin converting enzyme to the biologically active ET-1. ET-1 has a short half-
life, and when released from the endothelium, binds to the G-protein coupled ET-A
receptor on vascular smooth muscle cell, leading to an increase in intracellular
calcium concentration and enhanced vascular tone [Simonson & Dunn 1990]. ET-1
also enhances the vasoconstrictor actions of catecholamines, and vice versa. ET-1 is
present in healthy subjects in low concentrations, and contributes to the maintenance
of basal vascular resistance [Davenport et al 1990].
Platelet activating factor is a phospholipid that is not constitutively present in resting
human endothelial cells, but its production can be induced rapidly by humoral and
mechanical stimuli including thrombin, angiotensin II, vasopressin and bradykinin.
Platelet activating factor acts as a potent vasoconstrictor at high doses in the coronary
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circulation in a paracrine fashion, but may also have vasodilator properties at low
doses [Cincs et al 1998, Montrucchio et al 2000].
Angiotensin II, the central product of the renin-angiotensin-aldosterone system, is
well known to increase systemic blood pressure via its constrictor effects. The
vascular actions of angiotensin II are primarily mediated through the angiotensin II
type 1 receptor, a G-protein-coupled receptor expressed on endothelial cells,
monocytes and vascular smooth muscle cells. Angiotensin II type 1 receptor
activation induces a cascade of cellular responses, including rapid activation of
phospholipase C and intracellular calcium leading to enhanced vascular tone. More
sustained effects of angiotensin II are mediated by changes in gene transcription.
There is also emerging evidence that angiotensin II may play an important role in the
pathophysiology of cardiac hypertrophy and remodelling, heart failure, vascular
thickening, atherosclerosis and glomerulosclerosis [Kim & Iwao 2000, Brasier et al
2002],
1.2 The Endogenous Fibrinolytic System
The endogenous fibrinolytic system consists of a highly regulated enzymatic cascade
for extracellular proteolysis [Lijnen & Collen 1995]. Its principal role is to protect
the circulation from intravascular fibrin formation and thrombosis that would
otherwise result in vessel occlusion and tissue ischaemia. Plasmin, the central
enzyme in this system, is formed from the inactive precursor protein, plasminogen,
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by the action of plasminogen activators. In the circulation, plasmin degrades the
fibrin of haemostatic plugs and thrombi into soluble fibrin degradation products.
Inhibition of fibrinolysis occurs at two principal levels: plasminogen activation and
plasmin inhibition, through the actions of plasminogen activator inhibitors and 0x2-
antiplasmin. The physiological importance of the fibrinolytic system is demonstrated
by the clinical association between excessive or impaired fibrinolysis with the
tendency towards bleeding or thrombosis respectively [Fay et al 1992; Booth et al
1983; Kohler & Grant 2000]. Recent studies have also suggested that it may
contribute to the pathogenesis of atherosclerosis, restenosis, wound healing and
malignancy [Dano et al 1985; Kohler & Grant 2000]. The plasmin/plasminogen
system is also involved in other processes such as cell migration [Saksela & Rifkin
1988], tissue remodelling, ovulation [Strickland & Beers 1976] and angiogenesis.
1.2.1 Initiation of Fibrinolysis
1.2.1.1 Plasminogen and Plasmin
Plasminogen is a 92 kDA single-chain glycoprotein synthesised predominantly by
the liver and is present in plasma at a concentration of 1.5 - 2 pM. Plasminogen
consists of 791 amino acid residues and contains five homologous disulphide-bonded
triple-loop structures known as 'kringles', each composed of 80 - 85 amino acids
[Forsgren et al 1987]. These kringle domains are crucial in fibrinolysis as they
contain binding sites that mediate the specific interactions between plasminogen and
fibrin, and between plasmin and a2-antiplasmin [Collen 1980]. The plasminogen
gene is located on the long arm of chromosome 6 at band q26 or q27 and contains 19
exons covering 52.5 kb ofDNA [Petersen et al 1990].
Plasmin is formed from plasminogen as a result of enzymatic cleavage of the Arg
561 - Val 562 peptide bond by plasminogen activators. The mature plasmin
molecule is a two-chain trypsin-like serine protease composed of a heavy chain
containing the five kringles and a light chain with an active site that is able to
degrade fibrin.
1.2.1.2 Plasminogen Activators
There are two main physiological plasminogen activators: tissue-type plasminogen
activator (t-PA) and urokinase-type plasminogen activator (u-PA). Whilst t-PA is
primarily involved in fibrin dissolution in the circulation, u-PA may contribute to
pericellular proteolysis via degradation of matrix components or via activation of
latent proteases and growth factors. However, unlike t-PA, u-PA appears not to be
produced by most quiescent endothelial cells, and is only expressed by endothelial
cells actively involved in wound repair or angiogenesis.
1.2.2 Inhibition of Fibrinolysis
Plasmin and the plasminogen activators are both regulated by serine protease




Human a,2-antiplasmin is a 67 kDa glycoprotein containing 464 amino acids and is
the major physiological inhibitor of plasmin [Holmes et al 1987]. Present in the
circulation at a relatively high concentration of «1 pM, a2-antiplasmin also has a
long plasma half-life and thus a large capacity to neutralise plasmin. The reactive
site of a2-antiplasmin is the Arg 364 - Met 365 peptide bond and its gene is located
on chromosome 18, bands pi 1.1 — qll.2, contains 10 exons and covers
approximately 17 kb ofDNA.
Although free plasmin is readily inhibited by a.2-antiplasmin, plasmin formed on a
fibrin surface is protected from the actions of its inhibitors as both its active and
binding sites interact with fibrin. However, in the presence of activated coagulation
factor XIII, a.2-antiplasmin can cross-link to polymerising fibrin and inhibits
fibrinolysis by two consecutive reactions. It first forms a 1:1 molar reversible
complex with plasmin, followed by covalent binding between the carboxyl group of
its reactive site and the hydroxyl group of the active site of plasmin [Collen &
Linjnen 1991].
1.2.2.2 Plasminogen Activator Inhibitors
Plasminogen activator inhibitor type 1 (PAI-1) is the principal inhibitor of
plasminogen activation in man but several other inhibitors also exist. Plasminogen
activator inhibitor type 2 (PAI-2) predominantly inhibits u-PA and, to a lesser extent,
9
t-PA. Not normally present in plasma except during pregnancy [Kruithof et al 1987],
PAI-2 probably exerts a local rather than systemic role. Plasminogen activator
inhibitor type 3 (also known as the protein C inhibitor) has a much lower affinity for
u-PA and t-PA than PAI-1 but it is present in plasma at much higher concentrations
[Suzuki et al 1983]. CI esterase inhibitor, a2-macroglobulin and ai-antitrypsin are
broad spectrum inhibitors that have some reactivity towards plasminogen activators
[Bennett et al 1990] and may play a role when PAI-1 is completely consumed such
as during systemic thrombolytic therapy.
1.3 Plasminogen Activators and Inhibitors
1.3.1 Tissue Plasminogen Activator
1.3.1.1 Structure and Function
Tissue-type plasminogen activator is a 70 kDa glycoprotein consisting of 527 amino
acid residues, and has a molecular mass of 59 kDa excluding carbohydrates (or 70
kDa including carbohydrates) [Lijnen & Collen 1995]. The protein structure of t-PA
contains several autonomous domains: finger-like, growth factor-like, two kringle
structures, and the protease domains. The native t-PA protein is a single-chain
molecule that is converted into a two-chain form (A and B) by plasmin or other
proteases following cleavage of the Arg 275-Ile 276 peptide bond. The two chains
are connected by a disulphide bridge, and the resultant molecule is ellipsoidal and
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compact, stabilised by strong interactions between the protease, finger and growth
factor domains. The A-chain is required for the stimulation of t-PA by fibrin, and B-
chain contains the active sites for the activation of plasminogen.
Tissue-type plasminogen activator, a trypsin-like serine protease, is the key enzyme
that converts plasminogen to plasmin, and cleaves peptide bonds with arginine or
lysine. Although inefficient in activating plasminogen in solution, t-PA-induced
fibrinolytic activity is augmented 400-fold in the presence of fibrin [Collen 1980].
Fibrin potentiates plasminogen activation through the binding of both t-PA and
plasminogen to the fibrin clot to form a cyclic ternary complex, and thus act as
stimulator of plasminogen activation as well as final substrate of generated plasmin.
1.3.1.2 Synthesis and Secretion
Tissue-type plasminogen activator is synthesised mainly in vascular endothelial cells,
stored in small dense vesicles and can be released by constitutive or facultative
pathways [van den Eijnden-Schrauwen et al 1995; Emeis et al 1997]. In this latter
pathway, t-PA is released following endothelial cell activation through the
translocation of a dynamic storage pool rather than increased de novo synthesis. The
acute release of t-PA can be induced by agents that include thrombin, histamine,
bradykinin, substance P, and by sympathetic activation such as exercise and mental
stress [Tranquille & Emeis 1989; Newby et al 1997a; Brown et al 1999].
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The gene for t-PA is located on chromosome 8, covers 32.7 kb ofDNA, and consists
of 14 exons. An enhancer-like regulatory sequence is located more than 2 kb
upstream from the transcription initiation site and may be responsible for t-PA
expression. Tissue-type plasminogen activator has a plasma concentration of about 5
- 10 ng/ml that varies strongly under different physiological and pathological
conditions, and has a short half-life of about 5 minutes due to rapid hepatic clearance
[Chandler et al 1997].
1.3.1.3 Receptors
There are two major classes of t-PA receptors, responsible for t-PA clearance and for
t-PA localisation on cell surfaces. Clearance receptors are associated with
endocytosis and lysosomal degradation of t-PA and serve as negative regulators of
vascular fibrinolysis. The liver is the main organ responsible for t-PA clearance, and
hepatic parenchymal, endothelial and Kupffer cells are all capable of t-PA uptake.
These t-PA receptors include a well-characterised mannose receptor present on
hepatic endothelium and a low-density lipoprotein receptor related protein identified
on parenchymal hepatocytes. Tissue-type plasminogen activator receptors present on
vascular endothelial cell surface can promote pericellular plasminogen activation and
thereby have profibrinolytic consequences. One such receptor is annexin II which
mediates the assembly of plasminogen and t-PA to accelerate and localise plasmin
generation [Hajjar et al 1994].
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1.3.2 Plasminogen Activator Inhibitor Type 1
1.3.2.1 Structure and Function
Plasminogen activator inhibitor-1 is a linear glycoprotein composed of 379 amino
acid residues and has a molecular weight of 42 kDa [Lijnen & Collen 1995].
Plasminogen activator inhibitor-1 exists in at least four structurally different forms:
active, latent, non-inhibitory substrate and inactive cleaved forms. Synthesised as an
active inhibitor, the active PAI-1 is unstable and has a half-life of 30 minutes. It is
spontaneously converted into the latent form, which has a half-life of 4 hours in
plasma, and can also be partially reactivated by denaturing agents. The non-
inhibitory substrate form of PAI-1 does not form stable complexes with t-PA and can
be irreversibly degraded by target proteases including t-PA and thrombin.
Conversion of the inhibitory PAI-1 into the latent or substrate forms may represent a
regulatory mechanism of the fibrinolytic system.
Plasminogen activator inhibitor-1 is the primary inhibitor of plasminogen activation.
It first binds rapidly to either t-PA or u-PA, forming a reversible complex with a ratio
of 1:1. This is followed by a covalent complex in which the hydroxyl group of the
active site of the plasminogen activator forms an ester bond with the carboxyl group
of the reactive centre of PAI-1. When this ester bond hydrolyses, the cleaved and
inactive derivative of PAI-1 is formed. The t-PA-PAI-1 complex is also eliminated
from the circulation by hepatic cells. Vitronectin is a well established co-factor of
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PAI-1 that binds and stabilises active PAI-1 in plasma, protecting it against
inactivation by oxidants [Reilly et al 1994],
1.3.2.2 Synthesis and Secretion
The gene for PAI-1 is located on chromosome 7, covers approximately 12.2 kb DNA
and consists of nine exons. Although synthesised by a variety of cell types including
endothelial cells, megakaryocytes, monocytes and hepatic cell in vitro, the precise
source of PAI-1 in plasma is not known. In endothelial cells, the expression of PAI-1
is highly regulated and stimulated by a variety of agonists including endotoxin,
interleukin-1 (IL-1), tumour necrosis factor-a (TNF-a) and growth factors
[Andreasen et al 1990].
Plasminogen activator inhibitor-1 has a normal plasma concentration of about 20
ng/ml with platelets representing the main circulating pool. There is an
approximately 5-fold molar excess of PAI-1 compared to t-PA, so that most of the t-
PA circulates as t-PA-PAI-1 complex.
1.3.3 Diurnal Variation
Both t-PA and PAI-1 show distinct circadian variation [Kluft et al 1988]. Plasma
concentrations of PAI-1 peak in the morning and reach a trough in the late afternoon
and evening. In contrast, t-PA concentrations peak in late afternoon and reach a
trough in the morning. The exact reasons for this variation are not known.
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1.4 Inflammation
1.4.1 Circulating Inflammatory Cytokines and Markers
1.4.1.1 Tumour Necrosis Factor-a
Tumour necrosis factor-a is a trimeric 17 kDa, 157 amino acid polypeptide produced
mainly by monocytes and activated macrophages but also by many other cell types
[Azzawi & Hasleton 1999]. It is expressed as a 26 kDa integral transmembrane
precursor protein from which the 17 kDa subunit is released after proteolytic
cleavage, and exists in both secreted and transmembrane forms. The cytokine is
rapidly synthesised and released on demand, and is not stored in the cytoplasm.
Tumour necrosis factor-a is a pleiotropic cytokine and a mediator of systemic
responses to injury, sepsis and inflammation [Ferrari 1999]. It activates and
suppresses multiple transduction pathways and triggers the release of practically all
known mediators of inflammation such as the pro-inflammatory cytokines, IL-1 and
interleukin-6 (IL-6), as well as its own production, the final result ranging from
haemorrhagic necrosis to extensive fibrosis. However, it also has protective effects
and induces oxygen free-radical scavenging enzymes, such as mitochondrial
superoxide dismutase, and protective substances such as heat shock proteins
[Aggarwal & Natarajan 1996],
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Tumour necrosis factor-a acts at the cellular level via both type I (p55) and type II
(p75) receptors present on almost all nucleated cell types. Activation by TNF-a of
different transduction mechanisms may operate through separate TNF-a receptors,
and both receptors can be up or down-regulated under different pathophysiological
conditions [Torre-Amione et al 1995].
1.4.1.2 Interleukin-6
Interleukin-6 is a 26 kDa protein that consists of 212 amino acids with a hydrophilic
signal sequence of 28 residues [Kerr et al 2001]. The gene for IL-6 is mapped to
chromosome 7p21, consists of five exons covering 5 kb DNA, and has a fairly
complex transcriptional regulation involving 3 initiation sites. Interleukin-6 is
synthesised by a variety of cell types including activated monocytes and
macrophages, endothelial cells, adipose cells, and the Th-2 subset of T-helper cells.
Expression of IL-6 is regulated in response to a number of stimuli including
endotoxins, IL-1, TNF-a, Interleukin-4 and interferon-y, although different cell types
may respond differently to these stimuli.
Interleukin-6 is a multifunctional cytokine with a broad range of actions and plays a
central role in the host defence mechanism. Apart from the modulation of immune
responses and induction of acute phase reactant release from hepatocytes during
immunologic and inflammatory reactions, IL-6 also participates in many biologic
and pathophysiological processes such as bone metabolism, thrombopoiesis,
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epidermal proliferation and cancer [Kurihara et al 1990; Hill et al 1990; Grossman et
al 1989; Zhang et al 1989].
The functional effects of IL-6 are mediated through a specific receptor complex that
consists of two membrane-anchored glycoproteins, gp80 and gpl30, which are
responsible for ligand binding and initiation of the signal transduction cascade
respectively.
1.4.1.3 C-reactive Protein
C-reactive protein (CRP) is a major acute-phase plasma protein originally isolated as
a protein that binds to the C-polysaccharide of the Streptococcus pneumoniae cell
wall. It consists of five identical 23 kDa non-covalently associated subunits each
made up of 206 amino acids, and arranged in a ring resembling a doughnut. The CRP
gene has been mapped to human chromosome 1, and contains 2263 nucleotides with
a single intron [Volanakis 2001].
C-reactive protein is synthesised and secreted mainly by the liver and has a plasma
half-life of 19 hours. Interleukin-6 is the principal inducer of the CRP gene, while
IL-1, glucocorticoids and complement activation products can act synergistically
with IL-6 to enhance its effects [Toniatti et al 1990]. Under physiologic conditions,
CRP is synthesised at low rates, but during an inflammatory process in response to
injury or infection, its level can be elevated 100-fold within 24 - 48 hours.
17
The main biologic function of CRP is to recognise pathogens and damaged cells of
the host and to mediate their elimination by recruiting the complement system and
phagocytic cells. Thus CRP level may reflect the degree of underlying inflammatory
response and provide a useful measure of immune injury to tissues. Elevated in
many inflammatory disorders, serum CRP concentrations have been widely used to
predict clinical outcomes [Yeh et al 2001],
1.4.2 Inflammation and Atherosclerosis
Arterial inflammation has emerged as central to the progression of atherothrombosis,
a process initiated through an injury to the vascular endothelium [Ross 1999].
Activation of the vascular endothelium leads to increased expression of leucocyte
adhesion proteins, reduced anticoagulant activity and the release of growth factors,
inflammatory mediators and cytokines. Continued inflammation results in leucocyte
and monocyte recruitment, induction of atheroma formation and further arterial
damage. Cycles of further damage cause plaque expansion and disruption that can
lead to angina, crescendo angina and acute coronary syndromes including myocardial
infarction.
The pro-inflammatory cytokines, IL-6 and TNF-a, have been implicated in the
initiation and maintenance of systemic and vascular inflammation associated with
atherosclerosis and ischaemic heart disease [Biasucci et al 1996; Vaddi et al 1994;
Ridker et al 2000a, 2000b]. Together with IL-1, they are often co-activated and share
overlapping biological activities [Pober & Cotran 1990]. In particular, they share the
ability to initiate or suppress gene expression for several proteins and can activate
endothelial cells, cause expression of adhesion molecules and promote
thrombogenesis. Although usually absent or only present in small quantities in
normal cardiac tissue, TNF-a, IL-6 and CRP have all been demonstrated in
atherosclerotic lesions [Lagrand et al 1999; Reynolds & Vance 1987; Rus et al 1996;
Barath et al 1990]. Furthermore, TNF-a and IL-6 expression increases with the
severity of the lesion, suggesting that they may play a role in disease evolution.
1.4.3 Inflammation as Cardiovascular Risk Factor
Epidemiological and observational studies have suggested an association of systemic
infection and inflammation with the risk of major adverse cardiovascular events.
Cardiovascular death rates are greater in the winter and are increased by epidemics of
influenza. Infections by organisms, such as chlamydia pneumoniae and herpes
simplex type /, also seem to be associated with an increased risk [Roivainen et al
2000]. Moreover, approximately 4% of bacteraemic patients develop an acute
myocardial infarction within a month of infection and up to 10% of all strokes are
preceded by a bacterial infection [Valtonen et al 1993]. Increased cardiovascular
morbidity and mortality is also seen following respiratory tract infections, severe
illnesses requiring intensive care and surgery [Meier et al 1998; Quartin et al 1997;
Mamode et al 1995]. A recent large study further demonstrated that acute respiratory
tract infections as well as urinary tract infections are associated with a transient
increase in the risk ofmyocardial infarction and stroke [Smeeth et al 2004].
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Plasma concentrations of TNF-a, IL-6 and CRP are elevated in patients with
cardiovascular diseases [Liuzzo et al 1994; Biasucci et al 1996; Ridker et al 2000a,
2000b, 2000c]. In previously healthy individuals, elevated plasma CRP and IL-6
concentrations have been shown to predict the development of cardiovascular disease
and the risk of a first myocardial or cerebral infarction [Ridker et al 1997, 2000b,
2000c], In addition, elevated plasma IL-6 and TNF-a concentrations predict adverse
cardiovascular outcome in patients with acute coronary syndromes [Biasucci et al
1999; Ridker et al 2000a]. Reflecting its anti-inflammatory action, the beneficial
effects of aspirin in reducing cardiovascular risk are proportional to the plasma C-
reactive protein concentration [Ridker et al 1997].
These data suggest a link between chronic low-grade inflammation and the slow
process of atherogenesis, as well as an association between acute systemic
inflammation and a transiently increased risk of an acute cardiovascular event.
Furthermore, it appears that the effects of inflammation on cardiovascular risk may
be generic, rather than linked to specific types of infection. Although inflammation
may be argued to be a response to, rather than a cause of atherosclerosis, recent work
suggests that these inflammatory markers may also play a direct pathogenic role in
atherosclerotic lesion formation, and plaque destabilisation [Ross 1999; Pasceri et al
2000].
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1.4.4 Inflammation and Fibrinolysis
In vitro studies have demonstrated that inflammatory cytokines can alter the
fibrinolytic and haemostatic function of the endothelium [Bevilacqua et al 1986;
Schleef et al 1988]. Recombinant human TNF-a reduces t-PA and stimulates PAI-1
release from cultured human umbilical vein endothelial cells and also exerts a net
procoagulant effect by enhancing tissue factor and thrombin-induced von Willebrand
factor expression.
Using lipopolysaccharide administration in an in vivo model of systemic
inflammation, experimental endotoxaemia in chimpanzees induced an initial increase
in, followed by a marked suppression of fibrinolytic activity [Biemond et al 1995].
This response is markedly inhibited by the co-administration of anti-tumour necrosis
factor-a antibodies. These findings have been subsequently confirmed in clinical
studies of healthy volunteers where an identical pattern of responses to endotoxaemia
and anti-TNF-a antibodies was observed [van der Poll et al 1994a, 1997].
Moreover, systemic administration of TNF-a in healthy volunteers causes a rapid
fibrinolytic response that precedes a subsequent and more prolonged activation of the
coagulation system [van der Poll et al 1990, 1991], Primate and clinical studies of
IL-6 show a distinct response from that obtained with TNF-a. Interleukin-6
administration stimulates the coagulation system and augments the coagulation
response to endotoxaemia but does not appear to have a distinct action on the
fibrinolytic system [van der Poll et al 1994b; Stouthard et al 1996].
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1.5 Endothelial Dysfunction and Cardiovascular Disease
1.5.1 Clinical Assessment of Endothelial Function
In vivo techniques offer distinct advantages over in vitro studies in the assessment of
vascular endothelial function as the blood vessels are exposed to physiological
pressure and local and circulating vasoactive and growth factors [Webb 1995]. In
addition, they also have intact nervous mechanisms and have not been exposed to
potentially significant vessel trauma or hypoxia. In the last 15 years, several
techniques have been developed to assess arterial endothelial function in the
coronary and peripheral circulation in health and disease. Most of these have
investigated the ability of normal endothelium to release nitric oxide in response to
pharmacologic or mechanical stimuli. However, whilst endothelium-dependent
vasomotion is important, it may not be representative of other aspects of endothelial
function, such as the regulation of haemostasis, fibrinolysis and inflammation.
Recently, the in vivo assessment of endothelial fibrinolytic function has become
possible [Newby et al 1997a].
1.5.1.1 Coronary Circulation
In the coronary artery, quantitative angiography can be used to examine the changes
in diameter in response to intra-coronary infusions of endothelium-dependent
vasodilators such as acetylcholine [Ludmer et al 1986]. In healthy arteries,
acetylcholine stimulates the endothelial release of nitric oxide resulting in a
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vasodilatory response, whereas subjects with endothelial dysfunction may
demonstrate impaired acetylcholine mediated vasodilatation or paradoxical
vasoconstriction. Endothelial function of the coronary microcirculation can also be
assessed with intra-coronary Doppler techniques to measure coronary blood flow
[Drexler & Zeiher 1991]. Other non-invasive tests include Doppler
echocardiography, positron emission tomography and phase-contrast magnetic
resonance imaging.
1.5.1.2 Peripheral Circulation
The use of intra-coronary techniques is however limited by their invasive nature and
therefore has restricted application in research. Non-invasive or minimally invasive
methods have been developed to determine endothelial function in peripheral arteries
as a surrogate for coronary circulation. Two of the commonest modalities adopted
are brachial artery ultrasound and forearm venous occlusion plethysmography.
Brachial artery ultrasound is a non-invasive technique that evaluates flow-mediated
vasodilatation, an endothelium-dependent function, in the brachial artery.
[Celermajer et al 1992, Corretti et al 2002]. This stimulus provokes the endothelium
to release nitric oxide with subsequent vasodilatation that can be imaged and
quantified as an index of vasomotor function. In this test, the brachial artery is
imaged above or below the antecubital fossa in the longitudinal plane using an
ultrasound system equipped with a high-frequency vascular transducer, two-
dimensional imaging, and colour and spectral Doppler. Arterial occlusion is
typically created by inflating a sphygmomanometer cuff to suprasystolic pressure
placed either above the antecubital fossa or on the forearm for a standardised length
of time. This causes ischaemia and consequent dilatation of downstream resistance
vessels via autoregulatory mechanisms. Subsequent cuff deflation induces a brief
high-flow state through the brachial artery (reactive hyperaemia) to accommodate the
dilated resistance vessels. The resulting increase in shear stress causes the brachial
artery to dilate. Flow-mediated vasodilatation can then be quantified as percentage
change in post-stimulus brachial artery diameter compared to baseline, or in terms of
absolute change in diameter. In most studies to date, an exogenous nitric oxide
donor, such as sublingual nitroglycerine has also been given to determine the
maximum obtainable vasodilator response, and to serve as a measure of
endothelium-independent vasodilatation reflecting vascular smooth muscle function.
However, despite its widespread use, there are technical and interpretive limitations
to the use of brachial artery ultrasound [Corretti et al 2002]. Furthermore, there are
distinct phenotypic differences between conduit artery and microvascular vessel
endothelial cells, the major determinants of peripheral resistance. Therefore
assessment of flow mediated vasodilatation may not be wholly indicative of tissue
perfusion. Quantification of the endothelial fibrinolytic function is also not possible
with this technique.
In contrast, the use of bilateral forearm venous occlusion plethysmography combined
with unilateral brachial artery infusion of vasoactive drugs and venous sampling
provides a powerful and reproducible tool of direct assessment of vascular vasomotor
and fibrinolytic responses in the forearm resistance vessels [Newby et al 1997a,
1997b, 1998a]. This technique determines the change in forearm blood flow in
response to intra-arterial administration of endothelium-dependent agonists such as
acetylcholine, substance P and bradykinin, and the endothelium-independent
vasodilators such as sodium nitroprusside. In addition, simultaneous venous
sampling for t-PA and PAI-1 measurements allows the assessment of the acute
endothelial fibrinolytic capacity of the forearm circulation.
Although these peripheral artery techniques provide only surrogate measures of the
coronary endothelial function, several reports have indicated that they correlate with
findings from intra-coronary studies [Anderson et al 1995; Newby et al 1999, 2001],
and have provided important insights into the pathophysiology of atherogenesis and
the influence of cardiovascular risk factors.
1.5.2 Endothelial Dysfunction and Atherosclerosis
Endothelial dysfunction or injury is widely regarded as an important early event in
atherosclerosis. There is now extensive evidence of endothelial dysfunction and
abnormal endothelium-dependent vasomotion in patients with atherosclerosis and its
associated risk factors, such as smoking, hypercholesterolaemia, diabetes mellitus,
aging and hyperhomocysteinaemia [Celermajer et al 1993a, 1993b; Zeiher et al
1993; Calver et al 1992; Chowienczyk et al 1992]. Moreover, recent studies have
shown that endothelium-dependent vasodilatation is an independent predictor of
adverse cardiovascular events [Schachinger et al 2000; Halcox et al 2002],
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Impaired endothelial function actively participates in the process of lesion formation
by promoting the early and late mechanisms of atherosclerosis that include
upregulation of adhesion molecules, increased chemokine secretion and leukocyte
adherence, increased cell permeability, enhanced low-density lipoprotein oxidation,
platelet activation, cytokine elaboration and vascular smooth muscle cell
proliferation and migration [Celermajer 1997; Drexler 1997; Ross 1999].
Furthermore, endothelial dysfunction can modulate the clinical course of
atherosclerosis by altering plaque architecture, vulnerability of the lesion and the
likelihood of rupture, and thus accelerate the development of unstable coronary
syndromes.
1.5.3 Endothelial Dysfunction and Endogenous Fibrinolysis
Endogenous fibrinolysis plays an important role in the spontaneous reperfusion of
infarct-related arteries after acute myocardial infarction and can occur in as many as
30% of patients within 12 hours [Armstrong et al 1989; De Wood et al 1980;
Rentrop et al 1989]. The rapid mobilisation of t-PA from the endothelium is crucial,
as thrombus dissolution is much more effective if t-PA is incorporated during, rather
than after thrombus formation [Fox et al 1984]. Although it would be anticipated that
high plasma t-PA concentrations should protect against subsequent coronary events,
epidemiological studies of healthy men and patients with ischaemic heart disease
have indicated that higher plasma t-PA antigen concentrations positively predict
future coronary events [Thompson et al 1995; Ridker et al 1993]. This is explained
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by the concomitant elevation of PAI-1 that forms a complex with t-PA and thereby
causes an overall reduction in free t-PA activity [Meade et al 1993]. However, basal
concentrations of fibrinolytic factors may not reflect the capacity of endothelial cells
to release t-PA from intracellular storage pools.
Assessment of this acute endogenous fibrinolytic capacity has been recently
described [Newby et al 1997a]. Studies have shown that the acute release of t-PA is
reduced following experimental 'endothelial dysfunction' with nitric oxide synthase
inhibitor, as well as in smokers with and without coronary artery disease when
compared to non-smokers [Newby et al 1998b, 1999, 2001], However, the
association between the endogenous fibrinolytic capacity and inflammation and other
cardiovascular risk factors such as hyperhomocysteinaemia has not been established.
1.5.4 Endothelial Dysfunction and Hyperhomocysteinaemia
Several prospective and case-control studies have shown that elevated plasma
homocysteine concentrations are an independent risk factor for the development of
atherothrombotic vascular disease as well as a prognostic marker in ischaemic heart
disease [Clarke et al 1991; Stampfer et al 1992; Welch & Loscalzo 1998]. Although
the mechanism of vascular damage is unclear, homocysteine may promote
atherogenesis through oxidative endothelial injury that is mediated by cytotoxic
reactive oxygen species [Stamler et al 1993; Lentz et al 1996; Loscalzo 1996;
Kanani et al 1999], Indeed, acute and chronic hyperhomocysteinaemia are associated
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with impaired vasomotor tone [Celermajer et al 1993a; Tawakol et al 1997; Kanani
et al 1999],
Hyperhomocysteinaemia is a prothrombotic state [Welch & Loscalzo 1998],
Previous studies have shown that hyperhomocysteinaemia induced by oral
methionine loading is associated with alterations in endogenous fibrinolysis in
healthy subjects and patients with premature vascular disease [Labinjoh et al 2001;
Freyburger et al 1997], However, the influence of chronic hyperhomocysteinaemia
on the acute fibrinolytic capacity is unknown and is the subject of debate [Kuller &
Evans 1998]. Vitamin supplementation with folic acid, vitamin B6 and vitamin B12,
may reduce plasma homocysteine concentrations [Homocysteine Lowering Trialists'
Collaboration 1998]. Whilst endothelial function is enhanced following treatment
with folic acid in patients with hyperhomocysteinaemia [Woo et al 1999, 2002], the
response in patients with coronary artery disease has been variable [Chambers et al
2000; Title et al 2000; Thambyrajah et al 2001; van Dijk et al 2001; Doshi et al
2002]. Furthermore, the association between elevated plasma homocysteine
concentrations and resistance vessel vasomotor responses in patients with established
coronary artery disease has not been characterised.
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1.5.5 Endothelial Dysfunction and Coronary Stent Thrombosis and In-stent
Restenosis
Coronary artery stent implantation is a valuable adjunct to percutaneous transluminal
coronary angioplasty. However, there is a small but significant risk of acute
coronary stent thrombosis [Cutlip et al 2001] and in-stent restenosis that can have
devastating consequences including myocardial infarction and death [Albiero et al
1997], Whilst procedure-related complications such as persistent dissection, longer
stent length and final minimal lumen diameter may be implicated in some cases of
stent thrombosis or restenosis [Cutlip et al 2001], no underlying precipitant can be
identified in many patients.
Stent thrombus formation is principally initiated by platelet aggregation which, in the
absence of effective endothelium-derived vasoregulation and fibrinolysis, is then
stabilised by the deposition of a fibrin mesh. The chronology of in-stent restenosis
has been described as early thrombosis, followed by thrombus endothelialisation and
infiltration by lymphocytes and monocytes, and finally smooth muscle cell migration
and proliferation within the resolving thrombus [Schwartz et al 1993; Miller et al
1996; Komatsu et al 1998]. The initiation, propagation and stabilisation of acute
stent thrombosis and in-stent restenosis are therefore dependent on several
components: platelet aggregation, endothelial function, coagulation and fibrinolysis.
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1.6 Hypothesis and Aims
Although recent studies have investigated the effects of experimental inflammation
on the venous circulation and arterial endothelial function [Bhagat & Vallance 1997;
Hingorani et al 2000], the direct influence of inflammatory cytokines on arterial
endothelial function has not been explored. Furthermore, little is known about the
effects of systemic or local vascular inflammation on the acute fibrinolytic capacity.
The potential role of endogenous fibrinolysis and endothelial dysfunction in the
pathogenesis of prothrombotic conditions such as hyperhomocysteinaemia and
coronary stent thrombosis or in-stent restenosis have also not been investigated.
In a series of clinical studies, the following hypotheses will be addressed:
1. Acute systemic inflammation impairs endothelial function and alters the acute
endothelial fibrinolytic capacity
2. Direct intra-arterial TNF-a, IL-6 and endotoxin stimulates endogenous
fibrinolysis in the forearm vascular bed
3. Direct intra-arterial cytokines impair endothelium-dependent vasodilatation and
the acute release of t-PA
4. Endothelium-dependent vasomotion and fibrinolysis are impaired in patients with
recent myocardial infarction and hyperhomocysteinaemia
5. Vitamin supplementation would improve endothelial function in patients with
recent myocardial infarction and hyperhomocysteinaemia
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6. Endothelium-dependent vasomotion and endogenous fibrinolysis is impaired in
patients with acute stent thrombosis or in-stent restenosis
The aims of this thesis were
In healthy male volunteers (Chapter 3),
• To determine whether a mild acute systemic inflammatory response induced by
Salmonella typhi vaccination impairs endothelium-dependent vasodilatation
• To ascertain if the acute release of t-PA in the forearm circulation is altered by
acute systemic inflammation
In healthy male volunteers (Chapter 4),
• To establish an in vivo model of local vascular inflammation
• To examine the direct effects of local intra-arterial TNF-a, IL-6 and endotoxin on
basal vascular tone and the endogenous release of the fibrinolytic and coagulant
factors, t-PA, PAI-1 and von Willebrand factor
• To assess the effects of intra-arterial TNF-a infusion on endothelium-dependent
and -independent vasodilatation
• To ascertain ifTNF-a impairs the acute fibrinolytic capacity
In patients with recent myocardial infarction (Chapter 5),
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• To determine if patients with co-existing hyperhomocysteinaemia have impaired
endothelium-dependent vasodilatory and fibrinolytic responses compared to
those with normal plasma homocysteine concentrations
• To confirm that vitamin supplementation with folic acid, vitamins B6 and B12,
lowers plasma homocysteine concentration
• To assess the effects of vitamin supplementation on endothelial vasomotor and
fibrinolytic responses in those with hyperhomocysteinaemia
In patients with previous acute coronary stent thrombosis or in-stent restenosis
(Chapter 6),
• To determine if forearm endothelium-dependent vasodilatation is impaired
• To assess whether platelet aggregation is abnormal








Healthy subjects were recruited from medical students and a database of healthy
volunteers. Patient subjects were recruited from the Cardiology Out-Patient Clinics
or the Cardiology wards of the Royal Infirmary of Edinburgh, The Lothian
University Hospitals NHS Trust.
2.1.2 Subject Preparation
None of the normal healthy volunteers received vasoactive or non-steroidal anti¬
inflammatory drugs in the week before each phase of the study. Medications were
withheld on the day of the study in all patient subjects. All subjects abstained from
alcohol and caffeine-containing drinks for 24 hours and from food and tobacco for at
least four hours before each study. All studies were conducted in a quiet,
temperature-controlled room maintained at 22 - 25°C.
2.1.3 Ethics Committee Approval and Consent
All studies were undertaken with the approval of the Lothian Research Ethics
Committee and in accordance with the Declaration of Helsinki (1996) of the World
Medical Association. The written informed consent of each subject or patient was
obtained before entry into the study.
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2.2 Drugs
2.2.1 Endothelium-dependent and -independent Agonists
Pharmaceutical-grade compounds were used for all intra-arterial infusions of
vasoactive agents. The endothelium-dependent vasodilators, acetylcholine
(Cibavision Ophthalmics, Southampton, United Kingdom), substance P and
bradykinin (both from Clinalfa, Laufelflngen, Switzerland), and the endothelium-
independent vasodilator, sodium nitroprusside (David Bull Laboratories, Faulding,
United Kingdom) were administered following dissolution in 0.9% normal saline
(Baxter Healthcare Ltd., Berkshire, United Kingdom). Substance P and bradykinin
both induce endothelium-dependent vasodilatation and stimulate the acute release of
tissue-type plasminogen activator (t-PA) from the forearm vascular bed. Neither
sodium nitroprusside nor acetylcholine affects plasma t-PA or plasminogen activator
inhibitor type-1 (PAI-1) concentrations in the forearm [Newby et al 1997a; Brown et
al 1999]. All solutions were freshly prepared on the day of study.
2.2.2 Inflammatory Stimulus
A systemic inflammatory response was generated with typhoid vaccination using
Salmonella typhi capsular polysaccharide vaccine 0.025 mg (Typhim Vi, Aventis
Pasteur MSD, Berkshire, United Kingdom) [Hingorani et al 2000].
Lipopolysaccharide (lot G-l, USPCI, Rockville, Maryland, USA) [Pernerstorfer et al
1999] and the pro-inflammatory cytokines, tumour necrosis factor-a (TNF-a, Knoll
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Pharmaceuticals, Germany) [Janik et al 1999] and interleukin-6 (IL-6, Novartis
Pharma AG, Basel, Switzerland) [Tsigos et al 1997], were administered following
dissolution in 0.9% saline in order to generate a direct local inflammatory response.
Lipopolysaccharide, TNF-a and IL-6 were prepared as stock solutions and stored at
-80 °C in aliquots.
2.2.3 Vitamin Supplementation
Four weeks of sucrose placebo tablets (Thornton & Ross Ltd, Huddersfield, United
Kingdom) or vitamin supplementation was given as a once daily oral preparation.
Vitamin supplementation was administered as a combination therapy of folic acid (5
mg; Alpharma, Barnstaple, United Kingdom), vitamin B6 (pyridoxine 10 mg; B R
Pharma Ltd., Barnet, Untied Kingdom) and vitamin B12 (cyanocobalamin 100 pg;
Goldshield Pharmaceuticals Ltd., Croydon, Untied Kingdom). Vitamin
supplementation at these doses has been shown to be safe and effective and may
reduce plasma homocysteine concentrations [Homocysteine Trialists' Collaboration
1998],
2.3 Forearm Venous Occlusion Plethysmography
2.3.1 Brachial Artery Cannulation
The brachial artery of the non-dominant arm was cannulated with a 27-standard wire
gauge steel needle (Cooper's Needle Works Ltd., Birmingham, United Kingdom)
under 1% lidocaine (Xylocaine; Astra Pharmaceuticals Ltd., Kings Langley, United
Kingdom) local anaesthesia and attached to a 16-gauge epidural catheter (Portex
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Ltd., Hythe, United Kingdom) (Figure 2.1). Patency was maintained by infusion of
saline (0.9% sodium chloride) via a MS2000 syringe infusion pump (Graseby
Medical, Watford, United Kingdom). The total rate of intra-arterial infusion was
maintained constant throughout all studies at 1 mL/min.
Figure 2.1 Brachial artery cannulation.
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Figure 2.2 Application to the forearm of the mercury-in-silastic strain gauge,
brachial artery and venous cannulae, and wrist cuffs.
2.3.2 Forearm Blood Flow
Blood flow was measured in both forearms by venous occlusion plethysmography
using mercury-in-silastic strain gauges applied to the widest part of the forearm
(Figures 2.2 and 2.3) [Webb 1995]. During measurement periods the hands were
excluded from the circulation by rapid inflation of the wrist cuffs to 220 mmHg
using E20 rapid cuff inflators (DE Hokanson® Inc, Bellevue, Washington, USA).
Upper arm cuffs were inflated intermittently to 40 mmHg for 8 sec in every 10 sec to
achieve venous occlusion and obtain plethysmographic recordings. Analogue voltage
output from an EC-4 Strain Gauge Plethysmograph (DE Hokanson®) was processed
by a Powerlab®/400 analogue-to-digital converter and Chart™ v3.4.6 software (AD
Instruments Ltd., Castle Hill, Australia) and recorded onto an Acer 513TE computer
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(Acer Incorporated, Taipei, Taiwan). Calibration was achieved using the internal
standard of the plethysmograph.
Figure 2.3 Forearm venous occlusion plethysmography.
2.3.3 Blood Pressure and Heart Rate
Blood pressure and heart rate was monitored in the non-infused arm at intervals
throughout each study with a semiautomated noninvasive oscillometric
sphygmomanometer (Takeda UA 751, Takeda Medical Inc, Tokyo, Japan). Blood
pressure was measured immediately after forearm blood flow recordings to avoid any
effects of the venous congestion caused by this procedure on these measurements.
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2.4 Analysis of Blood Samples
2.4.1 Venous Sampling
Venous cannulae (17-gauge) were inserted into large subcutaneous veins of the
antecubital fossae of both arms (Figure 2.2). Fasting venous blood was withdrawn
into lithium heparin, ethylene diamine tetraacetic acid and serum bead tubes
(Monovette®, Sarstedt, Ntimbrecht, Germany) for IL-6, C-reactive protein (CRP) and
homocysteine assays respectively. Before and during intra-arterial drug infusion,
venous blood was withdrawn simultaneously from each arm and collected into
acidified buffered citrate (Biopool® Stabilyte™, Umea, Sweden; for t-PA assays) and
trisodium citrate tubes (Monovette®; for PAI-1 assays). All samples were kept on ice
before being centrifuged at 2000g for 30 min at 4°C except ethylene diamine
tetraacetic acid samples that were centrifuged at lOOOg for 10 min at 20°C. Platelet-
free plasma was decanted and stored at -80°C before assay.
2.4.2 Laboratory Assays
2.4.2.1 Fibrinolytic and Haemostatic Assays
Plasma t-PA and PAI-1 antigens concentrations were determined using enzyme-
linked immunosorbent assays (Coaliza® t-PA and Coaliza® PAI-1 respectively,
Chromogenix AB, Molndal, Sweden) [Newby et al 1997a]. Plasma t-PA and PAI-1
activities were determined by a photometric method (Coatest® t-PA and Coatest®
PAI-1, Chomogenix AB). Intra-assay coefficients of variation were 7.0% and 5.5%
for t-PA and PAI-1 antigen, and 4.0% and 2.4% for activity respectively. Inter-assay
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coefficients of variability were 4.0%, 7.3%, 4.0% and 7.6% respectively. The
sensitivities of the assays were 0.5 ng/mL, 2.5 ng/mL, 0.10 IU/mL and 5 AU /mL
respectively.
Von Willebrand factor antigen was determined using an enzyme-linked
immunosorbent assay (Dako A/S, Glostrup, Denmark) with a sensitivity of 0.05
IU/mL. The intra-assay and inter-assay coefficients of variability were 5.2% and
7.3% respectively.
2.4.2.2 Inflammatory Parameters
Plasma TNF-a, IL-6 and CRP concentrations were determined using specific
enzyme-linked immunosorbent assays (Quantikine human TNF and IL-6
immunoassays, R&D Systems, Abingdon, Untied Kingdom; CRP ELISA,
Eurogenetics, Belgium respectively). White cell count was determined using an
automated Coulter counter (Beckman-Coulter ACt.8, High Wycombe, Untied
Kingdom). Intra-assay coefficients of variation were 4.2% and 5.2% for IL-6 and
TNF-a antigen, and inter-assay coefficients of variability were 6.4% and 7.4%
respectively. The sensitivities of the assays were 0.7 pg/mL and 0.1 pg/mL
respectively.
2.4.2.3 Homocysteine and Vitamin Assays
Plasma homocysteine and serum folate and vitamin Bn concentrations were
determined using enzyme immunoassay (Axis® Homocysteine EIA, Axis-Shield
41
AS, Oslo, Norway; Bayer Immuno 1 ® automated immunoassay analyser, Bayer AG,
Leverkusen, Germany respectively).
2.4.2.4 Haematocrit Measurement
Haematocrit was determined by capillary tube centrifugation of blood anticoagulated
by ethylene diamine tetraacetic acid.
2.4.2.5 Thrombophilia Screen
Venous blood was screened for anti-thrombin, protein S and protein C deficiencies,
factor V (Leiden) and prothrombin A20210G genotypes and anti-phospholipid
antibodies.
2.4.3 Platelet Aggregometry
Fasting venous blood (30 mL) was collected into trisodium citrate tubes
(Monovette®) and immediately centrifuged at 120g for 10 min to obtain platelet-rich
plasma, which was aspirated, adjusted to give a platelet count of 250 x 109 /L and
pre-warmed to 37°C. Aggregation studies were performed on the platelet rich
plasma 30-40 min after blood sampling using a standard optical technique
(Chronolog Ca560 aggregometer; Labmedics, Stockport, United Kingdom)
[Labinjoh et al 2001] with the following agonists: adenosine diphosphate (ADP, 0.5
- 10 pmol/L), the thromboxane A2 analogue U46619 (0.5 - 6 pmol/L), thrombin
(200 -1000 mU/L) and collagen (1-5 pg/mL). Responses were recorded 5 min after
addition of agonists and the peak response adjusted for platelet count (250 x 109/L).
42
Platelet count was measured using an automated Coulter counter (Act. 8 Coulter
Counter; Beckman-Coulter).
2.5 Data Analysis and Statistics
2.5.1 Forearm Blood Flow
Plethysmographic data were extracted from the Chart™ data files and forearm blood
flow was calculated for individual venous occlusion cuff inflations by use of a
template spreadsheet (Excel 97, Microsoft Corporation, Cambridge, USA) (Figure
2.4). Recordings for the first sixty seconds after wrist cuff inflation were not used
because of the variability in blood flow and reflex vasoconstriction this causes
[Kerslake DMcK 1949]. The last five linear plethysmographic recordings in each 3
min measurement period were calculated and averaged for each arm.
2.5.2 Fibrinolytic Activity
The estimated net release of t-PA antigen and activity were defined as the product of
the infused forearm plasma flow (based on the mean haematocrit, Hct, and the
infused forearm blood flow, FBF) and the concentration difference between the
infused ([t-PA]inf) and noninfused ([t-PA]N0ninf) arms [Newby et al 1997a] using the
formula,
Estimated net t-PA release = FBF x (1 - Hct) x {[t-PA]jnf - [t-PA]N0ninf}
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The area under the curve (AUC) was calculated for estimated net t-PA antigen and
activity release during bradykinin and substance P infusion. Because basal t-PA
concentrations were altered by pre-treatment with TNF-a, t-PA antigen and activity
release during bradykinin infusion was calculated by subtracting the mean t-PA
release before, and 15 min after cessation of bradykinin infusion (Chapter 4).
2.5.3 General
Data were examined, where appropriate, by analysis of variance (ANOVA) with
repeated measures and two-tailed paired Student's /-test using Statview (SAS
Institute, Inc). All results are expressed as mean±SEM. Statistical significance was
assigned at the 5% level.
Figure 2.4 Plethysmographic graphs of blood flow from the infused forearm
(administered with intra-arterial vasodilators) (lower panel) compared with the non-
infused (control) forearm (upper panel).
Chapter 3
The Effects of Acute Systemic Inflammation on
Endothelium-Dependent Vasodilatation and Tissue
Plasminogen Activator Release in Men
Chia S, Ludlam CA, Fox KAA, Newby DE.
Acute Systemic Inflammation Enhances Endothelium-Dependent Tissue
Plasminogen Activator Release in Men.
JAm Coll Cardiol. 2003;41:333-9.
3.1 Summary
The current study was designed to investigate the effects of acute systemic
inflammation on the endogenous fibrinolytic capacity in vivo in man. Systemic
inflammation and endogenous fibrinolysis play a major role in the pathogenesis of
coronary artery disease. Although previous studies have shown impaired
endothelium-dependent vasomotor function, the effects of inflammation on the
endothelial release of the fibrinolytic factor, tissue plasminogen activator (t-PA) are
unknown. In a double-blind randomised placebo-controlled crossover trial, we
administered a mild inflammatory stimulus, Salmonella typhi vaccine, or saline
placebo to eight healthy men on two separate occasions. Six hours after vaccination,
blood flow and plasma fibrinolytic variables were measured in both arms during
intra-brachial infusions of bradykinin (40-1000 pmol/min), acetylcholine (5-20
pg/min), and sodium nitroprusside (2-8 pg/min). Compared to placebo, S. typhi
vaccination caused a rise in white cell count (11.1 vs 7.9 xl09/L; .P=0.004) and
plasma interleukin-6 concentrations (6.9+1.4 vs 1.6+0.4 pg/mL; P=0.01), and a
significant augmentation of t-PA antigen (45+9 vs 24+8 ng/100 mL/min at peak
dose; P=0.016) and activity (104+15 vs 54+12 IU/100 mL/min; P=0.006) release
during bradykinin infusion. Forearm blood flow increased in a dose-dependent
manner following bradykinin, acetylcholine and sodium nitroprusside infusions
(PO.OOl) but this was unaffected by vaccination. Acute systemic inflammation
augments local forearm t-PA release in man. This suggests that acute inflammation
may invoke a protective response by enhancing the acute endogenous fibrinolytic
capacity in healthy man.
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3.2 Introduction
Atherosclerosis is widely recognised to be an inflammatory disease process
involving dysfunction of the vascular endothelium [Ross 1999]. This dysfunction
leads to increased expression of leucocyte adhesion molecules, reduced anticoagulant
activity and the release of growth factors, inflammatory mediators and cytokines.
Continued inflammation leads to leucocyte and monocyte recruitment, arterial
damage and atherogenesis. Further cycles of damage cause plaque expansion and
disruption that may lead to angina, crescendo angina and acute coronary syndromes.
Recent epidemiological and observational studies have suggested a link between
systemic inflammation and coronary artery disease. Infections by organisms such as
chlamydia pneumoniae and herpes simplex virus type 1, appear to be associated with
an increased risk of cardiovascular mortality [Roivanen et al 2000], and
approximately 4% of bacteraemic patients will develop acute myocardial infarction
within a month of infection [Valtonen et al 1993]. Increased cardiovascular
mortality is also seen following respiratory tract infections [Meier et al 1998], severe
illnesses requiring intensive care [Quartin et al 1997] and surgery [Mamode et al
1995]. Markers of systemic inflammation, such as C-reactive protein (CRP), serum
amyloid A, interleukin-6 (IL-6) and tumour necrosis factor-a (TNF-a), are elevated
in patients with cardiovascular disease and are associated with an adverse prognosis
and recurrent coronary events [Liuzzo et al 1994; Ridker et al 2000a; Biasucci et al
1996, 1999]. Moreover, in previously healthy individuals, elevated plasma CRP and
IL-6 concentrations predict the development of cardiovascular disease [Ridker et al
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1997, 2000b, 2000c]. Indeed, reflecting its anti-inflammatory action, the preventative
benefits of aspirin in reducing cardiovascular risk are proportional to the plasma CRP
concentration [Ridker et al 1997]. These data collectively suggest two patterns of
association: a link between chronic inflammation and the slow process of
atherogenesis, and an association between acute systemic inflammation and a
transiently increased risk of an acute cardiovascular event.
The vascular endothelium plays a vital role in the control of blood flow, haemostasis,
fibrinolysis and inflammation [Vane et al 1990], and impaired endothelial function is
implicated in the pathogenesis of coronary artery disease. Tissue plasminogen
activator is a fibrinolytic factor released from the endothelium through the
translocation of a dynamic intracellular storage pool and regulates the degradation of
intravascular fibrin [van den Eijnden-Schrauwen et al 1995]. If endogenous
fibrinolysis is to be effective, then the rapid mobilisation of t-PA from the
endothelium is essential because thrombus dissolution is much more effective if t-PA
is incorporated during, rather than after, thrombus formation [Fox et al 1984;
Brommer 1984], However, in the presence of pro-inflammatory states or an
imbalance in endogenous fibrinolysis, such microthrombi may propagate, ultimately
leading to arterial occlusion and tissue infarction [Rosenberg & Aird 1999].
We have previously described an in vivo model to assess the acute release of t-PA in
man [Newby et al 1997a] and demonstrated an association between t-PA release and
endothelial dysfunction [Newby et al 1998b, 1999]. Hingorani and colleagues have
also recently shown that acute inflammation causes dysfunction of endothelium-
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dependent vasodilatation in humans [Hingorani et al 2000]. However, there have
been no studies to assess directly the acute local fibrinolytic capacity following acute
inflammation. The aim of this study is therefore to test the hypothesis that the acute





Eight healthy non-smoking men aged between 20 and 27 participated in the study,
which was undertaken with the approval of the local research ethics committee and
in accordance with the Declaration of Helsinki. The written informed consent of
each subject was obtained before entry into the study. All subjects were
normotensive without a history of diabetes mellitus, vascular or coronary artery
disease and none of the subjects had undergone typhoid vaccination in the previous
year.
3.3.2 Drugs
An inflammatory response was generated with typhoid vaccination using Salmonella
typhi capsular polysaccharide vaccine 0.025 mg (Typhim Vi, Aventis Pasteur MSD,
Berkshire, United Kingdom). Pharmaceutical-grade bradykinin and acetylcholine
(both from Clinalfa, Laufelfingen, Switzerland) and sodium nitroprusside (David
Bull Laboratories, Faulding, United Kingdom) were administered following
dissolution in saline. All solutions were freshly prepared on the day of study.
3.3.3 Study Design
S. typhi vaccine or saline placebo were injected into the deltoid muscle of the
dominant arm at 8.30 AM in a randomised, balanced block, double-blind crossover
manner at least two weeks apart. Previous reports have indicated that vaccination-
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induced endothelial dysfunction is transient and resolves within thirty-two hours
[Hingorani et al 2000].
Six hours after vaccination, and after a four-hour fast, strain gauges and cuffs were
applied. The brachial artery of the non-dominant arm was cannulated and venous
cannulae were inserted into both arms. Forearm blood flow was measured every six
to ten minutes. After thirty minutes equilibration with saline infusion, intra-arterial
bradykinin was administered at 40, 200, 1000 pmol/min for ten minutes at each dose,
acetylcholine at 5, 10, 20 pg/min and sodium nitroprusside at 2, 4, 8 pg/min for six
minutes at each dose. The drugs were separated by twenty minutes of saline infusion
and administered in a randomised order that was kept constant for each individual.
Venous samples were taken at baseline and during infusion of each bradykinin dose
but not during sodium nitroprusside or acetylcholine infusion since they do not affect
plasma t-PA or PAI-1 concentrations in this forearm model [Newby et al 1997a;
Brown et al 1999]. White cell count, haematocrit, IL-6 and CRP were determined six
hours after vaccination and haematocrit was repeated at the end of the forearm study.
3.3.4 Data Analysis and Statistics
Estimated net release of t-PA antigen and activity was defined previously [Newby et
al 1997a] as the product of the infused forearm plasma flow (based on the mean
haematocrit, Hct, and the infused forearm blood flow, FBF) and the concentration
difference between the infused ([t-PA]jnf) and noninfused ([t-PA]N0ninf) arms. The
area under the curve (AUC) was calculated for estimated net t-PA antigen and
\
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activity release during bradykinin infusion. Data were examined, where appropriate,
by analysis of variance (ANOVA) with repeated measures and 2-tailed paired
Student's /-test using Excel 97 (Microsoft). All results are expressed as mean±SEM.




All subjects remained well throughout the study and reported no localised discomfort
or systemic side effects following vaccination. Compared to placebo injection, there
was a marked elevation in white cell count (11,1±0.5 vs 7.9±0.8xl09/L; .P=0.004, t-
test) and plasma IL-6 concentrations (6.9±1.4 vs 1.6±0.4 pg/mL; P=0.01, t-test) six
hours after typhoid vaccination, although serum CRP concentrations (1.8±1.2 vs
1.0±0.6 pg/mL; P=NS, t-test) and temperature (P=NS, t-test; Table 3.1) were
unchanged.








Heart Rate 57±1 57±2 beats/min
Haematocrit 0.41+0.01 0.41±0.01
Infused Forearm Blood Flow 3.0±0.6 2.8±0.6 mL/100 mL tissue/ min
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3.4.2 Assessment of Endothelium-dependent Vasomotion
There were no significant effects of vaccination on heart rate, blood pressure, or
baseline forearm blood flow. There were no significant changes in heart rate, blood
pressure and non-infused forearm blood flow during drug infusion on either study
day. Forearm blood flow increased in a dose-dependent manner during bradykinin,
acetylcholine, and sodium nitroprusside infusions (PO.OOl, ANOVA), but there was
no change in the blood flow response following vaccination (P=NS, ANOVA; Figure
3.1).
3.4.3 Assessment of Fibrinolytic Activity
Following vaccination, there were no changes in baseline plasma t-PA and PAI-1
antigen concentrations or plasma t-PA activity concentration. Compared with the
non-infused arm, bradykinin caused dose-dependent increases in plasma t-PA
antigen and activity (P<0.001 for both, ANOVA) concentrations in the infused arm
that was significantly higher following vaccination (P<0.03, ANOVA; Table 3.2). S.
typhi vaccination caused a significant augmentation in the net release of t-PA antigen
and activity (P=0.016 and P=0.006 respectively, ANOVA), and a two-three fold
increase in the AUC for net t-PA antigen (37+12 vs 13+9 ng/100 mL/min; P=0.14, /-
test) and activity (70±12 vs 36+8 IU/100 mL/min; P^O.037, /-test) release compared
to placebo (Figure 3.2). Plasma PAI-1 concentrations did not change during
bradykinin infusion (Table 3.2).
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Infused forearm blood flow during bradykinin (circles), acetylcholine (triangles)
and sodium nitroprusside (squares) infusions in subjects who were administered
typhoid vaccination (closed symbols) and saline placebo (open symbols).





































































t-PA Antigen t-PA Activity
Figure 3.2
Estimated net release of t-PA antigen (solid line) and activity (dashed line) in
subjects who were administered typhoid vaccination (closed circles and bare)
and saline placebo (open circles and bare). Lower panel represents area under
the curve for the response.
ANOVA *P<0.05; j"P=0.006 (vaccination vs placebo)
f-test j;f<0.05 (vaccination vs placebo)
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3.5 Discussion
We have demonstrated that an acute mild systemic inflammatory stimulus causes
potentiation of bradykinin-induced t-PA release. We conclude that acute systemic
inflammation enhances local endothelial t-PA release in man. This may reflect an
adaptive mechanism of the vascular endothelium to augment its fibrinolytic response
under circumstances of acute inflammation.
3.5.1 Endothelium-dependent Vasomotion
We assessed basal and stimulated forearm blood flow following intra-arterial
infusions of the endothelium-dependent vasodilators, bradykinin and acetylcholine,
and the endothelium-independent vasodilator sodium nitroprusside, six to eight hours
after vaccination. Bradykinin and acetylcholine have both been widely used to
investigate the function of vascular endothelium. Impaired arterial vasodilatory
response to endothelium-dependent agonists has been shown in patients with
hypertension [Panza et al 1990], diabetes mellitus [Calver et al 1992] and
hypercholesterolemia [Chowienczyk et al 1992]. Hingorani and colleagues
[Hingorani et al 2000] have previously reported that S. typhi vaccination generated
an inflammatory response that was associated with a temporary suppression of
endothelium-dependent vasodilatation in the forearm circulation of six healthy
volunteers. Although we applied a similar protocol to their study and included
overlapping doses of both bradykinin and acetylcholine, we did not replicate their
findings of impaired forearm endothelium-dependent vasodilatation following
vaccination at 6-8 hours (Figure 3.1). This discrepancy may be partly explained by
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the variability in vasodilatory response with acetylcholine [Chowienczyk et al 1994]
and the higher maximal vasodilator dose used in our studies, although we have used
a larger sample size and employed a double-blind randomised placebo-controlled
crossover trial.
3.5.2 Endogenous Fibrinolysis
Tissue plasminogen activator, the key enzyme in the initiation of fibrinolysis, is
synthesised in endothelial cells and stored in small, dense vesicles. It is secreted both
basally and in response to thrombin and several vasoactive agents through a calcium-
dependent and G protein-coupled pathway [Emeis et al 1997], The regulated
endogenous release of t-PA plays a major role in the defense against intravascular
thrombosis, especially in the coronary circulation [Rosenberg & Aird 1999].
Bradykinin is a vasoactive peptide and potent stimulant for the acute release of t-PA
from the vasculature [Brown et al 1997, 1999; Labinjoh et al 2000, 2001] and is
produced locally through activation of the kallikrein-kinin system on the surface of
endothelial cells [Rojkjaer & Schmaier 1999]. In the present study, bradykinin-
induced t-PA antigen and activity release was augmented two-three fold following
typhoid vaccination in the absence of systemic haemodynamic effects (Figure 3.2).
The underlying mechanisms for our findings are unknown. Inflammation is
recognised to induce a protective response towards tissue injury, and it functions as
part of normal host surveillance mechanisms. Various compounds associated with
the inflammatory response, including histamine, thrombin and endotoxin, have been
shown to increase cellular t-PA transcription and expression [Dichek & Quertermous
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1989; Levin & Santell 1988]. However, we did not observe an increase in the basal
plasma concentrations of either t-PA or PAI-l. The inflammatory stimulus, therefore,
appears to augment specifically the storage or acute release of t-PA rather than a
generalised upregulation of protein synthesis and basal secretion. This may be
mediated by pro-inflammatory cytokines, such as IL-6, that modulate cellular
activation leading to alterations in endothelial function. In particular, molecular and
pharmacological evidence supports the role of bradykinin B2 receptors in the acute
phase of inflammation, and upregulation of B2 receptors may account for the
potentiation ofbradykinin-induced t-PA release.
3.5.3 Clinical Implications
The augmentation of acute t-PA release following typhoid vaccination suggests that
mild acute inflammation may induce anti-thrombotic properties in the forearm
circulation. This may represent an adaptive response to inhibit intravascular
thrombus deposition under circumstances of acute vascular inflammation. This
observation is consistent with the increase in endogenous fibrinolysis in systemic
inflammation induced by experimental endotoxaemia in healthy subjects [van der
Poll et al 1997]. However, in susceptible individuals, such as those with ischaemic
heart disease and chronic inflammation, this adaptive and protective acute response
may fail or become depleted, leading to thrombus propagation and vessel occlusion.
The fibrinolytic response to acute systemic inflammation in patients with ischaemic
heart disease and the influence of anti-inflammatory therapies, such as aspirin, now
needs to be established. Indeed, recent evidence has suggested that aspirin pre-
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treatment is able to reverse inflammation-induced endothelial dysfunction
[Kharbanda et al 2002],
Epidemiological studies have demonstrated an association between the risk of future
cardiovascular events and both plasma inflammatory markers [Ridker et al 1997,
2000b, 2000c] and fibrinolytic factors [Hamsten et al 1985]. The current
observations are, therefore, consistent with the suggestion that elevated plasma t-PA
concentrations may provide a marker of vascular inflammation. Irrespective of
whether these common associations are partly or wholly explained by inflammation-
induced t-PA release, understanding the regulation of both acute and chronic t-PA
release will have important clinical implications and may help to develop more
effective strategies in the management of atherosclerotic disease.
3.5.4 Study Limitations
There are some limitations to our study. We administered the typhoid vaccination in
the deltoid muscle of the control dominant arm rather than the gluteus muscle.
However, as blood flow was assessed in the forearm and intra-arterial vasodilators
were administered in the contralateral non-dominant arm, it would be highly unlikely
that the site of vaccination would have affected the response in the infused forearm.
It would also have been preferable to assess the vascular responses immediately
before and 6-8 hours after vaccination on the same day. However, this would require
repeated arterial cannulations within the same day and we have previously
demonstrated that endothelium-dependent vasodilatation and t-PA release is
reproducible when performed at least one week apart [Newby et al 1997b, 2002].
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The study subjects are healthy and young, and we acknowledge that the response in
older subjects may be quite different. Finally, we studied peripheral vascular function
and thus these findings may not be directly applicable to other vascular beds.
However, endothelial dysfunction is often a generalised process, and we have
previously shown [Newby et al 1999, 2001] consistent endogenous fibrinolytic
responses between the forearm and coronary circulation.
3.5.5 Conclusion
In conclusion, we have demonstrated that mild inflammation generated by typhoid
vaccination resulted in a significant potentiation of bradykinin-induced t-PA release
from the vascular endothelium. Additional work is now required to determine the
underlying mechanism and to assess the effects of acute and chronic inflammation on
endogenous fibrinolysis in health and disease.
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Chapter 4
The Direct Effects of Inflammatory Cytokines and Endotoxin
on Local Endothelial Vasomotor and Fibrinolytic Function in
Man
Chia S, Qadan M, Newton R, Ludlam CA, Fox KAA, Newby DE.
Intra-arterial Tumor Necrosis Factor-alpha Impairs Endothelium-Dependent
Vasodilatation and Stimulates Local Tissue Plasminogen Activator Release In
Humans.
Arterioscler Thromb Vase Biol. 2003;23:695-701.
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4.1 Summary
Systemic and vascular inflammation contribute to the pathogenesis of cardiovascular
disease, potentially through the actions of pro-inflammatory cytokines. The aims of
this study were to assess the direct effects of local intra-arterial tumour necrosis
factor-a (TNF-a), interleukin-6 (IL-6) and endotoxin on blood flow and endogenous
tissue-type plasminogen activator (t-PA) release in vivo in man. In a double-blind
randomised placebo-controlled trial, blood flow, and plasma cytokine and
fibrinolytic factor concentrations were measured in both forearms of healthy male
volunteers using venous occlusion plethysmography and blood sampling. Ten
subjects received intra-brachial infusions of TNF-a (80 or 240 ng/min), IL-6 (30
ng/min), endotoxin (100 pg/min) or saline placebo. Eight further subjects received
intra-brachial bradykinin, acetylcholine and sodium nitroprusside, following pre-
treatment with TNF-a (80 ng/min). TNF-a, but not IL-6, endotoxin or placebo,
caused a gradual and sustained ~20-fold increase in plasma t-PA concentrations
(PO.OOl) that was associated with elevated plasma IL-6 concentrations (/5<0.05) but
without an effect on blood flow or plasminogen activator inhibitor type 1 antigen.
Compared to placebo, TNF-a pre-treatment impaired bradykinin- and acetylcholine-
induced vasodilatation (P<0.03), and resulted in a doubling of bradykinin-induced t-
PA release (P<0.05). We conclude that intra-arterial TNF-a causes an acute local
vascular inflammation that is associated with impaired endothelium-dependent
vasomotion as well as sustained and substantial increase in endothelial t-PA release.




There is emerging evidence that systemic inflammation plays a major role in the
pathogenesis of cardiovascular disease. The pro-inflammatory cytokines, TNF-a and
IL-6, in particular, have been implicated in the initiation and maintenance of systemic
and vascular inflammation associated with atherosclerosis and coronary artery disease.
Indeed, plasma concentrations of these cytokines are elevated in patients with
ischaemic heart disease [Biasucci et al 1999; Ridker et al 2000a], and have been shown
to predict the future risk of myocardial infarction in apparently healthy individuals
[Ridker et al 2000b].
The vascular endothelium plays a vital role in the control of blood flow, haemostasis,
fibrinolysis and inflammation, and changes in endothelial function may underlie the
association between inflammation and the risk of cardiovascular disease. Tissue-type
plasminogen activator is a fibrinolytic factor released from the endothelium and lyses
intravascular fibrin [van den Eijnden-Schrauwen et al 1995]. If endogenous
fibrinolysis is to be effective, then the rapid mobilisation of t-PA from the
endothelium is essential because thrombus dissolution is much more effective if t-PA
is incorporated during, rather than after, thrombus formation [Fox et al 1984],
However, in the presence of pro-inflammatory states or an imbalance in endogenous
fibrinolysis, intravascular thrombus may propagate, ultimately leading to arterial
occlusion and tissue infarction [Rosenberg & Aird 1999].
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TNF-a and endotoxin have been reported to induce local vascular inflammation and
impair endothelium-dependent vasodilatation in the venous circulation of man
[Bhagat & Vallance 1997], Although mild systemic inflammation has also been
shown to alter endothelial function [Hingorani et al 2000], the underlying
mechanisms for these observations have not been elucidated and the direct in vivo
effects of cytokines and inflammatory stimuli on local arterial endothelial vasomotor
and fibrinolytic function are unknown.
The aims of this study were to investigate the acute effects of local intra-arterial
inflammatory cytokines (IL-6, TNF-a) and bacterial endotoxin (lipopolysaccharide,




Eighteen healthy non-smoking men aged between 21 and 25 years participated in the
study which was undertaken with the approval of the local research ethics committee,
in accordance with the Declaration of Helsinki and the written informed consent of
each subject. None of the subjects had infective illnesses or received medication in
the week before study.
4.3.2 Cytokines and Drugs
TNF-a (Knoll Pharmaceuticals, Germany) [Janik et al 1999], IL-6 (Novartis Pharma
AG, Basel, Switzerland) [Tsigos et al 1997], LPS (lot G-l, USPCI, Rockville,
Maryland, USA) [Pernerstorfer et al 1999], bradykinin (Clinalfa, Laufelfingen,
Switzerland), acetylcholine (Cibavision Ophthalmics, Southampton, Untied
Kingdom) and sodium nitroprusside (David Bull Laboratories, Faulding, United
Kingdom) were administered following dissolution in 0.9% saline. TNF-a, IL-6 and
LPS were prepared as stock solutions and stored at -80 °C in aliquots. All other
drugs were freshly prepared on the study day.
4.3.3 Study Design
Subjects rested recumbent, strain gauges and cuffs were applied, and venous
cannulae were inserted into both antecubital fossae. The brachial artery of the non-
dominant arm was cannulated under local anaesthesia. Venous sampling was
performed on both arms for cytokine, coagulation and fibrinolytic factor assays
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4.3.3.1 Protocol 1: Cytokine and Endotoxin Administration
In a randomised double-blind study, ten subjects attended on three occasions at least
one week apart and saline was infused for 30 min to allow time for equilibration.
Subjects were then randomised to receive intra-arterial infusions of low dose TNF-a
(80 ng/min; n=6), high dose TNF-a (240 ng/min; n=6), IL-6 (30 ng/min; n=6), LPS
(100 pg/min; n=6) or saline placebo (1 mL/min; n=6) over 60 min. This was
followed by a further 60 min saline washout infusion. Venous samples were obtained
at baseline, 10, 20, 40 and 60 min during drug infusion, and 30, 60 and 180 min after
cessation of drug infusion (Figure 4.1). Cytokine and LPS doses were chosen to
achieve local concentrations comparable to healthy volunteer studies [Bhagat &
Vallance 1997; Pernerstorfer et al 1999; van der Poll et al 1991], and those seen in
cardiovascular diseases [Biasucci et al 1999; McMurray et al 1991].
4.3.3.2 Protocol 2: Effect of TNF-a on Endothelial Function
Eight subjects attended on two occasions at least one week apart in a randomised,
double-blind placebo-controlled crossover trial. They received an intra-arterial
infusion of either TNF-a (80 ng/min) or saline placebo (1 mL/min) over 60 min.
After a further 60 min saline infusion, intra-arterial bradykinin was administered at
100, 300, 1000 pmol/min for 10 min at each dose, acetylcholine at 5, 10, 20 pg/min
and sodium nitroprusside at 2, 4, 8 pg/min for 5 min at each dose (Figure 4.2).
Infusions of the vasoactive drugs were separated by 15 min saline washout infusions.
Venous samples were obtained at baseline, after 60 min of TNF-a/placebo infusion,
before and during each dose of bradykinin and 15 min after cessation of bradykinin
infusion. Venous samples were not obtained during acetylcholine or sodium
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nitroprusside infusion since they do not affect plasma t-PA or plasminogen activator
inhibitor type 1 (PAI-1) concentrations in this forearm model [Newby et al 1997a;
Brown et al 1999; Jern et al 1994],
4.3.4 Data Analysis and Statistics
Estimated net t-PA antigen and activity release has been defined previously in
Chapter 2.5.2. Because basal t-PA concentrations were altered by pre-treatment with
TNF-a, t-PA antigen and activity release during bradykinin infusion was calculated
by subtracting the mean t-PA release before, and 15 min after cessation of bradykinin
infusion. Data were examined, where appropriate, by analysis of variance (ANOVA)
with repeated measures and two-tailed paired Student's /-test. All results are
expressed as mean±SEM. Statistical significance was assigned at the 5% level.
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All subjects remained well throughout the study and reported no adverse effects.
There were no effects on haematocrit, body temperature or white cell count
throughout all studies (Tables 4.1 and 4.2).
4.4.1 Protocol 1: Cytokine and Endotoxin Administration
4.4.1.1 Cytokine Assays
Plasma TNF-oc concentrations increased from 1+0 and 2±1 pg/mL to 539±71 and
1164±41 pg/mL in the infused arm (P<0.001 for both), and to 20+2 and 62+8 pg/mL
in the non-infused arm (PO.OOl for both) during 80 and 240 ng/min of TNF-a
respectively (Figure 4.3). This was accompanied by a gradual increase in plasma IL-
6 concentrations (Figure 4.3).
In the infused arm, IL-6 infusion increased plasma IL-6 concentrations from 2±1 to
14±3 pg/ml (P=0.01), and LPS infusion increased plasma TNF-a and IL-6




Intra-arterial saline placebo, TNF-a, IL-6 and LPS infusions had no effect on heart
rate, blood pressure or forearm blood flow throughout all studies (Tables 4.1 and
4.3).
4.4.1.3 Fibrinolytic and Haemostatic Assays
There were no changes in plasma t-PA antigen concentrations during IL-6, LPS or
saline placebo infusions (Table 4.4).
Plasma t-PA antigen and activity concentrations increased in the infused arm by up
to 20-fold following both low and high dose TNF-a infusions (P<0.001; Figure 4.4).
Plasma t-PA concentrations increased slowly, being detectable at 20 min and peaking
at 60 min of infusion. Thereafter, plasma t-PA concentrations fell but remained
elevated 4 hours after initiation of the infusion with an apparently stable elevation
between 2 and 4 hours.
Plasma PAI-1 and von Willebrand factor antigen concentrations were unchanged
throughout all studies although plasma PAI-1 activity was reduced in the infused arm
only following high dose TNF-a infusion (P=0.003; Table 4.5).
72
Table 4.1
Protocol 1: Temperature, White cell count, Haematocrit, Heart rate and Blood

















Base 36.5±0.1 36.5±0.0 36.5+0.1 36.5+0.1 36.5±0.1






































4 hours 36.310.1 36.410.1 36.4+0.1 36.3+0.1 36.310.2
White Cell Count, xl09/L
Baseline 5.210.6 4.910.5 4.910.4 4.910.4 5.710.4
6.010.5
7.110.9 5.910.4 6.810.9 6.6+0.3
0.3910.01 0.3810.01 0.39+0.01 0.3810.01 0.39+0.01









Protocol 2: White Cell Count and Haematocrit During TNF-a Infusion



















Protocol 1: Forearm blood flow (FBF) during TNF-a, IL-6, LPS and Saline
infusions




































2 hours 2.9+0.7 2.4+0.5 1.8+0.2 1.8+0.2 1.9+0.3
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Table 4.4
Protocol 1: Plasma t-PA Antigen Concentrations During IL-6, LPS and Saline
Infusion
IL-6 (30 ng/min) LPS (100 pg/min) Saline (1 ml/min)
Infused Non- Infused Non- Infused Non-
















Protocol 1: Plasma plasminogen activator inhibitor type 1 (PAI-1) antigen and
activity concentrations during TNF-a infusion























































Figure4.3Protocol1:PlasmaconcentrationsofTNF-a(upperan l)andIL-6(lowerp el)intheinfused(closedcircl s)a dnon-infusearm (opencircles),followi g1h urintra-arterialinfusi nofTNF aat80g/min(leftp el),a d240ng/m(rightpanel).F<0.01(ANOVA)forall responsesexceptIL-6concentrationsinnon-infusedarm.F<0.05(ANOVA,infusedvsnon-infu edarm)follrespo ses.*P<0.05(pair df-te t;vsbaseline)
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Figure4.4Protocol1:lasmaconcentrationsft-PAantigen(s lidlin )nda ivity(d sh di )hinfus( lc rcles)anon-i fused arms(opencircles),f llowing1hourintr -arterialinfusiofTNF-t80ng/min( ftpanel),d240ng/min(ri htp el).P< .001(ANOVA)r responsesxceptnon-i fusedarmfoll wingTNF-a80ng/ iinfusion.?<0.001(ANOVA,infuvnon-infusedarm)f rlle o s.*F< .05 (paired/-test;v.?bas line)
4.4.2 Protocol 2: Effects of TNF-a on Endothelial Function
4.4.2.1 Cytokine Assays
Intra-arterial TNF-a infusion (80 ng/min) increased plasma TNF-a concentrations in
the infused and non-infused arm from 2±1 and 2±1 pg/mL to 561±108 and 15±1
pg/mL respectively (PO.OOl for both).
4.4.2.2 Haemodynamic Effects
Intra-arterial TNF-a or placebo infusion had no significant effects on heart rate,
blood pressure or basal forearm blood flow up to 2 hours after commencement of the
infusion (P=NS for both). Forearm blood flow increased in a dose-dependent
manner during bradykinin, acetylcholine and sodium nitroprusside infusions
(P<0.02; Figure 4.5). Compared to placebo, TNF-a infusion caused impaired
endothelium-dependent vasodilatation to bradykinin (P=0.029) and acetylcholine
(.P=0.01) but had no effect on endothelium-independent vasodilatation to sodium
nitroprusside (P=0.43; Figure 4.5).
4.4.2.3 Fibrinolytic Assays
Plasma t-PA antigen and activity concentrations increased from 3.5±0.6 to 8.5±1.6
ng/mL (P=0.004), and from 1.1+0.3 to 9.2+1.9 IU/mL (/M1.003) respectively after
60 min of TNF-a infusion. Again, this rise was sustained with an apparently stable
elevation between 2 and 3 hours i.e. 1 to 2 hours after cessation of TNF infusion
(Figure 4.6). Plasma t-PA antigen and activity concentrations were unchanged in the
non-infused arm and during placebo infusion.
Plasma t-PA antigen and activity concentrations increased in a dose-dependent
manner during bradykinin infusion (P<0.01). Compared to placebo, pre-treatment
with TNF-a resulted in higher plasma t-PA antigen and activity concentrations
during bradykinin infusion (11.3±0.8 vs 6.8±0.5 ng/mL and 16.5±3.9 vs 6.6±2.0
IU/mL at peak bradykinin dose; P<0.002) (Figure 4.6) and a marked augmentation in
the estimated net release of t-PA antigen and activity (P=0.018 and P=0.037
respectively; Figure 4.7). For the 30 min bradykinin dose-response infusion, pre-
treatment with TNF-a resulted in 83% and 132% increases in area under the curve
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Figure 4.5 Protocol 2: Infused (solid line) and non-infused (dashed line) forearm blood flow
responses to incremental doses of (a) bradykinin, (b) acetylcholine and (c) sodium nitroprusside
in subjects who were pre-treated with TNF-a (closed circles) or saline placebo (open circles).
F<0.02 (ANOVA) for all infused arm responses. *P<0.03 (ANOVA, TNF-a vs saline placebo)
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TNF-a 80 ng Saline Bradykinin Saline
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0 12 3
Time (hrs)
Figure 4.6 Protocol 2: Plasma concentrations of t-PA antigen (solid lines) and activity (dashed
lines) in infused (closed symbols) and non-infused arm (open symbols) following 1 hour intra¬
arterial infusion ofTNF-a (circles) or saline placebo (triangles) and during bradykinin infusion.
PO.OOl (ANOVA) for all infused arm responses. P<0.001 (ANOVA, infused vsnon-infused arm)
for all responses. P<0.001 (ANOVA, TNF-a vs saline placebo) for infused aim responses.

















































Figure 4.7 Protocol 2: Estimated net t-PA antigen (solid lines) and activity (dashed lines)
release during bradykinin infusion corrected for baseline t-PA concentrations in subjects who
were pre-treated with TNF-a (closed circles) or saline placebo (open circles).
P<0.001 (ANOVA) for all responses. *P<0.05 (ANOVA, TNF- a vs saline placebo).
tP.i0.O5 (paired f-test; TNE-a vs saline placebo) .
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4.5 Discussion
We have demonstrated for the first time that local intra-arterial TNF-a administration
can be used to generate an in vivo local vascular inflammatory model in humans that
is associated with endothelial dysfunction and a unique profile of endogenous t-PA
release. In contrast to IL-6 and LPS, TNF-a causes a slow-onset, sustained and
selective release of t-PA from the vascular endothelium in the absence of basal
vasomotor effects. Moreover, pre-treatment with TNF-a attenuates endothelium-
dependent vasodilatation, but augments acute bradykinin-induced t-PA release.
These findings indicate that TNF-a and acute vascular inflammation have complex
effects on endothelial function. Whilst the pro-fibrinolytic actions may reflect a
protective mechanism in acute inflammation, TNF-a also directly impairs
endothelium-dependent vasomotor responses.
4.5.1 Model of Local Vascular Inflammation
We have here developed a model of local vascular inflammation in vivo in man.
Using unilateral intra-brachial infusions, we achieved high local plasma TNF-a
concentrations that were comparable to the plasma concentrations seen in patients
with severe heart failure [McMurray et al 1991]. A direct local vascular and
endothelial inflammatory response was confirmed by the local rise in plasma IL-6
and t-PA concentrations. However, the fibrinolytic effects of TNF-a were not
mediated through IL-6 release since isolated IL-6 infusion had no effect on t-PA
release. Indeed, in pilot studies, we have found that high dose intra-brachial IL-6
infusion, sufficient to increase plasma IL-6 concentrations to >100 pg/mL, have also
failed to produce significant effects on forearm blood flow or t-PA release.
4.5.2 Effects of TNF-a on t-PA Release
The profile of t-PA release during local intra-arterial TNF-a administration is unique
and has not been previously described in vivo in man. Previous studies in healthy
volunteers have reported changes in plasma fibrinolytic and coagulation factors
during systemic TNF-a administration [van der Poll et al 1990, 1991]. TNF-a has
pleiotropic effects and may cause these effects through actions on specific tissues or
via secondary mediators released from organs such as the liver. In the present study,
we have assessed local peripheral vascular responses to direct intra-arterial TNF-a
and have shown that it causes selective endothelial t-PA release in the forearm
without demonstrable effects on plasma von Willebrand factor or PAI-1 antigen
concentrations. Although there was a modest rise in the IL-6 and t-PA concentrations
in the non-infused arm, this may represent overspill from the infused arm where the
concentrations increased by up to 20-fold. In contrast to previous systemic studies
[van der Poll et al 1990, 1991], subjects here remained asymptomatic and there was
no associated pyrexia consistent with the absence of a major systemic response.
We [Newby et al 1997a] and others [Brown et al 1999; Jern et al 1994] have
previously reported acute rapid t-PA release during intra-arterial substance P,
bradykinin and methacholine infusions. Using these agents, there is a near
instantaneous onset and offset of action with no sustained increase in t-PA release
after cessation of administration. Moreover, there is always an associated change in
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vascular tone and regional blood flow since these agents also cause vasodilatation. In
contrast, TNF-oc administration had no effect on basal blood flow, and caused a slow
onset and sustained release of t-PA that was not apparent until 20 min after
commencement of the infusion and continued for at least 3 hours after its cessation.
Endothelial cells synthesise and secrete t-PA both constitutively and facultatively.
The facultative release of t-PA occurs in response to stimulation by a number of
physiological agonists including thrombin and bradykinin [Tranquille & Emeis
1989]. This large and rapid release arises from the translocation of a dynamic
intracellular storage pool of t-PA [van den Eijnden-Schrauwen et al 1995; Tranquille
& Emeis 1989]. Agonists, such as bradykinin, are likely to stimulate t-PA release via
exocytosis of these granules because of the near instantaneous release of t-PA and
the ex vivo animal evidence that inhibition of protein synthesis by cycloheximide has
no effect on bradykinin-induced acute t-PA release [Tranquille & Emeis 1989]. The
profile of t-PA release seen with TNF-a is distinct from this pathway. Although the
mechanism has not been elucidated in our study, we speculate that it is likely to arise
from an increase in de novo t-PA synthesis and its constitutive release rather than
through the previously described facultative pathways. However, the initial
detectable rise in t-PA release seen at 20 min may be too early for protein synthesis
to occur. Other potential mechanisms such as activation of adherent leukocytes may
cause the generation of secondary mediators that enhance t-PA release.
Infusion ofTNF-a appears to cause an isolated increase in local t-PA release without
affecting other endothelium-derived fibrinolytic or haemostatic factors: namely PAI-
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1 and von Willebrand factor respectively. This suggests a selective and specific
action of TNF-a on the endothelium and forearm vascular bed. The fall in plasma
PAI-1 activity seen in the infused arm during high dose TNF-a infusion is likely to
reflect the magnitude of the local t-PA released and its immediate binding with PAI-
1. Although other workers have reported elevated plasma PAI-1 antigen
concentrations within three hours of systemic administration of TNF-a and
endotoxin [van der Poll et al 1991, 1997], we did not detect any changes in PAI-1
antigen concentrations. This suggests that cytokine-induced increases in PAI-1
release are mediated through a systemic mechanism, such as hepatic or adipocyte
synthesis, or produced in response to markedly elevated systemic plasma t-PA
concentrations.
4.5.3 Effects of TNF-a on Endothelium-dependent Vasomotion
Bhagat and Vallance have previously shown that TNF-a directly induced endothelial
dysfunction in the venous circulation of healthy volunteers [Bhagat & Vallance
1997]. We have extended these findings and demonstrated that TNF-a also impairs
resistance vessel endothelium-dependent vasodilatation, possibly through the
development of acute arterial endothelial injury. The effects of TNF-a were specific
for the endothelium since endothelium-independent vasodilatation to the nitric oxide
donor, sodium nitroprusside, was unaltered.
TNF-a may alter endothelial vasomotor responses through various mechanisms
including decreased constitutive nitric oxide synthase expression, increased inducible
nitric oxide synthase expression, and enhanced production of reactive oxygen species
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[Yoshizumi et al 1993; Matsubara et al 1986]. Further studies are needed to clarify
the precise mechanism, although it is tempting to speculate that TNF-a may, in part,
be responsible for inducing endothelial dysfunction in cardiovascular conditions
associated with inflammation.
4.5.4 Effects of TNF-a on Acute Endogenous Fibrinolysis
We have further demonstrated that TNF-a potentiates bradykinin-induced
endothelial t-PA release despite reduced endothelium-dependent vasodilatation. This
suggests that acute local vascular inflammation induces anti-thrombotic properties
that may represent an adaptive response to inhibit intravascular thrombus deposition
at sites of vascular injury. In particular, molecular and pharmacological evidence
supports the role of bradykinin B2 receptors in the acute phase of inflammation, and
upregulation of B2 receptors by TNF-a may account for the observed pro-
fibrinolytic effect. The augmented bradykinin response is also likely to reflect the
proposed increase in de novo t-PA production induced by TNF-a pre-treatment.
4.5.5 Clinical Implications
There is a consistent link between endothelial dysfunction and cardiovascular
disease, with impaired endothelium-dependent vasodilatation having been described
in atherosclerotic conditions [Zeiher et al 1991] and its associated risk factors, such
as hypercholesterolaemia [Chowienczyk et al 1992], The major findings of our
study will be particularly pertinent to cardiovascular conditions, such as acute
coronary syndromes and congestive heart failure, in which inflammation and
impaired endothelium-dependent vasodilatation occur.
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We have found that while TNF-a adversely affects certain aspects of endothelial
function, such as endothelium-dependent vasodilatation, it enhances other protective
mechanisms, such as the endogenous fibrinolytic capacity. This reflects the complex
and pleiotropic nature of TNF-a which functions as part of the normal host
surveillance mechanisms and responses to tissue injury. These diverse effects may
explain some of the contradictory findings of recent clinical studies. For example, in
patients with heart failure, TNF-a antagonism causes marked improvements in
endothelium-dependent vasodilatation [Fichtlscherer et al 2001] but has failed to
demonstrate clinical benefit in the RECOVER and RENAISSANCE randomised
controlled trials [Louis et al 2001]. Thus, the benefits of restoring endothelium-
dependent vasomotor function by TNF-a antagonism may be counterbalanced by
inhibiting other potentially beneficial effects such as enhancing acute endogenous t-
PA release.
4.5.6 Conclusions
This is the first study to delineate the direct effects of intra-arterial TNF-a
administration on local vascular tone and endogenous fibrinolysis in vivo in man. It
supports the crucial role of TNF-a in cardiovascular disease and provides evidence
for its direct and pleiotropic effects on the circulation and endogenous fibrinolysis.
Our findings have particular implications for the future development of effective
anti-cytokine and anti-inflammatory strategies in cardiovascular disease.
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Chapter 5
Endothelial Dysfunction In Patients With Recent
Myocardial Infarction And Hyperhomocysteinaemia
Effects of Vitamin Supplementation
Chia S, Wilson R, Ludlam CA, Webb DJ, Flapan AD, Newby DE.
Endothelial Dysfunction In Patients With Recent Myocardial Infarction And
Hyperhomocysteinemia. Effects ofVitamin Supplementation.
Clinical Science (Lond). 2005;108:65-72
5.1 Summary
Hyperhomocysteinaemia is a pro-thrombotic condition that may cause oxidative
endothelial injury and impair endogenous fibrinolysis. Vitamin supplementation
enhances endothelial function in hyperhomocysteinaemic patients, but responses in
patients with co-existing coronary artery disease have been variable. It is unknown
whether hyperhomocysteinaemia is associated with reduced fibrinolytic responses in
patients with coronary artery disease. The study aims were to test the hypothesis that
patients with recent myocardial infarction and hyperhomocysteinaemia have
impaired endothelium-dependent vasomotion and fibrinolysis that is rectified by
vitamin supplementation. From a cohort of one hundred and twenty patients
admitted with acute myocardial infarction, eighteen patients were recruited from the
upper («=9) and lower (n=9) plasma homocysteine quartiles into a randomised
double-blind placebo-controlled crossover trial. Following a 4-week course of
placebo or folate/cyanocobalamin/pyridoxine supplements, forearm blood flow
(FBF) was measured using venous occlusion plethysmography during intra-arterial
substance P (4-16 pmol/min), acetylcholine (5-20 pg/min) and sodium nitroprusside
(2-8 pg/min) infusions. All vasodilators caused dose-dependent increases in infused
FBF (P<0.05). Patients in the upper homocysteine quartile (16.8+2.9 vs 7.9±0.7
pmol/L; P=0.003) had reduced vasodilatation to acetylcholine (P=0.01) and
substance P (P<0.05) but not sodium nitroprusside. There were no differences in
substance P-induced tissue plasminogen activator (t-PA) release. Vitamin
supplementation increased serum folate and vitamin B12 concentrations (P<0.05) but
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did not significantly lower homocysteine, or affect FBF or fibrinolytic responses. In
patients with recent myocardial infarction, we conclude that hyperhomocysteinaemia
is associated with impaired endothelium-dependent vasodilatation but no alteration
in the acute fibrinolytic capacity. This endothelial vasomotor dysfunction is
unaltered by vitamin supplementation.
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5.2 Introduction
Several prospective and case-control studies have shown that elevated plasma
homocysteine concentrations are an independent risk factor for the development of
atherothrombotic vascular disease as well as a prognostic marker in ischaemic heart
disease [Clarke et al 1991; Stampfer et al 1992; Welch & Loscalzo 1998], Plasma
homocysteine concentrations are consistently higher in patients with premature
peripheral and cerebrovascular diseases [Boers et al 1985], and almost a third of
patients with premature coronary artery disease are found to have
hyperhomocysteinaemia [Clarke et al 1991]. In addition, apparently healthy men
with plasma homocysteine concentrations 12% above the upper limit of normal have
a threefold increased risk of acute myocardial infarction [Stampfer et al 1992], and in
patients with ischaemic heart disease there is an increased mortality associated with
plasma concentrations greater than 9 pmol/L [Nygard et al 1997].
The vascular endothelium plays a central role in the control of blood flow,
haemostasis and endogenous fibrinolysis [Vane et al 1990], and endothelial
dysfunction independently predicts cardiovascular events [Heitzer et al 2001; Halcox
et al 2002]. Although the mechanism of vascular damage is unclear, homocysteine
may promote atherogenesis through oxidative endothelial injury that is mediated by
cytotoxic reactive oxygen species [Stamler et al 1993; Lentz et al 1996; Loscalzo
1996; Kanani et al 1999]. Indeed, acute and chronic hyperhomocysteinaemia are
associated with impaired endothelium-dependent flow-mediated dilatation of the
brachial artery [Celermajer et al 1993a; Tawakol et al 1997; Kanani et al 1999].
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Hyperhomocysteinaemia is a prothrombotic state [Welch & Loscalzo 1998]. We
[Labinjoh et al 2001] and others [Freyburger et al 1997] have previously shown that
hyperhomocysteinaemia induced by oral methionine loading is associated with
alterations in endogenous fibrinolysis in healthy subjects and patients with premature
vascular disease. However, the influence of chronic hyperhomocysteinaemia on the
acute fibrinolytic capacity is unknown and is the subject of debate [Kuller & Evans
1998]. Interestingly, there is an association between plasma homocysteine and t-PA
antigen concentrations in stroke patients [Lindgren et al 1996].
Homocysteine is formed by the demethylation of methionine and is an intermediate
in the formation of cystathionine and cysteine (Figure 5.1). The trans-sulphuration of
homocysteine to cysteine is dependent upon pyridoxine (vitamin Bg), and the
demethylation of methionine upon cobalamin (vitamin B12) and folate (Ueland &
Refsum 1989; Kang et al 1992). Vitamin supplementation with folic acid, vitamin B6
and vitamin B12, is safe and may reduce plasma homocysteine concentrations
[Homocysteine Lowering Trialists' Collaboration 1998]. Whilst endothelial function
is enhanced following treatment with folic acid in patients with
hyperhomocysteinaemia [Woo et al 1999, 2002] and hypercholesterolemia [Verhaar
et al 1999], the response in patients with coronary artery disease has been variable
[Chambers et al 2000; Title et al 2000; Thambyrajah et al 2001; van Dijk et al 2001;
Doshi et al 2002]. Furthermore, it is not known whether elevated plasma
homocysteine concentrations are associated with reduced resistance vessel
vasomotor responses in patients with established coronary artery disease.
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The aim of this study was to test the hypotheses that,
(1) In patients with recent myocardial infarction, elevated plasma homocysteine
concentrations are associated with impaired endothelium-dependent
vasodilatation and endogenous fibrinolytic capacity, and
(2) Vitamin supplementation (with folic acid, vitamin B6 and vitamin B12) would


























One hundred and twenty patients admitted with an acute myocardial infarction were
recruited into the trial. Myocardial infarction was defined as typical ischaemic
cardiac pain associated with elevation of cardiac markers (greater than twice the
upper limit of normal) and electrocardiographic evidence of myocardial ischaemia.
Exclusion criteria were atrial fibrillation on warfarin therapy, impaired renal function
(serum creatinine >120 pmol/L), diabetes mellitus, requirement for folic acid
supplementation or pernicious anaemia. The written informed consent of each
subject was obtained before entry into the study. All studies were undertaken with
the approval of the local research ethics committee and in accordance with the
Declaration ofHelsinki (1996).
5.3.2 Drugs
Sucrose placebo tablets (Thornton & Ross Ltd, Huddersfield, Untied Kingdom) or
vitamin supplementation was given as a once daily oral preparation. Vitamin
supplementation was administered as a combination therapy of folic acid (5 mg;
Alpharma, Barnstaple, United Kingdom), vitamin B6 (pyridoxine 10 mg; B R
Pharma Ltd., Barnet, Untied Kingdom) and vitamin B12 (cyanocobalamin 100 fag;
Goldshield Pharmaceuticals Ltd., Croydon, Untied Kingdom).
Pharmaceutical-grade substance P (Clinalfa, Laufelfingen, Switzerland),
acetylcholine (Cibavision Ophthalmics, Southampton, UK) and sodium nitroprusside
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(David Bull Laboratories, Faulding, UK) were administered as intra-arterial infusions
following dissolution in saline. All solutions were freshly prepared on the day of
study.
5.3.3 Study Design (Figure 5.2)
Fasting plasma homocysteine concentrations were determined in all patients on days
5-7 following acute myocardial infarction [Egerton et al 1996]. From the upper and
lower plasma homocysteine concentration quartiles, 9 patients in each quartile were
recruited into a randomised, double blind, balanced-block, placebo-controlled
crossover trial at least 4 months after the index event. All patients received 2
separate 4-week courses of oral sucrose placebo or vitamin supplementation, and
attended at the end of each 4-week treatment period. On each study day, medications
were withheld and subjects attended after a 4-hour fast and rested recumbent in a
quiet, temperature-controlled room. Strain gauges and cuffs were applied, and the
brachial artery of the non-dominant arm was cannulated. Venous cannulae were
inserted into large subcutaneous veins of both arms. After 30 min equilibration with
saline infusion, intra-arterial substance P (4-16 pmol/min), acetylcholine (5-20
jig/min) and sodium nitroprusside (2-8 pg/min) were administered in a randomised
order for 6-10 min at each dose and separated by 20 min washout periods [Newby et
al 1997a, 1998a]. Venous samples were taken at baseline for determination of
plasma homocysteine and serum folate and vitamin B12 concentrations (as described
in Chapter 2.4.2.3), and during substance P infusion for fibrinolytic factor assays (as
described in Chapter 2.4.2.1).
96
Admittedwi h Acute Myocardial Infarction 120Patients screened
Days5-7After>4months4-w ekTre tm nt wsm Plasma Homocysteine Determination
StudyDesign
18 Patients recruited
Placebo tablets Vitamin— Supplementation



















Figure5.2 StudyDesign(upperanel)anfor rmstuprotocolintra-arteriadr gfulowan l).
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5.3.4 Data Analysis and Statistics
Estimated net t-PA antigen and activity release has been defined previously in
Chapter 2.5.2. Data were examined, where appropriate, by analysis of variance
(ANOVA) with repeated measures and two-tailed paired Student's t-test. All results
are expressed as mean (SEM) or mean (95% Confidence Interval, CI). Statistical
significance was assigned at the 5% level.
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5.4 Results
5.4.1 Baseline and Biochemical Characteristics
From the upper and lower plasma homocysteine quartiles, 18 patients (9 patients in
each quartile) were recruited into the randomised controlled trial. Apart from plasma
homocysteine concentrations (PO.Ol, /-test), which were significantly different by
design, there were no significant differences between the baseline clinical
characteristics or medical therapies in the two groups of patients (Tables 5.1 and
5.2).
All subjects tolerated placebo and vitamin supplementation and no side effects were
reported or noted. Serum folate and vitamin B12 concentrations were increased
following vitamin supplementation compared to placebo in both patients groups
(Table 5.2; PO.OOl and P<0.05 respectively, /-test), and plasma homocysteine
concentrations appeared to be reduced by »16% with active treatment in
hyperhomocysteinaemic patients, but this was not statistically significant (P=0.3, /-
test). Vitamin supplementation had no significant effects on heart rate, blood
pressure or basal forearm blood flow in either patient group.
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Table 5.1 Patients Characteristics
Patients in Upper Patients in Lower
Quartile (n=9) Quartile (n=9)
Age, years 54±2 5715
Sex (male:female) 9:0 8:1
Mean Arterial Pressure, mmHg 88±5 8612
Heart rate, bpm 59+2 5412












Anti-platelet therapy, (%) 9 (100) 9 (100)
P-adrenoceptor antagonists, (%) 8(89) 6(67)
ACE inhibitors, (%) 5 (56) 5(56)
HMG CoA reductase inhibitors, (%) 8(89) 7(77)
Risk Factors
Smokers, (%) 6(67) 3 (33)
History of hypertension, (%) 3 (33) 2(22)
Hypercholesterolemia, (%) 8(89) 7(77)









Serum Vitamin B12, ng/L
Upper Quartile Lower Quartile








*P<0.01 Upper v.s' Lower Quartile, /-test
tP<0.05 Vitamin v.s' placebo, /-test
f Upper limit of serum folate assay was 20 pg/L - 13 patients had concentrations
above this after supplementation and were taken as 20 pg/L.
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5.4.2 Endothelium-dependent Vasomotion
Substance P, acetylcholine and sodium nitroprusside caused dose-dependent
increases in blood flow of the infused forearm in both patient groups on each study
day (Figure 5.3; P<0.05, ANOVA). In comparison to patients in the lower quartile,
hyperhomocysteinaemic patients had significantly reduced forearm blood flow
responses to acetylcholine and substance P (Figure 5.3; P=0.01 and P<0.05
respectively, ANOVA), but there were no significant differences in the blood flow
responses to sodium nitroprusside (P=NS, ANOVA).
Neither endothelium-dependent nor -independent vasodilatation were significantly
influenced by vitamin treatment in either patient group (P=NS for all, ANOVA). For
the hyperhomocysteinaemic group, the mean difference for the response to vitamin
treatment at the peak dose was 1.1 mL/100 mL/min (95% CI, -0.8 to +2.9) for
substance P, 0.3 mL/100 mL/min (95% CI, -1.3 to +1.8) for acetylcholine, and -0.3
mL/100 mL/min (95% CI, -2.8 to +2.1) for sodium nitroprusside. For the lower
quartile group, the mean difference for the response to vitamin treatment at the peak
dose was 2.0 mL/100 mL/min (95% CI, -0.6 to +4.6) for substance P, -0.8 mL/100
mL/min (95% CI, -2.9 to +1.2) for acetylcholine, and 1.7 mL/100 mL/min (95% CI, -
2.8 to +6.2) for sodium nitroprusside.
5.4.3 Fibrinolytic Responses
Baseline plasma t-PA and PAI-1 antigen, and t-PA activity concentrations were
similar in both groups (Tables 5.3 and 5.4). Substance P caused dose-dependent
increases in plasma t-PA antigen and activity concentrations in the infused forearm
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of all patients (Tables 5.3 and 5.4; P<0.05 for both, ANOVA). The responses were
similar in both patient groups and were not influenced by vitamin supplementation
(P=NS, ANOVA). The mean difference of t-PA antigen release for the response to
vitamin supplementation at the peak substance P dose was -2.7 ng/100 mL/min (95%
CI, -15.5 to +10.2, P=NS, /-test) in the upper quartile group and -7.4 ng/100 mL/min
(95% CI, -24.3 to +9.5, P=NS, /-test) in the lower quartile group. Plasma PAI-1




Figure 5.3 Infused (solid line) and non-infused (dashed line) forearm blood flowresponses to
incremental doses of substance P (upper panel) and acetylcholine (lower panel) in patients in
upper (closed symbols) and lower quartiles (open symbols) following placebo (left panel) and
vitamin supplementation (right panel). P<0.05 (ANOVA, for all infused arm responses);
*^<0.05 (ANOVA, upper v.? lower quartile).
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t-PAantigen (ng/ml) Estimatedt-PA antigenrelease (ng/100mL/min) Nett-PAantigen release(AUC) PAI-1antigen (ng/mL)
Baseline 4 8 16 Baseline 4 8 16 Baseline 16
7.7±1.2 9.8±1.5 9.4+1.5 12.7±2.4* -1.1+0.7 4.0±3.2 4.7+4.1 21.6+6.7* 18.9±9.3 47±5 48±4
8.611.4 8.311.3 8.111.1 7.810.9 4814 5413
7.511.0 9.211.0 10.311.1 11.111.4* -1.211.1 5.413.4 11.114.2 18.915.2* 25.419.0 4414 4514
8.211.4 7.711.3 7.811.0 7.611.1 4815 5015
6.611.2 7.610.9 9.311.4 10.611.2* 0.410.7 3.412.2 9.813.7 24.318.4* 24.218.5 45114 44115
6.511.3 7.011.1 7.111.2 6.711.3 46114 44115
7.211.3 8.111.4 8.911.5 10.511.6 -0.310.4 1.411.5 5.912.4 15.613.9* 14.914.2 44111 46112
7.611.3 7.611.4 7.611.5 7.911.4 46113 49115
AUC=reaundercurveMean±SEM *P<0.05forallresponsesduringsubsta ceinf ion,ANOVA
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Baseline 4 8 16
0.9±0.2 1.7±0.6 1.9+0.7 3.1±0.8*
0.8+0.2 0.7+0.2 0.8+0.3 1.0+0.2
0.5+0.1 1.5+0.3 2.3+0.4 2.9+0.5*
0.6+0.1 0.8+0.1 0.7+0.2 0.8+0.2
1.0+0.3 2.5+0.8 2.8+0.9 3.9+1.1*
1.0+0.3 1.2+0.4 1.2+0.4 1.5+0.4
0.8+0.2 1.5+0.6 2.0+0.9 2.7+1.0*
0.8+0.3 0.9+0.2 0.9+0.2 0.9+0.2
Estimatedt-PA activityrelease (IU/100mL/min)
Baseline 4 8 16
0.0+0.1 2.5+1.4 3.6+1.6 9.3+2.9*
-0.1+0.1 3.1+1.3 7.0+1.7 11.7+3.6*
-0.0+0.1 6.0+2.1 8.4+3.6 16.4+6.9*






AUC=reaundercurve Mean±SEM *P<0.05forallresponsesduri gsubstanceinf ion,ANOVA
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5.5 Discussion
We have demonstrated that, in patients with a recent myocardial infarction, elevated
plasma homocysteine concentrations is associated with impaired endothelium-
dependent vasodilatation without affecting acute endogenous t-PA release. However,
vitamin supplementation failed to reduce plasma homocysteine concentrations or
improve endothelial vasomotor function.
5.5.1 Endothelium-dependent Vasodilatation
Recent studies have shown that homocysteine is associated with endothelial
dysfunction. Lentz et al [Lentz et al 1996] reported that in monkeys with diet-
induced hyperhomocysteinaemia, endothelium-dependent vasodilatation is impaired
in carotid artery rings in vitro and hindlimb resistance vessels in vivo. Celermajer et
al [Celermajer et al 1993a] documented abnormal endothelium-dependent
vasodilatation in children with severe hyperhomocysteinaemia due to homozygous
homocystinuria. Impaired endothelium-dependent vasodilatation is detected in
healthy subjects with acute hyperhomocysteinaemia induced by oral methionine
loading [Bellamy et al 1998; Kanani et al 1999], as well as in patients with chronic
hyperhomocysteinaemia who are free from clinical manifestations of atherosclerotic
disease [Tawakol et al 1997; Woo et al 1999]. In this study, we have extended these
findings to patients with recent myocardial infarction and demonstrated impaired
vasomotor responses in those with elevated plasma homocysteine concentrations.
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The vascular endothelium plays a critical role in the control of vascular homeostasis
by regulating vascular tone, platelet activity, coagulation and fibrinolysis [Vane et al
1990], and endothelial dysfunction is believed to be an early step in the pathogenesis
and pathophysiology of atherosclerosis. Although patients with coronary artery
disease typically demonstrate endothelial dysfunction, there is considerable
heterogeneity in the magnitude of impairment in individuals with similar risk factor
profiles. This is of particular interest because the extent of coronary as well as
peripheral endothelial dysfunction independently predicts the long-term risk of acute
cardiovascular events, including sudden cardiac death, myocardial infarction and
revascularisation procedures [Heitzer et al 2001; Halcox et al 2002]. Recent
prospective data have indicated that in patients with established coronary artery
disease, homocysteine is a significant predictor of mortality independent of other
traditional risk factors [Nygard et al 1997; Anderson et al 2000]. Our findings
therefore support the role of homocysteine as a secondary risk marker, suggesting
that this may be mediated through its effects on endothelial function.
5.5.2 Endogenous Fibrinolysis
Although homocysteine impairs endothelial vasomotor function, it does not appear to
have a major effect on endothelium-dependent fibrinolytic capacity, as both basal
and stimulated release of t-PA or PAI-1 were not significantly different between the
two patient groups. Hyperhomocysteinaemia is a prothrombotic condition and may
interfere with the anti-thrombotic and fibrinolytic mechanisms of the endothelium
and alter endothelial protein secretory pathways. Although endothelial cell-
associated t-PA activity is reduced in homocysteine-treated cells [Hajjar 1993], our
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present study failed to detect reduced fibrinolytic activity in vivo. This is consistent
with data indicating that homocysteine might perturb the intrinsic fibrinolytic
potential by reducing the functional binding site for t-PA without altering the
catalytic capability of t-PA or affecting t-PA synthesis and secretion [Hajjar 1993].
5.5.3 Effects of Vitamin Supplementation on Plasma Homocysteine
Previous studies have shown that treatment with folic acid and B vitamins can lower
plasma homocysteine concentrations to varying degree. The Homocysteine
Lowering Trialists' meta-analysis predicted a 20-30% reduction in homocysteine in
patients with plasma concentrations above 12 pmol/L taking folic acid, and a further
small additional effect with vitamin B12 but not B6 [Homocysteine Lowering
Trialists' Collaboration 1998]. However, a more modest 11-14% reduction is seen in
patients with coronary artery disease who consumed fortified breakfast cereals
[Malinow et al 1998; Bostom et al 2002], The limited homocysteine lowering seen in
our study was probably related to the relatively mild hyperhomocysteinaemia and
normal folate concentrations in our study population as well as the confounding
effects of dietary folate fortification.
5.5.4 Effects of Vitamin Supplementation on Endothelial Responses
We did not detect an improvement in endothelium-dependent vasodilatation or
endogenous fibrinolytic capacity following vitamin supplementation in this present
study. Although this may not be surprising in the absence of significant
homocysteine reduction, Doshi et al [Doshi et al 2002] have suggested that the acute
effects of folic acid on endothelial function may occur by a mechanism independent
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of homocysteine lowering. Moreover, the evidence on the beneficial effects of
vitamin supplementation on endothelial function is conflicting. Chambers et al
[Chambers et al 2000] and Title et al [Title et al 2000] demonstrated improved
endothelial function in patients with coronary artery disease following folic acid
treatment with or without vitamin B12. However, our findings are consistent with
those of other investigators who failed to detect improved endothelial function in a
similar patient population, in healthy siblings of patients with premature
atherothrombotic disease or in patients with renal impairment [Thambyrajah et al
2000, 2001; van Dijk et al 2001]. These contradictory findings may be related in part
to the presence of other cardiovascular risk factors such as hypertension or
hypercholesterolaemia, which may contribute to endothelial injury [Panza et al 1990;
Chowienczyk et al 1992] but would not be expected to respond to folic acid or B
vitamins. The vascular endothelium in patients with established coronary artery
disease may have also been subjected to chronic injury and therefore less responsive
to intervention. Furthermore, while the above studies adopted flow-mediated
dilatation as a non-invasive method of assessing conduit artery endothelial function,
in this and other studies, we have focussed on the function of endothelium within
resistance vessels [Newby et al 1997a, 2001]. Conduit artery and microvascular
endothelial cells have distinct phenotypic differences, and responses to mechanical
rather than pharmacological stimuli may also differ, and may contribute to the
apparent disparity in the responses.
There is further controversy regarding the effects of vitamin supplementation on
cardiovascular outcomes in patients undergoing percutaneous coronary intervention.
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Contrary to earlier reports that vitamin supplementation may reduce the rate of
restenosis and adverse outcomes following coronary artery angioplasty [Schnyder et
al 2001, 2002], Lange et al [Lange et al 2004] have recently demonstrated that folate
therapy following coronary stenting may increase the risk of in-stent restenosis. The
underlying mechanism for these findings remains uncertain, but it is possible that the
proliferative effects of folic acid may promote the growth of neointimal cells within
implanted stents. Therefore more prospective data are needed before any
recommendations can be made at all regarding the use of vitamin supplementation in
coronary artery disease.
5.5.5 Study Limitations
There are several potential limitations to our study. First, we studied peripheral
vascular function and thus these findings may not be directly applicable to other
vascular beds. However, endothelial dysfunction is often a generalised process, and
we have previously shown consistent vasomotor and endogenous fibrinolytic
responses between the forearm and coronary circulation [Newby et al 1999, 2001].
Second, the failure to improve endothelial function may be related to inadequate
treatment duration, although studies have suggested that a 4-6 week treatment with
folic acid can improve endothelial function [Verhaar et al 1999; Doshi et al 2002].
Third, the size of the study was small, and although it was powered to detect a 15-
20% difference in t-PA release or forearm vasodilatation, it is possible that a smaller
effect may have been missed. Fourth, we had used a placebo-controlled crossover
design and there was the possibility of a carry-over effect of the vitamin therapy on
endothelial function during placebo administration, despite a significant difference in
the serum concentrations of folate and vitamin B12. Finally, we cannot rule out that
homocysteine may be a marker of vascular injury rather than a mediator of
endothelial dysfunction, although experimental data support the direct role of
homocysteine in causing endothelial damage [Harker et al 1976; Hajjar 1993; Lentz
et al 1996].
5.5.6 Conclusion
We have demonstrated that endothelium-dependent vasodilatation but not
endogenous fibrinolysis is impaired in patients with recent myocardial infarction and
elevated plasma homocysteine, and that this endothelial vasomotor dysfunction is not
rectified by vitamin supplementation. These results provide further evidence for the
role of homocysteine in vascular damage, but do not support the hypothesis that
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Acute stent thrombosis and in-stent restenosis are serious complications of
percutaneous coronary intervention (PCI) and may be associated with vascular or
platelet abnormalities. We aimed to assess endothelium-dependent vasomotion,
endogenous fibrinolysis and platelet function in patients with acute stent thrombosis
or in-stent restenosis. Thirty-six subjects were enrolled into four groups: acute stent
thrombosis, in-stent restenosis, uncomplicated PCI with stent implantation, and
healthy matched controls. Forearm blood flow was measured using bilateral venous
occlusion plethysmography during intra-brachial acetylcholine, substance P and
sodium nitroprusside infusion. Venous blood samples were withdrawn for estimation
of plasma fibrinolytic variables and platelet aggregometry. Acetylcholine, substance
P and sodium nitroprusside caused dose-dependent increases in blood flow
(PO.OOl), and substance P caused a dose-dependent increase in tissue-type
plasminogen activator (t-PA) release (PO.OOl) in all groups. Thrombin, collagen,
adenosine diphosphate and the thromboxane A2 analogue, U46619, caused dose-
dependent platelet aggregation (PO.OOl) in all groups. There were no significant
between group differences in these responses except that, in keeping with aspirin
therapy, collagen induced platelet aggregation was impaired in patient groups
compared with healthy controls (PO.Ol). Post-hoc analysis demonstrated a
significant impairment of acute t-PA release in current smokers compared to non-
smokers (P<0.05). Despite previous reports suggesting impaired vascular function,
we conclude that endothelium-dependent vasomotion, endogenous fibrinolysis and
platelet aggregation do not appear to play a major role in the pathogenesis of acute
stent thrombosis or in-stent restenosis.
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6.2 Introduction
Coronary artery stent implantation is a valuable adjunct to percutaneous transluminal
coronary angioplasty. It reduces the absolute incidence of restenosis compared with
balloon angioplasty by 10% to 15% and improves 6-month event free survival by
10% to 20% [Fischman et al 1994; Serruys et al 1994], However, there is a small but
significant risk of acute coronary stent thrombosis [Cutlip et al 2001] and in-stent
restenosis that can have devastating consequences including myocardial infarction
and death [Albiero et al 1997]. Whilst procedure-related complications such as
persistent dissection, longer stent length and final minimal lumen diameter may be
implicated in some cases of stent thrombosis or restenosis [Cutlip et al 2001], no
underlying precipitant can be identified in many patients.
Stent thrombus formation is principally initiated by platelet aggregation which, in the
absence of effective endothelium-derived vasoregulation and fibrinolysis, is then
stabilised by the deposition of a fibrin mesh. The chronology of in-stent restenosis
has been described as early thrombosis, followed by thrombus endothelialisation and
infiltration by lymphocytes and monocytes, and finally smooth muscle cell migration
and proliferation within the resolving thrombus [Schwartz et al 1993; Miller et al
1996; Komatsu et al 1998]. The initiation, propagation and stabilisation of acute
stent thrombosis and in-stent restenosis are therefore dependent on several
components: platelet aggregation, endothelial function, coagulation and fibrinolysis.
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The purpose of the present study was to identify potential factors that may be
implicated in the predisposition to acute stent thrombosis or in-stent restenosis using
a case-control methodology. We assessed endothelium-dependent vasomotion,
platelet aggregation and the acute endogenous fibrinolytic capacity in patients who




Twenty-six patients who had undergone PCI with stent implantation at least 6
months previously and ten age-and sex-matched healthy control subjects were
recruited into the study. In the patient group, sixteen had developed complications of
acute stent thrombosis within 48 hours of stent implantation (n=6) or in-stent
restenosis within six months of intervention (n=10), and ten had no clinical evidence
of stent thrombosis or restenosis at least one year following the procedure. Patients
with procedural complications or sub-optimal stent insertion were excluded. All
patients received thieopyridine therapy for 4 weeks after undergoing PCI, and none
received a glycoprotein Ilb/IIIa receptor antagonist during the procedure.
The investigation was performed with the written informed consent of each subject
and the approval of the local research ethics committee, and conformed to the
principles outlined in the Declaration of Helsinki.
6.3.2 Drugs
Pharmaceutical-grade substance P (Clinalfa, Laufelfingen, Switzerland),
acetylcholine (Cibavision Ophthalmics, Southampton, United Kingdom) and sodium
nitroprusside (David Bull Laboratories, Faulding, United Kingdom) were
administered following dissolution in 0.9% saline. All solutions were freshly
prepared on the day of study.
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6.3.3 Study Design
Subjects attended on a single day following a 4-hour fast and then rested recumbent
throughout the study. Venous blood was collected at baseline for platelet
aggregometry and thrombophilia screen (as described in Chapters 2.4.2.5 and 2.4.3).
Strain gauges and cuffs were applied, and the brachial artery of the non-dominant
arm was cannulated under local anaesthesia. Venous cannulae were inserted into
large subcutaneous veins of both arms. After 30 min equilibration with saline
infusion, intra-arterial substance P was administered at 4, 8, 16 pmol/min,
acetylcholine at 5, 10, 20 pg/min and sodium nitroprusside at 2, 4, 8 pg/min for 10
min at each dose [Newby et al 1997a, 1998a]. The drugs were separated by 20 min
of saline infusion and administered in a randomised order. All infusions were given
at a constant infusion rate of 1 mL/min. Bilateral venous sampling was performed at
baseline and during infusion of each substance P dose for fibrinolytic factors assays
(as described in Chapter 2.4.2.1).
6.3.4 Data Analysis and Statistics
Estimated net t-PA antigen and activity release has been defined previously in
Chapter 2.5.2. Data were examined, where appropriate, by analysis of variance
(ANOVA) with repeated measures and two-tailed paired Student's /-test. All results




The baseline characteristics of all subjects are shown in Table 6.1. The patient
groups are matched for age, smoking history, diabetes mellitus, hypertension and
severity of coronary artery disease although there appeared to be a greater proportion
of female subjects in the acute stent thrombosis group. No significant abnormalities
were demonstrated in the thrombophilia screen in all study subjects.
6.4.2 Endothelium-dependent Vasomotion
There were no significant changes in heart rate, blood pressure and non-infused
forearm blood flow during drug infusion in all studies. Forearm blood flow increased
in a dose-dependent manner during substance P, acetylcholine, and sodium
nitroprusside infusions (P<0.05, ANOVA) (Table 6.2). However, there were no
significant differences between the four groups.
6.4.3 Endogenous Fibrinolysis
Compared to the non-infused arm, substance P caused dose-dependent increases in
plasma t-PA antigen and activity concentrations in the infused arm in all subjects
(P<0.05, Table 6.3), but this increase was not different between the groups. Patients
with acute stent thrombosis had an apparently higher t-PA antigen release but this did
not achieve statistical significance nor was this seen with t-PA activity. Post-hoc
analysis demonstrated a significant reduction of t-PA antigen and activity release in
current smokers compared to non-smokers (P<0.05, Figure 6.1).
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Table 6.1 Baseline Characteristics
Acute Stent In-stent Control Healthy
Thrombosis Restenosis Patients Subjects
(n=6) (n=10) (n=10) (n=10)
Sex (male:female) 2:4 9 : 1 8 : 2 9 : 1
Age 65 ±3 62 ±2 63 ±2 58 ±3
Current Smoker, % (n) 17(1) 20 (2) 20 (2) 20 (2)
Diabetes mellitus, % (n) 17(1) 30(3) 20 (2) 0(0)
Hypertension, % (n) 50(3) 60 (6) 30(3) 0(0)
Three-vessel disease, % (n) 33 (2) 30(3) 20 (2) 0(0)
Normal or mild left ventricular 84 (5) 90 (9) 80(8) 100(10)
impairment, % (n)
Average Stent Diameter, mm
3.3±0.2 3.0±0.1 3.2±0.2




100(6) 100(10) 100(10) 0(0)
(5-adrenoceptor antagonists, % (n) 50(3) 50(5) 60 (6) 0(0)
Angiotensin converting enzyme
inhibitors, % (n) 33 (2) 60 (6) 40 (4) 0(0)
Statins, % (n) 100 (6) 80 (8) 80 (8) 0(0)
Calcium channel blockers, % (n) 50(3) 60 (6) 10(1) 0(0)
OralNitrates, % (n) 50 (3) 30(3) 20 (2) 0(0)
Mean ± SEM
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Figure 6.1 Estimated net release oftissue plasminogen activator (t-PA) antigen and activity in
current smokers (black), ex-smokers (grey) and non-smokers (white). Lower panel represents
areaunder the curve (AUC) for the response. ANOVA for smoking status *P<0.01; tP<0.05.
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6.4.4 Platelet Aggregation
All patients were on aspirin therapy and had reduced platelet aggregation in response to
collagen (P<0.01) compared to healthy volunteers (Figure 6.2). There was no
significant difference in platelet aggregation to thrombin, collagen or U46619 between
the patient groups (Figure 6.2). However, platelet aggregation was increased in patients
with acute stent thrombosis in response to ADP compared to in-stent restenosis
(PO.OOl), although this was not significant when compared to the control group
(P=0.19).
124
V 5 1 1
-0.25 0.25 0.75 1.25
log[ADP] GxM)
log[collagen] (jig/ml) log[U46619] (jiM)
\ i i i i
2.3 2.5 2.7 2.9 3.1
log [Thrombin] (mil/ml)
Figure 6.2 Platelet aggregation in response to thrombin, collagen, ADP and U46619 in
patients with acute stent thrombosis (open inverted triangles), in-stent restenosis (closed
triangles) and uncomplicated PCI with stent implantation (open circles), and healthy




We have assessed three critical aspects of vascular function in patients who have
undergone PCI. We have found no evidence to indicate that endothelial vasomotor or
fibrinolytic function plays a major role in the pathogenesis of acute stent thrombosis or
in-stent restenosis. Moreover, in vitro platelet function appeared to be normal with little
evidence of alterations in platelet sensitivity to a number of agonists. In contrast, we
have been able to confirm our previous findings [Newby el al 1999, 2001] of the
marked inhibition of acute t-PA release in current smokers. We conclude that
endothelial and platelet functions do not appear to be major determinants of acute stent
thrombosis or in-stent restenosis.
6.5.1 Endothelial Vasomotor Function
The endothelium plays a critical role in the regulation of vasomotor tone [Furchgott &
Zawadzki 1980; Vanhoutte et al 1986] and its injury or dysfunction is an important
contributing factor in atherothrombosis. There is progressive impairment of
endothelium-dependent vasodilatation with the development of coronary atherosclerosis
[Zeiher et al 1991] and its associated risk factors, such as hypercholesterolemia
[Creager et al 1990], smoking [Newby et al 1999] and diabetes mellitus [Calver et al
1992], In this study, we assessed forearm blood flow following intra-arterial infusions
of the endothelium-dependent vasodilators, substance P and acetylcholine, and the
endothelium-independent vasodilator, sodium nitroprusside. We found no differences in
the forearm blood flow responses either between the patient groups or comparing the
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patient and healthy control groups. Given the absence of risk factors and clinically
evident disease, one would have anticipated greater endothelium-dependent
vasodilatation in the healthy control subjects. However, ageing has a marked effect on
the regulation of basal [Singh et al 2002] and stimulated [Egashira et al 1993]
endothelium-dependent vascular tone and we studied a predominantly elderly
population with a mean age of 62 years. Moreover, we recognise that subjects who are
apparently healthy in this age group commonly have subclinical atherosclerosis that
cannot be excluded in the absence of invasive investigation such as coronary
angiography.
6.5.2 Endogenous Fibrinolysis
The regulated release of endothelial t-PA is important mechanism in the defence against
intravascular thrombosis especially in the coronary circulation [Rosenberg & Aird
1999]. Several investigators have suggested that impaired endogenous fibrinolysis is
associated with restenosis after PCI [Huber et al 1992; Kirschstein et al 1989], and in
particular, a rise in plasma PAI-1 antigen concentrations [Sakata et al 1996]. In the
present study, we were unable to find any evidence of impaired endogenous fibrinolysis
in our patients with no apparent differences in plasma PAI-1 antigen concentrations or
acute endothelial t-PA release. However, when stratifying the subjects according to
smoking habit, post-hoc analysis indicated that acute t-PA release was markedly
impaired in smokers compared to non-smokers. This confirms our previous findings of
impaired t-PA release in smokers [Newby et al 1999, 2001] and gives support to our
conclusions that, rather than a lack of power, there appears to be no major impairment
of endogenous fibrinolysis in patients with acute stent thrombosis or in-stent restenosis.
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6.5.3 Platelet Function
Platelet adherence to the arterial wall occurs within minutes of arterial injury.
Pathological studies [Serruys et aI 1991] in both porcine coronary arteries and in human
saphenous vein grafts have shown that the earliest vascular response to stent
implantation is extensive platelet deposition. However, despite important reductions in
periprocedural events [The EPILOG Investigators 1997; The EPISTENT Investigators
1998], the glycoprotein Ilb/IIIa receptor antagonist abciximab does not reduce in-stent
restenosis [The ERASER Investigators 1999]. Consistent with this observation, platelet
aggregation in response to thrombin, ADP, the thromboxane A2 analogue U46619 or
collagen was unaffected in our study patient populations. In keeping with long-term
aspirin use, patients in all three groups demonstrated reduced collagen-dependent
platelet aggregation in comparison with healthy subjects. Again, this suggests that,
rather than a lack of power, there appears to be no major difference in platelet
aggregation in patients with acute stent thrombosis or in-stent restenosis. Although
assessment of platelet function should ideally be performed after aspirin has been
withheld for at least one week, aspirin use was unavoidable in our patient population.
6.5.4 Study Limitations
There are several potential limitations to our clinical study. First, complications from
stent implantation may arise due to procedural difficulties or suboptimal stent
deployment. However, we were careful to exclude such patients with overt technical
problems during the PCI procedure. Second, acute stent thrombosis is a fortunately rare
complication of PCI but this makes recruitment of such patients problematic. This is
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reflected in the modest number of patients with acute stent thrombosis in our study and
means that we lack sufficient power to address the influence of all the individual
variables associated with thrombosis, particularly given the higher proportion of female
patients in this group. This relatively low number of patients and subjects in the whole
study may also raise the potential possibility of a type II error. Third, the assessment in
our study is performed at least six months following PCI and stent implantation in order
to exclude the development of late restenosis in the control patient group. Whilst this
avoids the influence of acute confounding factors, we may have missed a transient
impairment in endothelial or platelet function. It is therefore possible that changes in
platelet behaviour, fibrinolysis or vascular function may occur in the acute phase of
stent-thrombosis and this study does not definitely exclude that changes in these factors
contribute to the development of acute stent thrombosis. Finally, we used a clinical
diagnosis of restenosis and cannot exclude a degree of subclinical angiographic
restenosis in the control patient group.
6.5.5 Conclusion
In conclusion, our study suggests that endothelial dysfunction, platelet aggregation and
endogenous fibrinolysis do not appear to play a major role in the pathogenesis of acute
stent thrombosis or in-stent restenosis.
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CHAPTER 7
Conclusions and Future Directions
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7.1 Vasomotor Effects of Inflammation
In a series of studies, we have explored the mechanistic links between inflammation,
endothelial dysfunction and endogenous fibrinolysis. We adopted a previously reported
model ofmild systemic inflammation [Hingorani et al 2000], and also further developed
a model of local vascular inflammation in vivo in man using unilateral intra-brachial
infusion of human recombinant tumour necrosis factor-a (TNF-a). This direct local
vascular and endothelial inflammatory response was confirmed by the local rise in
plasma interleukin-6 (IL-6) and tissue-type plasminogen activator (t-PA)
concentrations. We assessed the effects of systemic and local inflammatory stimuli on
endothelial vasomotor and fibrinolytic function and demonstrated their complex effects
on endothelial function.
7.1.1 Systemic Inflammation
In a randomised controlled study, we assessed the effects ofmild systemic inflammation
generated by Salmonella typhi vaccination on basal and stimulated forearm blood flow
following intra-arterial infusions of endothelium-dependent and -independent
vasodilators. Contrary to a previous report [Hingorani et al 2000], we demonstrated
that mild systemic inflammation was not associated with a major alteration in basal or
stimulated vasomotor tone in the forearm circulation.
7.1.2 Inflammatory Cytokines
Although isolated intra-arterial TNF-a, IL-6 or lipopolysaccharide (LPS) infusions had
no direct effect on basal forearm blood flow, we demonstrated that TNF-a impaired
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resistance vessel endothelium-dependent vasodilatation (to bradykinin and
acetylcholine), possibly through the development of acute arterial endothelial injury.
The effects of TNF-a were specific for the endothelium since endothelium-independent
vasodilatation to the nitric oxide donor, sodium nitroprusside, was unaltered.
TNF-a may alter endothelial vasomotor responses through various mechanisms
including decreased constitutive nitric oxide synthase expression, increased inducible
nitric oxide synthase (iNOS) expression, and enhanced production of reactive oxygen
species [Yoshizumi et al 1993; Matsubara et al 1986], although the precise mechanism
was not elucidated in our studies.
7.2 Endogenous Fibrinolytic Effects of Inflammation
7.2.1 Systemic Inflammation
Acute systemic inflammation generated by vaccination is associated with a two- to
threefold augmentation of endothelial bradykinin-induced t-PA release in the absence of
systemic haemodynamic effects. The inflammatory stimulus appears to potentiate
specifically the storage or acute release of t-PA rather than a generalised upregulation of
protein synthesis and basal secretion, as basal plasma concentrations of both t-PA and
plasminogen activator inhibitor type 1 (PAI-1) were not affected. This suggests that
mild acute inflammation may induce anti-thrombotic properties in the forearm
circulation, and may represent an adaptive response to inhibit intravascular thrombus
deposition under circumstances of acute vascular inflammation.
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7.2.2 Inflammatory Cytokines
Local intra-arterial TNF-a administration is associated with a unique profile of
endogenous t-PA release. In contrast to IL-6 and LPS, TNF-a causes a slow-onset,
sustained and selective release of t-PA from the vascular endothelium in the absence of
demonstrable effect on basal vasomotor tone or plasma von Willebrand factor or PAI-1
antigen concentrations. Moreover, pre-treatment with TNF-a augments acute
bradykinin-induced endothelial t-PA release despite reduced endothelium-dependent
vasodilatation.
7.2.3 Mechanisms of t-PA Release
Several authors [Newby et al 1997a; Brown et al 1999; Jern et al 1994] have previously
reported acute rapid t-PA release during intra-arterial substance P, bradykinin and
methacholine infusions, with a near instantaneous onset and offset of t-PA release but
with no sustained release after cessation of administration. In contrast, we have
demonstrated that TNF-a administration was associated with a unique profile of
endothelial t-PA release that was gradual and sustained.
Endothelial cells synthesise and secrete t-PA both constitutively and facultatively, and
the acute rapid facultative release of t-PA arises from the translocation of a dynamic
intracellular storage pool of t-PA [van den Eijnden-Schrauwen et al 1995; Tranquille &
Emeis 1989]. Agonists, such as substance P and bradykinin, are likely to stimulate t-PA
release via exocytosis of these granules because of the near instantaneous release of t-
PA. The profile of t-PA release seen with TNF-a is distinct from this pathway.
Although the exact mechanism was not elucidated in these studies, it is likely to arise
from an increase in de novo t-PA synthesis and its constitutive release rather than via
facultative pathways. However, the initial detectable rise in t-PA release may be too
early for protein synthesis to occur, and may be due to other potential mechanisms that
include the activation of adherent leukocytes to cause the generation of secondary
mediators that enhance t-PA release.
7.3 Vascular Inflammation and Fibrinolysis in Patients with Coronary Artery
Disease
Our studies have characterised the complex effects of local vascular inflammation in
healthy individuals. Patients with atherosclerosis [Ludmer et al 1986] as well as
vascular inflammation [Hingorani et al 2000; Kharbanda et al 2002] exhibit extensive
evidence of altered endothelial function, and previous studies have indicated a direct
association between elevated plasma fibrinolytic factors and markers of systemic
inflammation [Haverkate et al 1995]. This raises the question as to whether vascular
inflammation and underlying endothelial injury are causally related to the elevation in
plasma concentrations of endothelium-derived fibrinolytic factors in coronary artery
disease. Moreover, whilst increases in fibrinolytic factors may be expected to protect
against the propagation of intravascular thrombosis, it may also reflect widespread
endothelial dysfunction. A dominant pro-inflammatory vascular response that occurs
with acute plaque rupture may overwhelm any locally protective fibrinolytic effect.
Hence the clinical outcome of acute vascular inflammation may depend on the relative
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balance between the protective anti-thrombotic actions and potential plaque
destabilisation associated with increased vascular t-PA release.
We have confirmed the direct association between plasma t-PA, TNF-a and systemic
inflammation in healthy men and these studies will now be extended to investigate this
potential causal relationship in patients with stable coronary artery disease using this
acute local vascular inflammatory model. Understanding this link can in part explain the
adverse prognosis associated with increased plasma t-PA concentrations. Preliminary
data have replicated the findings that acute cytokine-induced arterial inflammation
impairs vasomotor function whilst enhancing endothelial t-PA release in patients with
coronary artery disease [Robinson et al 2005].
The association between local vascular inflammation and endogenous fibrinolysis in
patients with stable coronary artery disease is the subject of an on-going British Heart
Foundation Research Project (FS/2001/047, PG/2001/068).
7.4 Anti-cytokine Therapy in Heart Disease
Data from our work and other authors have illustrated the pivotal role inflammation
plays in the pathophysiology of endothelial dysfunction and atherothrombosis. Several
studies have also indicated that both the acute coronary syndromes and congestive heart
failure are acute and chronic inflammatory states respectively [Ross 1999], with
elevated plasma inflammatory mediator concentrations that correlate with disease
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severity [Biasucci et al 1996, 1999; McMurray 1991]. Therefore, inhibiting the actions
of these inflammatory mediators has been proposed to represent potential therapeutic
strategies.
7.4.1 Inhibition of Inflammatory Cytokine: TNF-a Antagonism
Tumour necrosis factor-a is implicated in the progression of ischaemic heart disease,
and we have shown in Chapter 4 that TNF-a directly impairs endothelial vasomotor
function, a finding common to both acute coronary syndromes and heart failure.
Tumour necrosis factor-a antagonism is possible with specific cytokine inhibitors.
Etanercept is a recombinant human TNF-a receptor that binds to soluble TNF-a and
functionally inactivates TNF-a by preventing it from binding to its receptors on cell
surface membranes [Deswal et al 1999; Mann et al 2004], Infliximab is a recombinant
immunoglobulin G1-k, human-murine chimeric monoclonal antibody that specifically
and potently binds to and neutralises soluble TNF-a and its membrane-bound precursor
[Chung et al 2003]. These drugs have been shown to be effective therapies for
psoriasis, ankylosing spondylitis, Crohn's disease and active rheumatoid arthritis when
conventional treatments are inadequate.
7.4.2 Anti-cytokine Therapy in Patients with Chronic Heart Failure
In experimental animals, exogenous administration and transgenic overexpression of
proinflammatory cytokines could mimic many aspects of the heart failure phenotype,
including left ventricular remodelling and reduced survival [Bozkurt et al 1998; Kubota
et al 1997; Sivasubramanian et al 2001], leading to the hypothesis that TNF-a
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antagonism may be beneficial in heart failure. Preclinical studies indeed demonstrated
that TNF-a antagonism reversed some of the deleterious effects of TNF-a in vitro and
in vivo, and preliminary clinical trials also showed an improvement in functional status
[Deswal et al 1999], increase in left ventricular ejection fraction and decrease in left
ventricular volumes [Bozkurt et al 2001] in patients with advanced heart failure.
Flowever, two recently published randomised placebo-controlled trials that evaluated
targeted anti-cytokine therapy in heart failure have failed to demonstrate any significant
benefit. The RENEWAL (Randomized Etanercept Worldwide Evaluation) [Mann et al
2004] and ATTACH (Anti-TNF Therapy Against Congestive Heart Failure) [Chung et
al 2003] trials assessed the effects of etanercept and infliximab on patients with
moderately severe chronic heart failure respectively and both have ruled out any
clinically relevant benefit on the rate of death or hospitalisation. On the contrary, high
doses (10 mg/kg) of infliximab may adversely affect the clinical condition of patients.
The reasons for the lack of benefit in heart failure are not clear. However, it is possible
that the short-term benefits of etanercept observed in earlier studies were offset in the
long term by the ability of etanercept to stabilise biologically active TNF-a, thereby
acting as TNF-a agonists. The observation that a higher proportion of patients who had
undergone longer duration of etanercept therapy had a worse outcome was consistent
with this view. A further possibility was that sustained lowering of TNF-a may have
led to the loss of the beneficial aspects of cytokine signalling which were necessary for
cardiovascular homeostasis in heart failure.
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7.4.3 Anti-cytokine Therapy in Patients with Acute Coronary Syndrome
The excessive mortality in acute coronary syndromes is attributed primarily to rupture
and thrombotic transformation of the atherosclerotic plaque. Inflammation is recognised
to be widespread in the coronary and remote vascular beds and plays a critical role in
plaque destabilisation and vulnerability. This is evident in the association of elevated
inflammatory marker concentrations in acute coronary syndromes with adverse
prognosis and recurrent coronary events [Biasucci et al 1996; Ridker et al 2000a].
Inhibiting the acute effects of cytokine-mediated inflammation may therefore reduce the
extent of endothelial injury. In our studies, we have demonstrated that TNF-a not only
modifies endothelial vasomotor function, but also augments fibrinolytic function. This
suggests that although TNF-a antagonism may improve vascular function in acute
inflammation, it can also potentially attenuate fibrinolytic function and aggravate
endothelial injury. This remains speculative, thus assessing the effects of TNF-a
antagonism on endothelial dysfunction will be of great interest in elucidating the role of
inflammation in acute coronary syndromes. Understanding the effects of cytokine
antagonism will help ascertain its potential as an alternative therapeutic avenue in
ischaemic heart disease.
The effect of TNF-a antagonism with etanercept in patients with unstable angina is the
subject of an on-going British Heart Foundation Research Project (PG/2001068).
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7.5 Endothelial Function and Endogenous Fibrinolysis in Ischaemic Heart
Disease
Endothelial dysfunction is now believed to be an early step in the pathogenesis and
pathophysiology of atherosclerosis. Several studies have assessed endothelium-
dependent vasomotion and demonstrated that endothelial function is impaired by a
number of risk factors associated with coronary artery disease, such as
hypercholesterolaemia [Chowienczyk et al 1992], diabetes mellitus [Calver et al 1992]
and smoking [Newby et al 1999], Recent data have also indicated that in patients with
established coronary artery disease, homocysteine is a significant predictor of mortality
independent of other traditional risk factors, and is associated with abnormal endothelial
vasomotion [Nygard et al 1997; Anderson et al 2000]. However, endothelial regulation
of vascular tone is but one of the many aspects of endothelial function and represents a
surrogate marker for the role of the endothelium in atherothrombosis. We have therefore
extended these investigations and assessed endothelial fibrinolytic capacity in patients
with hyperhomocysteinaemia, and in patients with thrombotic complications following
percutaneous coronary intervention (PCI) with stent implantation.
7.5.1 Patients with Recent Myocardial Infarction and Hyperhomocysteinaemia
In patients with recent myocardial infarction, we demonstrated that elevation of plasma
homocysteine concentration is associated with impaired endothelium-dependent
vasodilatation. However, endogenous fibrinolysis is not affected in this group of
patients. Furthermore, we have shown that this endothelial vasomotor dysfunction is not
rectified by vitamin supplementation with folate, pyridoxine and cyanocobalamin.
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These results provide further evidence for the role of homocysteine in vascular damage,
but do not support the hypothesis that vitamin supplementation improves endothelial
function in patients with established coronary artery disease.
Although earlier studies have reported a potential beneficial effect on cardiovascular
outcome following coronary angioplasty [Schnyder et al 2002], our findings are
consistent with recent data that showed vitamin supplementation failed to reduce
adverse events. On the contrary, folate therapy may paradoxically lead to an increase in
restenosis following coronary stent implantation [Lange et al 2004]. Thus the role of
vitamin therapy in cardiovascular disease remains controversial, and more prospective
data are needed before any recommendations can be made at all regarding the use of
vitamin supplementation in coronary artery disease. Several multi-centre randomised
controlled trials are under way and will provide useful answers to these issues within the
next few years [Mangoni & Jackson 2002],
7.5.2 Patients with Acute Stent Thrombosis or In-stent Restenosis
Acute stent thrombosis and in-stent restenosis are serious complications of percutaneous
coronary intervention and may be associated with vascular or platelet abnormalities. We
assessed three critical aspects of vascular function in patients who have undergone
percutaneous coronary intervention. We have found no evidence to indicate that
endothelial vasomotor or fibrinolytic function plays a major role in the pathogenesis of
acute stent thrombosis or in-stent restenosis. Moreover, in vitro platelet function
appeared to be normal with little evidence of alterations in platelet sensitivity to a
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number of agonists. We conclude that endothelial and platelet functions do not appear to
be major determinants of acute stent thrombosis or in-stent restenosis.
7.6 Future Directions
In addition to our work on the direct role of inflammation on endothelial function in
patients with heart disease, there are other regulatory mechanisms that contribute to the
control of vascular tone and fibrinolytic function. Furthermore, the release of
inflammatory mediators can lead to the activation of several vasoactive compounds that
can lead to vascular dysfunction evident in a number of inflammatory conditions
including sepsis and endotoxaemia. Regulatory mechanisms that may influence this
dynamic relationship between inflammation and endothelial function, as well as other
potential therapeutic candidates warrant further investigation.
7.6.1 Role ofGlucocorticoid Metabolism in Local Vascular Inflammation
Both inflammation and endothelial function are regulated by glucocorticoids. Elevated
circulating levels of glucocorticoids, for example in Cushing's syndrome, cause many
of the risk factors for cardiovascular disease, including hypertension, hyperglycaemia,
dyslipidaemia and central obesity. A long-term influence of glucocorticoids on
endogenous basal plasma fibrinolytic variables and von Willebrand factor has also been
described [Fatti et al 2000], The effects of glucocorticoid on vascular tone are well
established and include potentiation of vasoconstrictor responses to noradrenaline and
impaired endothelium-dependent vasodilatation [Ullian 1999].
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Glucocorticoids are classically anti-inflammatory and their role during physical stress is
to modify the acute inflammatory response to injury or infection, which they achieve by
diverse effects on humoral and cellular immunity. However, attempts to exploit these
actions in the blood vessel wall by administering short-term methylprednisolone therapy
in patients with unstable angina or following coronary artery stent insertion have failed
to show any beneficial effects [Azar et al 2000; Reimers et al 1998]. Conversely, such
therapy has been associated with a potentially adverse outcome. Whether these
disappointing clinical results reflect systemic or local intra-vascular effects of
glucocorticoids remain unclear. Within vessel walls, it is likely that there is a balance
between beneficial as well as adverse effects of glucocorticoid, which can be modulated
independent of their systemic effects. Thus local control of vascular responses to
glucocorticoid may potentially be more important than variations in systemic Cortisol
concentrations in influencing the progression of vascular lesions.
Glucocorticoid availability is regulated locally within the vascular wall by two key
enzymes, 1 ip-hydroxysteroid dehydrogenase types 1 and 2. Regulation of these
enzymes by TNF-a and other cytokines predicts that vascular inflammation is
associated with increased local glucocorticoid levels [Thieringer et al 2001; Heiniger et
al 2001], which may be important not only to counter-regulate the inflammatory
response, but also to mediate changes in endothelial function. Both these enzymes are
altered in subjects with cardiovascular risk factors, and animal models suggest that these
changes are reflected in the vessel wall [Takeda et al 1998]. Thus pathological
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variation in glucocorticoid availability may contribute to variations in response to
inflammation and hence to the development and progression of disease.
Understanding the mediation and counter-regulation of vascular inflammation by
glucocorticoids may allow new approaches to modifying the development and
progression of cardiovascular disease. Using murine and clinical models, the
determination of the effects of local glucocorticoid metabolism in the vascular wall on
local endothelial vasomotor and fibrinolytic function during vascular inflammation is
the subject of an ongoing British Heart Foundation Research Project
(PG/02/113/14452).
7.6.2 Anti-inflammatory Strategies
7.6.2.1 Lessons From Anti-cytokine Therapy in Heart Failure
In spite of promising preclinical and preliminary data suggesting that anti-TNF-a
strategies may be beneficial to cardiac performance, two recent large multi-centre
randomised controlled clinical studies in patients with symptomatic heart failure
(ATTACH, RENEWAL) have failed to demonstrate salutary benefits [Chung et al
2003; Mann et al 2004]. Although the reasons for these disappointing results were not
clear, one possible explanation was that while excessive levels of inflammatory
cytokines such as TNF-a may be harmful, reduced levels of these mediators may also
have adverse effects on the myocardium reflecting the involvement of these cytokines in
both maladaptive and adaptive responses [Meldrum 1998]. Our studies lend support to
this hypothesis, as we have shown that although acute vascular inflammation with TNF-
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a directly impairs endothelium-dependent vasodilatation, it also augments the acute
fibrinolytic capacity. This suggests that vascular inflammation may also have a
protective effect on the endothelium. Therefore, whilst anti-cytokine therapy has been
shown to improve vasomotor function, fibrinolytic function may potentially be
impaired, and could account in part for the lack of benefit in ATTACH and
RENEWAL. It is however not known whether targeting acute inflammation in acute
coronary syndromes would alter the balance of vasomotor and fibrinolytic function.
Therefore, exploring the interaction between endothelial function and acute vascular
inflammation in cardiovascular disease could help answer this conundrum, an issue
which would be addressed in an on-going British Heart Foundation Research Project
(PG/2001068).
7.6.2.2 Future Possibilities
Although results from the initial trials with etanercept and infliximab in heart failure
were disappointing, a better understanding of the complexities that might impinge on
the use of these agents may still hold some promise for the potential application of anti-
cytokine strategies in left ventricular dysfunction [Aukrust et al 2004; Feldman &
McTiernan 2004], Animal studies suggest that patient selection and possibly gender
may be important factors in identifying patients who are likely to benefit. It is also
probable that patients with earlier disease are more likely to achieve a beneficial long-
term response. Anti-TNF-a therapy might also be beneficial in patients with acute
decompensation in whom elevated cytokine levels produce a negative inotropic effect.
Thus these observations may serve as a platform for future evaluation of the efficacy of
anti-TNF-a therapies.
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7.6.2.3 Other Potential Immunomodulators
Apart from cytokine antagonists, other potential immunomodulators have been assessed
in congestive heart failure [Sliwa et al 1998]. Pentoxifylline, a xanthine-derived agent
known to inhibit the production of TNF-a, was the first immunomodulatory agent that
showed beneficial effects in heart failure patients. Although there was improvement in
symptoms and left ventricular dysfunction, this was not accompanied by a decrease in
plasma levels of Fas, a member of the TNF receptor super family. Thus the potential
benefits of pentoxifylline treatment may not be directly related to its anti-cytokine
properties. Thalidomide has both anti-inflammatory and anti-oncogenic properties, and
interestingly, was recently shown to improve left ventricular ejection fraction in
congestive heart failure, accompanied by a marked decrease in plasma levels of TNF-a
[Gullestad et al 2002]. However, its use will probably be limited by its anti-angiogenic
properties. Therapy with intravenous immunoglobulin has recently been shown to
enhance left ventricular ejection fraction in patients with congestive heart failure
independent of the aetiology [Gullestad et al 2001]. Intravenous immunoglobulin
influences the levels of several cytokines and cytokine modulators, resulting in down-
regulation of inflammatory responses. Clinical application of this therapy will require
further evaluation in large randomised trials.
Other potential candidates that have been investigated in animal models include
interleukin-10, interleukin-1 receptor antagonist as well as activators of peroxisome
proliferators activated receptors (PPPARs). Further research in this area will be
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required to identify the role of these important factors in the immunopathogenesis of
acute coronary syndromes and congestive heart failure.
7.6.3 Role of Inducible Nitric Oxide Synthase (iNOS) in Vasoregulation
Nitric oxide is a key mediator of vascular tone, and excessive synthesis of nitric oxide
by inducible nitric oxide synthase (iNOS), activated in response to inflammatory
mediators, may account for the vascular dysfunction evident in a number of
inflammatory conditions including sepsis and endotoxaemia. Congestive heart failure is
a chronic inflammatory disease with evidence of endothelium-dependent vasomotor
dysfunction and possible altered basal nitric oxide release. It is however not known
whether induction of iNOS in heart failure provides the link between inflammation and
the alteration in vascular tone.
Until recently, it has not been possible to distinguish clearly between constitutive and
inducible NOS activity due to the lack of specificity of inhibitors. N-(3-(Aminomethyl)
benzyl) acetamidine (1400W) is a novel selective inhibitor of human iNOS that has
recently become available for clinical use [Garvey et al 1997; Boer et al 2000], It
competes with L-arginine to bind irreversibly with iNOS and is at least 5000-fold more
selective for iNOS than eNOS making it the most selective iNOS inhibitor to date.
Therefore, assessing the contribution of functional iNOS activity to peripheral vascular
tone in patients with symptomatic heart failure will help us understand the role of nitric
oxide in vascular inflammation and endothelial dysfunction, and also identify potential
therapeutic targets.
The role of iNOS activity in the maintenance of peripheral vascular tone in severe
chronic heart failure is the subject of an on-going British Heart Foundation Research
Project (FS/2001049).
7.7 Clinical Relevance
A consistent link between endothelial dysfunction, inflammation and cardiovascular
disease is now well established, although most studies have focused predominantly on
endothelium-dependent vasomotor function. We have demonstrated that the interaction
between inflammation and endothelial function is more complex than previously
appreciated. In particular, the effects of TNF-a are diverse which may explain some of
the discordant clinical findings where marked improvement in endothelial vasomotion
following TNF-a antagonism failed to translate into clinical benefits in patients with
heart failure. Our findings therefore suggest that a more selective strategy in anti-
cytokine therapy would be necessary, an approach that is currently investigated in an
ongoing British Heart Foundation Research Project (PG/2001068).
The importance of endogenous fibrinolysis has been highlighted in recent studies, and
reduction in t-PA-activity or release is associated with increased incidence of major
adverse cardiac events in patients with acute coronary syndromes. Our studies indicated
that there were no significant association between fibrinolysis and
hyperhomocysteinaemia, coronary stent complications. However, the unique role of
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systemic inflammation and specifically, TNF-a has been identified. Therefore
modulating cytokine actions and their interaction with fibrinolysis may be critical in the
prevention of thrombotic coronary occlusion and myocardial ischaemia as well as in the
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Tissue Plasminogen Activator Release in Men
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OBJECTIVES The purpose of this study was to investigate in vivo the effects of acute systemic inflammation
on the endogenous fibrinolytic capacity in men.
BACKGROUND Systemic inflammation and endogenous fibrinolysis play a major role in the pathogenesis of
coronary artery disease. Although previous studies have shown impaired endothelium-
dependent vasomotor function, the effects of inflammation on the endothelial release of the
fibrinolytic factor tissue plasminogen activator (t-PA) are unknown.
METHODS In a double-blind randomized placebo-controlled crossover trial, we administered a mild
inflammatory stimulus, Salmonella typhi vaccine, or saline placebo to eight healthy men on
two separate occasions. Six hours after vaccination, blood flow and plasma fibrinolytic
variables were measured in both arms during intrabrachial infusions of bradykinin (40 to
1,000 pmol/min), acetylcholine (5 to 20 /ag/min), and sodium nitroprusside (2 to 8 /xg/min).
RESULTS Compared with placebo, the S. typhi vaccination caused a rise in white cell count (11.1 ± 0.5
X10 /I vs. 7.9 ± 0.8 X109/l; p = 0.004) and plasma interleukin-6 concentrations (6.9 ± 1.4
pg/ml vs. 1.6 ± 0.4 pg/ml; p = 0.01) in addition to a significant augmentation of t-PA
antigen (45 ± 9 ng/100 ml/min at peak dose vs. 24 ± 8 ng/100 ml/min at peak dose; p =
0.016, analysis of variance) and activity (104 ± 15 IU/100 ml/min vs. 54 ± 12 IU/100
ml/min; p = 0.006, analysis of variance) release during bradykinin infusion. Forearm blood
flow increased in a dose-dependent manner after bradykinin, acetylcholine and sodium
nitroprusside infusions (p < 0.001), but this was unaffected by vaccination.
CONCLUSIONS Our results showed that acute systemic inflammation augmented local forearm t-PA release
in men, which suggests that acute inflammation may invoke a protective response by
enhancing the acute endogenous fibrinolytic capacity in healthy men. Further studies are
needed to clarify whether this response is impaired in patients with cardiovascular
disease. (J Am Coll Cardiol 2003;41:333-9) © 2003 by the American College of
Cardiology Foundation
Atherosclerosis is widely recognized to be an inflammatory
disease process involving dysfunction of the vascular endo¬
thelium (1). This dysfunction leads to increased expression
of leukocyte adhesion molecules, reduced anticoagulant
activity and the release of growth factors, inflammatory
mediators, and cytokines. Continued inflammation leads to
leukocyte and monocyte recruitment, arterial damage, and
atherogenesis. Additional cycles of damage cause plaque
expansion and disruption that may lead to angina, crescendo
angina, and acute coronary syndromes.
Recent epidemiological and observational studies have
suggested a link between systemic inflammation and coro¬
nary artery disease. Infections by organisms, such as Chla¬
mydiapneumoniae and herpes simplex virus type 1, appear to
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be associated with an increased risk of cardiovascular mor¬
tality (2), and approximately 4% of bacteremic patients will
develop acute myocardial infarction within a month of
infection (3). Increased cardiovascular mortality also is seen
after respiratory tract infections (4), severe illnesses requir¬
ing intensive care (5), and surgery (6). Markers of systemic
inflammation, such as C-reactive protein (CRP), serum
amyloid A, interleukin-6 (IL-6), and tumor necrosis factor-
alpha, are elevated in patients with cardiovascular disease and
are associatedwith an adverse prognosis and recurrent coronary
events (7-10). Moreover, in previously healthy individuals,
elevated plasma CRP and IL-6 concentrations predict the
development ofcardiovascular disease (11-13). Indeed, reflect¬
ing its anti-inflammatory action, the preventative benefits of
aspirin in reducing cardiovascular risk are proportional to the
plasma CRP concentration (11). These data collectively sug¬
gest two patterns of association: a link between chronic
inflammation and the slow process of atherogenesis and an
association between acute systemic inflammation and a tran¬
siently increased risk of an acute cardiovascular event.
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Abbreviations and Acronyms
ANOVA = analysis of variance
CRP = C-reactive protein
FBF = forearm blood flow
IL-6 = interleukin-6
PAI-1 = plasminogen activator inhibitor type 1
t-PA = tissue-type plasminogen activator
The vascular endothelium plays a vital role in the control
of blood flow, hemostasis, fibrinolysis, and inflammation
(14), and impaired endothelial function is implicated in the
pathogenesis of coronary artery disease. Tissue plasminogen
activator (t-PA) is a fibrinolytic factor released from the
endothelium through the translocation of a dynamic intra¬
cellular storage pool and regulates the degradation of intra¬
vascular fibrin (15). If endogenous fibrinolysis is to be
effective, then the rapid mobilization of t-PA from the
endothelium is essential because thrombus dissolution is
much more effective if t-PA is incorporated during, rather
than after, thrombus formation (16,17). However, in the
presence of pro-inflammatory states or an imbalance in
endogenous fibrinolysis, such microthrombi may propagate,
ultimately leading to arterial occlusion and tissue infarction
(18).
We have previously described an in vivo model to assess
the acute release of t-PA in men (19) and demonstrated an
association between t-PA release and endothelial dysfunc¬
tion (20,21). Hingorani et al. (22) also have recently shown
that acute inflammation causes dysfunction ofendothelium-
dependent vasodilation in humans. However, there have
been no studies to assess directly the acute local fibrinolytic
capacity after acute inflammation. Therefore, the aim of this
study was to test the hypothesis that the acute fibrinolytic
capacity is altered by a mild systemic inflammatory response
generated by typhoid vaccination.
METHODS
Subjects. Eight healthy nonsmoking men between 20 and
27 years of age participated in the study, which was
undertaken with the approval of the local research ethics
committee and in accordance with the Declaration of
Helsinki. The written informed consent of each subject was
obtained before entry into the study.
All subjects were normotensive without a history of
diabetes mellitus and vascular or coronary artery disease.
None of the subjects had undergone typhoid vaccination in
the previous year or received vasoactive or nonsteroidal
anti-inflammatory drugs in the week before the study. All
subjects abstained from alcohol for 24 h and from food and
caffeine-containing drinks for at least 4 h before each
forearm study. All studies were performed in a quiet,
temperature-controlled room maintained at 22 to 25°C.
Drugs. An inflammatory response was generated with a
typhoid vaccination using Salmonella typhi capsular polysac¬
charide vaccine 0.025 mg (Typhim Vi, Aventis Pasteur
MSD, Berkshire, United Kingdom). Pharmaceutical-grade
bradykinin (Clinalfa, Laufelfingen, Switzerland), acetylcho¬
line (Clinalfa), and sodium nitroprusside (David Bull Lab¬
oratories, Faulding, United Kingdom) were administered
after dissolution in saline (0.9%; Baxter Healthcare Ltd.,
Berkshire, United Kingdom). All solutions were freshly
prepared on the day of study.
Hemodynamic measurements. Blood flow was measured
in both forearms by venous occlusion plethysmography
using mercury-in-silastic strain gauges as previously de¬
scribed (19-21). Blood pressure was monitored in the
noninfused arm at intervals throughout each study with a
semiautomated noninvasive oscillometric sphygmomanom¬
eter (Takeda UA 751, Takeda Medical Inc., Tokyo, Japan).
Blood sampling and assays. Blood was withdrawn simul¬
taneously from each arm and collected into acidified buff¬
ered citrate (Biopool Stabilyte, Umea, Sweden) for t-PA
assays and trisodium citrate, ethylene diamine tetraacetic
acid, and serum bead tubes (Monovette, Sarstedt, Niim-
brecht, Germany) for plasminogen activator inhibitor type 1
(PAI-1), IL-6, and CRP assays, respectively, and kept on
ice before being centrifuged at 2,000g- for 30 min at 4°C.
Platelet-free plasma was decanted and stored at — 80°C
before assay. Plasma t-PA, PAI-1, IL-6, and CRP concen¬
trations were determined using specific enzyme-linked im¬
munosorbent assays (Coaliza t-PA and Coaliza PAI-1,
Chromogenix AB, Molndal, Sweden; Quantikine human
IL-6 immunoassays, R&D Systems, United Kingdom;
C-reactive protein enzyme-linked immunosorbent assay,
Eurogenetics, Belgium, respectively) and plasma t-PA ac¬
tivity using a photometric method (Coatest t-PA, Chro¬
mogenix AB, Molndal, Sweden). Hematocrit and white cell
count were determined using an automated Coulter counter
(Beckman-Coulter ACt.8 Coulter Counter, High Wy¬
combe, United Kingdom).
Study design. The S. typhi vaccine or saline placebo were
injected into the deltoid muscle of each subject's dominant
arm at 8:30 AM in a randomized, balanced block, double-
blind crossover manner at least two weeks apart. Previous
reports have indicated that vaccination-induced endothelial
dysfunction is transient and resolves within 32 h (22).
Six hours after vaccination and after a 4-h fast, strain
gauges and cuffs were applied. The brachial artery of each
subject's nondominant arm was cannulated with a 27-
standard wire gauge steel needle (Cooper's Needle Works
Ltd., Birmingham, United Kingdom) under 1% lidocaine
(Xylocaine; Astra Pharmaceuticals, Wayne Pennsylvania)
local anesthesia and attached to a 16-gauge epidural catheter
(Portex Ltd., Hythe, United Kingdom). Patency was main¬
tained by infusion of saline via a MS2000 syringe infusion
pump (Graesby Medical, Watford, United Kingdom). Ve¬
nous 17-gauge cannulae were inserted into large subcuta¬
neous veins of the antecubital fossae of both arms. Forearm
blood flow (FBF) was measured every 6 to 10 min. After 30
min of equilibration with saline infusion, intra-arterial
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bradykinin was administered at 40, 200, and 1,000 pmol/
min for 10 min at each dose, acetylcholine at 5, 10, and 20
jttg/min, and sodium nitroprusside at 2, 4, and 8 /xg/min for
6 min at each dose. The drugs were separated by 20 min of
saline infusion and administered in a randomized order that
was kept constant for each individual. Venous samples were
taken at baseline and during infusion of each bradykinin
dose but not during sodium nitroprusside or acetylcholine
infusion because they do not affect plasma t-PA or PAI-1
concentrations in this forearm model (19,23). White cell
count, hematocrit, IL-6, and CRP were determined 6 h
after vaccination and hematocrit was repeated at the end of
the forearm study.
Data analysis and statistics. Plethysmographic data were
extracted from the chart data files, and FBF was calculated
for individual venous occlusion cuff inflations by use of a
template spreadsheet (Microsoft Excel 97). Recordings for
the first 60 s after wrist cuff inflation were not used because
of the variability in blood flow this initial inflation causes.
The last five linear plethysmographic recordings in each
3-min measurement period were calculated and averaged for
each arm. The estimated net release of t-PA antigen and
activity was defined previously (19) as the product of the
infused forearm plasma flow (based on the mean hematocrit
and the infused FBF) and the concentration difference
between the infused ([t-PA]inf) and noninfused ([t-
PA]noninf) arms and is shown as follows:
Estimated net t-PA release = FBF X (1 — Hct)
X ([t-PA],n/ - [t-PA],,,;,^
The area under the curve (AUC) was calculated for
estimated net t-PA antigen and activity release during
bradykinin infusion.
Data were examined, where appropriate, by analysis of
variance (ANOVA) with repeated measures and two-tailed
paired Student / test using Excel 97 (Microsoft). All results
are expressed as mean ± SEM. Statistical significance was
assigned at the 5% level.
RESULTS
Inflammatory response. All subjects remained healthy
throughout the study and reported no localized discomfort
or systemic side effects after vaccination. Compared with
placebo injection, there was a marked elevation in white cell
count (11.1 ± 0.5 X 109/1 vs. 7.9 ± 0.8 X 109/1; p = 0.004,
/ test) and plasma IL-6 concentrations (6.9 ± 1.4 pg/ml vs.
1.6 ± 0.4 pg/ml; p = 0.01, / test) 6 h after typhoid
vaccination, although serum CRP concentrations (1.8 ± 1.2
jug/ml vs. 1.0 ± 0.6 jug/ml; p = NS, / test) and temperature
(p = NS, /-test) (Table 1) were unchanged.
Assessment of endothelium-dependent vasomotion.
There were no significant effects of vaccination on heart
rate, blood pressure, or baseline FBF. There were no
significant changes in heart rate, blood pressure, or nonin¬
fused FBF during drug infusion on either study day.
Table 1. Baseline Characteristics
Vaccination Placebo
Temperature (°C) 37.0 ± 0.1 36.9 ± 0.1
Systolic blood pressure (mm Hg) 131 ± 4 129 ± 5
Diastolic blood pressure (mm Hg) 62 ± 3 66 ± 3
Heart rate (beats/min) 57 ± 1 57 ±2
Hematocrit 0.41 ± 0.01 0.41 ± 0.01
Infused forearm blood flow 3.0 ± 0.6 2.8 ± 0.6
(ml/100 ml tissue/min)
Forearm blood flow increased in a dose-dependent manner
during bradykinin, acetylcholine, and sodium nitroprusside
infusions (p < 0.001, ANOVA), but there was no change in
the blood flow response after vaccination (p = NS,
ANOVA) (Fig. 1).
Assessment of fibrinolytic activity. After vaccination,
there were no changes in baseline plasma t-PA and PAI-1
antigen concentrations nor plasma t-PA activity concentra¬
tion. Compared with the noninfused arm, bradykinin
caused dose-dependent increases in plasma t-PA antigen
and activity (p < 0.001 for both, ANOVA) concentrations
in the infused arm that were significantly higher after
vaccination (p < 0.03, ANOVA) (Table 2). The S. typhi
vaccination caused a significant augmentation in the net
release of t-PA antigen (45 ± 9 vs. 24 ± 8 ng/100 ml/min
at peak dose; p = 0.016, ANOVA) and activity (104 ± 15
vs. 54 ± 12 IU/100 ml/min; p = 0.006, ANOVA) during
bradykinin infusion, and a two- to threefold increase in the
AUC for net t-PA antigen (37 ± 12 ng/100 ml/min vs. 13
± 9 ng/100 ml/min; p = 0.14, / test) and activity (70 ± 12
IU/100 ml/min vs. 36 ± 8 IU/100 ml/min; p = 0.037, /
test) release compared with placebo (Fig. 2). Plasma PAI-1
£ o I I I i I
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Figure 1. Infused forearm blood flow during bradykinin (circles), acetyl¬
choline (triangles), and sodium nitroprusside (squares) infusions in sub¬
jects who were administered typhoid vaccination (closed symbols) and
saline placebo (open symbols). Analysis of variance, p < 0.001 for all
(dose-response).
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Table 2. Plasma t-PA and PAI-1 Antigen and t-PA Activity/Concentrations
Bradykinin Infusion
(pmol/min)
Typhoid Vaccination Placebo Injection
0 40 200 1,000 0 40 200 1,000
t-PA antigen (ng/ml)
Noninfused arm 2.3 ± 0.3 2.7 ± 0.5 2.9 ± 0.5 3.5 ± 0.5 2.8 ± 0.6 3.2 ± 0.8 3.6 ± 0.7 4.4 ± 0.8
Infused arm 3.0 ± 0.5 3.2 ± 0.5 3.9 ± 0.5 6.7 ± 0.7* 2.8 ± 0.6 3.0 ± 0.7 3.8 ± 0.8 6.1 ± 0.9*
Concentration differences 0.7 ± 0.4 0.5 ± 0.4 1.0 ± 0.6 3.3 ± 0.8§ 0.0 ± 0.2 -0.1 ± 0.4 0.2 ± 0.3 1.7 ± 0.5§4
between forearms
t-PA activity (IU/ml)
Noninfused arm 1.3 ± 0.2 1.4 ± 0.2 1.7 ± 0.2 2.6 ± 0.4 1.1 ± 0.2 1.2 ± 0.2 1.5 ± 0.2 2.5 ± 0.5
Infused arm 1.1 ± 0.2 1.6 ± 0.3 3.3 ± 0.6 9.9 ± 1.2* 1.0 ± 0.2 1.3 ± 0.2 2.5 ± 0.5 6.5 ± 1.3*f
Concentration differences -0.2 ± 0.1 0.2 ± 0.1 1.6 ± 0.5 7.4 ± 1.0* -0.1 ± 0.1 0.1 ± 0.1 0.9 ± 0.5 3.9 ± 1.0*4
between forearms
PAI antigen (ng/mi)
Noninfused arm 17 ± 4 16 ± 2 15 ± 2 16 ± 3
Infused arm 18 ±5 14 ± 2 16 ± 3 15 ± 2
Concentration differences 1.3 ± 2.4 -1.2 ± 1.3 0.4 ± 0.8 -0.5 ± 1.7
between forearms
One-way analysis of variance (ANOVA): *p < 0.001, §p < 0.01 (dose-response). Two-way ANOVA: tp = 0.026, +p < 0.01 (vaccination vs placebo); p < 0.001 for all
(dose-response).
PAI-1 = plasminogen activator inhibitor type 1; t-PA = tissue-type plasminogen activator.
concentrations did not change during bradykinin infusion
(Table 2).
DISCUSSION
We have demonstrated that an acute mild systemic inflam¬
matory stimulus causes potentiation of bradykinin-induced
t-PA release. We conclude that acute systemic inflamma¬
tion enhances local endothelial t-PA release in men. This
may reflect an adaptive mechanism of the vascular endothe¬
lium to augment its fibrinolytic response under circum¬
stances of acute inflammation.
Endothelium-dependent vasomotion. We assessed basal
and stimulated FBF after intra-arterial infusions of the
endothelium-dependent vasodilators bradykinin and acetyl¬
choline, and the endothelium-independent vasodilator so¬
dium nitroprusside 6 to 8 h after vaccination. Bradykinin
and acetylcholine have both been widely used to investigate
the function of vascular endothelium. Impaired arterial
vasodilatory response to endothelium-dependent agonists
has been shown in patients with hypertension (24), diabetes
mellitus (25), and hypercholesterolemia (26). Hingorani et
al. (22) have previously reported that S. typhi vaccinations
generated an inflammatory response that was associated
with a temporary suppression of endothelium-dependent
vasodilation in the forearm circulation of six healthy volun¬
teers. Although we applied a similar protocol to their study
and included overlapping doses of both bradykinin and
acetylcholine, we did not replicate their findings of impaired
forearm endothelium-dependent vasodilation after vaccina¬
tion at 6 to 8 h (Fig. 1). This discrepancy may be partly
explained by the variability in vasodilatory response with
acetylcholine (27) and the higher maximal vasodilator dose
used in our studies, although we used a larger sample size
and a double-blind, randomized, placebo-controlled, cross¬
over trial.
Endogenous fibrinolysis. Tissue plasminogen activator,
the key enzyme in the initiation of fibrinolysis, is synthe¬
sized in endothelial cells and stored in small, dense vesicles.
It is secreted both basally and in response to thrombin and
several vasoactive agents through a calcium-dependent and
G protein-coupled pathway (28). The regulated endogenous
release of t-PA plays a major role in the defense against
intravascular thrombosis, especially in the coronary circula¬
tion (18). Bradykinin is a vasoactive peptide and potent
stimulant for the acute release of t-PA from the vasculature
(23,29-31) and is produced locally through activation of the
kallikrein-kinin system on the surface of endothelial cells
(32). In the present study, bradykinin-induced t-PA antigen
and activity release were augmented two to threefold after
typhoid vaccination in the absence of systemic hemody¬
namic effects (Fig. 2).
The underlying mechanisms for our findings are un¬
known. Inflammation is recognized to induce a protective
response towards tissue injury, and it functions as part of
normal host surveillance mechanisms. Various compounds
associated with the inflammatory response, including hista¬
mine, thrombin and endotoxin, have been shown to increase
cellular t-PA transcription and expression (33,34). How¬
ever, we did not observe an increase in the basal plasma
concentrations of either t-PA or PAI-1. The inflammatory
stimulus, therefore, appears to augment specifically the
storage or acute release of t-PA rather than a generalized
upregulation of protein synthesis and basal secretion. This
may be mediated by pro-inflammatory cytokines, such as
IL-6, that modulate cellular activation, leading to alter¬
ations in endothelial function. In particular, molecular and
pharmacologic evidence supports the role of bradykinin B2
receptors in the acute phase of inflammation, and upregu¬
lation of B2 receptors may account for the potentiation of
bradykinin-induced t-PA release.
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Figure 2. Estimated net release of tissue-type plasminogen activator (t-PA) antigen (solid line) and activity (dotted line) in subjects who were administered
typhoid vaccination (closed circles and bars) and saline placebo (open circles and bars). Lower panel represents area under the curve for the response.
Analysis of variance, *p < 0.0S; fp = 0.006 (vaccination vs. placebo); t test, 4p < 0.05 (vaccination vs. placebo).
Clinical implications. The augmentation of acute t-PA
release after typhoid vaccination suggests that mild acute
inflammation may induce antithrombotic properties in the
forearm circulation. This may represent an adaptive re¬
sponse to inhibit intravascular thrombus deposition under
circumstances of acute vascular inflammation. This obser¬
vation is consistent with the increase in endogenous fibri¬
nolysis in systemic inflammation induced by experimental
endotoxemia in healthy subjects (35). However, in suscep¬
tible individuals, such as those with ischemic heart disease
and chronic inflammation, this adaptive and protective
acute response may fail or become depleted, leading to
thrombus propagation and vessel occlusion. The fibrinolytic
response to acute systemic inflammation in patients with
ischemic heart disease and the influence of anti¬
inflammatory therapies, such as aspirin, now needs to be
established. Indeed, recent evidence has suggested that
preventative treatment with aspirin is able to reverse
inflammation-induced endothelial dysfunction (36).
Epidemiologic studies have demonstrated an association
between the risk of future cardiovascular events and both
plasma inflammatory markers (11-13) and fibrinolytic fac¬
tors (37). Therefore, the current observations are consistent
with the suggestion that elevated plasma t-PA concentra-
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tions may provide a marker of vascular inflammation.
Irrespective of whether these common associations are
partly or wholly explained by inflammation-induced t-PA
release, understanding the regulation of both acute and
chronic t-PA release will have important clinical implica¬
tions and may help to develop more effective strategies in
the management of atherosclerotic disease.
Study limitations. There are some limitations to our study.
We administered the typhoid vaccination in the deltoid
muscle of each subject's dominant arm rather than the
gluteus muscle. However, because blood flow was assessed
in the forearm and intra-arterial vasodilators were adminis¬
tered in the contralateral nondominant arm, it would be
highly unlikely that the site of vaccination would have
affected the response in the infused forearm. It would also
have been preferable to assess the vascular responses imme¬
diately before and 6 to 8 h after vaccination on the same day.
However, this would require repeated arterial cannulations
within the same day, and we have previously demonstrated
that endothelium-dependent vasodilation and t-PA release
is reproducible when performed at least one week apart
(38.39). The study subjects were healthy and young, and we
acknowledge that the response in older subjects may be
quite different. Finally, we studied peripheral vascular func¬
tion; therefore, these findings may not be directly applicable
to other vascular beds. However, endothelial dysfunction is
often a generalized process, and we have previously shown
(21.40) consistent endogenous fibrinolytic responses be¬
tween the forearm and coronary circulation.
Conclusions. We have demonstrated that mild inflamma¬
tion generated by typhoid vaccination results in a significant
potentiation of bradykinin-induced t-PA release from the
vascular endothelium. Additional studies are now required
to determine the underlying mechanism and to assess the
effects of acute and chronic inflammation on endogenous
fibrinolysis in health and disease.
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Intra-Arterial Tumor Necrosis Factor-a: Impairs
Endothelium-Dependent Vasodilatation and Stimulates Local
Tissue Plasminogen Activator Release in Humans
Stanley Chia, Motaz Qadan, Richard Newton, Christopher A. Ludlam,
Keith A.A. Fox, David E. Newby
Objective—Inflammation contributes to the pathogenesis of cardiovascular disease, potentially through the actions of
proinflammatory cytokines. We assessed the direct effects of local intra-arterial tumor necrosis factor-a (TNF-a),
interleukin-6, and endotoxin on blood flow and endogenous tissue plasminogen activator (t-PA) release in vivo in
humans.
Methods and Results—In a double-blind, randomized, placebo-controlled trial, blood flow, plasma cytokine, and
fibrinolytic parameters were measured using venous occlusion plethysmography and blood sampling. Ten subjects
received intrabrachial TNF-a, interleukin-6, and endotoxin infusions, and 8 additional subjects received intrabrachial
infusions of bradykinin, acetylcholine, and sodium nitroprusside after pretreatment with TNF-a. TNF-a but not
interleukin-6, endotoxin, or placebo caused a gradual and sustained --20-fold increase in plasma t-PA concentrations
(P<0.001) that was associated with elevated plasma interleukin-6 concentrations (P<0.05) but without an effect on
blood flow or plasminogen activator inhibitor type 1 antigen. Compared with placebo, TNF-a pretreatment impaired
bradykinin- and acetylcholine-induced vasodilatation (P<0.03) and resulted in a doubling of bradykinin-induced t-PA
release (P<0.05).
Conclusions Intra-arterial TNF-a causes an acute local vascular inflammation that is associated with impaired
endothelium-dependent vasomotion as well as a sustained and substantial increase in endothelial t-PA release. TNF-a
has potentially both adverse vasomotor and beneficial profibrinolytic effects on endothelial function. (Arterioscler
Thromb Vase Biol. 2003;23:695-701.)
Key Words: cytokines ■ endothelium ■ fibrinolysis ■ inflammation ■ vasodilatation
There is emerging evidence that systemic inflammationplays a major role in the pathogenesis of cardiovascular
disease. The proinflammatory cytokines, tumor necrosis
factor-a (TNF-a) and interleukin-6 (IL-6) in particular, have
been implicated in the initiation and maintenance of systemic
and vascular inflammation associated with atherosclerosis
and coronary artery disease. Indeed, plasma concentrations of
these cytokines are elevated in patients with ischemic heart
disease1-2 and have been shown to predict the future risk of
myocardial infarction in apparently healthy individuals.3
The vascular endothelium plays a vital role in the control
of blood flow, hemostasis, fibrinolysis, and inflammation,
and changes in endothelial function may underlie the associ¬
ation between inflammation and the risk of cardiovascular
disease.
Tissue plasminogen activator (t-PA) is a fibrinolytic factor
released from the endothelium and lyses intravascular fibrin.4
If endogenous fibrinolysis is to be effective, then the rapid
mobilization of t-PA from the endothelium is essential,
because thrombus dissolution is much more effective if t-PA
is incorporated during, rather than after, thrombus formation.5
However, in the presence of proinflammatory states or an
imbalance in endogenous fibrinolysis, intravascular thrombus
may propagate, ultimately leading to arterial occlusion and
tissue infarction.6
TNF-a and endotoxin have been reported to induce local
vascular inflammation and impair endothelium-dependent
vasodilatation in the venous circulation ofhumans.7 Although
mild systemic inflammation has also been shown to alter
endothelial function,8 the underlying mechanisms for these
observations have not been elucidated, and the direct in vivo
effects of cytokines and inflammatory stimuli on local arterial
endothelial vasomotor and fibrinolytic function are unknown.
The aims of this study were to investigate the acute effects
of local intra-arterial inflammatory cytokines (IL-6 and
TNF-a) and bacterial endotoxin (lipopolysaccharide [LPS])
exposure on vasomotor function and endothelial t-PA release
in vivo in humans.
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Methods
Subjects
Eighteen healthy nonsmoking men 21 to 25 years of age participated
in the study, which was undertaken with the approval of the local
research ethics committee in accordance with the Declaration of
Helsinki and the written informed consent of each subject. None of
the subjects had infective illnesses or received medication in the
week before study. All subjects abstained from alcohol for 24 hours
and from food and caffeine-containing drinks for at least 4 hours
before each study. All studies were performed in a quiet,
temperature-controlled room.
Cytokines and Drugs
TNF-a (Knoll Pharmaceuticals),9 1L-6 (Novartis Pharnta AG),10
LPS (lot G-l, USPCI),11 bradykinin (Clinalfa), acetylcholine
(Cibavision Ophthalmics), and sodium nitroprusside (David Bull
Laboratories) were administered after dissolution in 0.9% saline.
TNF-a, IL-6, and LPS were prepared as stock solutions and stored at
— 80°C in aliquots. All other drugs were freshly prepared on the
study day.
Hemodynamic Measurements
Blood flow was measured in both forearms by venous occlusion
plethysmography using mercury-in-silastic strain gauges, as previ¬
ously described.12 Blood pressure was monitored in the noninfused
ann at intervals throughout each study with a semiautomated
noninvasive oscillometric sphygmomanometer.
Venous Sampling and Assays
Venous blood (10 mL) was withdrawn simultaneously from each
arm and collected into tubes containing acidified buffered citrate (for
t-PA assays), trisodium citrate (for plasminogen activator inhibitor
type 1 [PAI-1] assays), and potassium ethylene diamine tetraacetic
acid (F.DTA) (for cytokine assays). Citrate and acidified buffered
citrate samples were centrifuged at 2000g for 30 minutes at 4°C and
EDTA samples at lOOOg for 10 minutes at 20°C. Platelet-free plasma
was decanted and stored at — SOT" before assay. Plasma t-PA, PAI-1,
TNF-a, IL-6, and von Willebrand factor (vWF) antigen concentra¬
tions were determined as previously described13-14 using enzyme-
linked immunosorbent assays (Coaliza t-PA and PAI-1, Chromoge-
ttix AB; Quantikine human TNF and IL-6 immunoassays, R&D
Systems: and Dako A/S, respectively) and fibrinolytic activities
using a photometric method (Coatest t-PA and PAI-1, Chomogenix
AB). Hematocrit and white cell count were determined using an
automated Coulter counter (Beckman-Coulter ACt.8).
Study Design
Subjects rested recumbent, strain gauges and cuffs were applied, and
venous cannulae (17-G) were inserted into both antecubital fossae.
The brachial artery of the nondominant arm was cannulated with a
27-SWG needle under local anesthesia. The total rate of intra-arterial
infusion was maintained constant throughout at 1 mL/min. Forearm
blood flow was measured evety 6 to 10 minutes.
Cytokine and Endotoxin Administration
In a randomized, double-blind study, 10 subjects attended on 3
occasions at least 1 week apart, and saline was infused for 30
minutes to allow time for equilibration. Subjects were then random¬
ized to receive intra-arterial infusions of low-dose TNF-a (80
ng/min; n=6), high-dose TNF-a (240 ng/min; n=6), IL-6 (30
ng/min; n=6), LPS (100 pg/min; n=6), or saline placebo (1 mL/min;
n=6) over 60 minutes. This was followed by an additional 60-minute
saline washout infusion. Venous samples were obtained at baseline,
10,20, 40, and 60 minutes during drug infusion, and 30, 60, and 180
minutes after cessation of drug infusion. Cytokine and LPS doses
were chosen to achieve local concentrations comparable with healthy
volunteer studies7-"-15 and those seen in cardiovascular disease.1-16
Effect of Tumor Necrosis Factor-a on Endothelial Function
Eight subjects attended on 2 occasions at least 1 week apart in a
randomized, double-blind, placebo-controlled, crossover trial. They
received an intra-arterial infusion of either TNF-a (80 ng/min) or
saline placebo (1 mL/min) over 60 minutes. After an additional 60
minutes of saline infusion, intra-arterial bradykinin was administered
at 100. 300, and 1000 pmol/min for 10 minutes at each dose,
acetylcholine at 5, 10, and 20 pg/min, and sodium nitroprusside at 2,
4, and 8 pg/min for 5 minutes at each dose. Infusions of the
vasoactive drags were separated by 15-minute infusions of saline.
Venous samples were obtained at baseline, after 60 minutes of
TNF-a/placebo infusion, before and during each dose of bradykinin,
and 15 minutes after cessation of bradykinin infusion. Venous
samples were not obtained during acetylcholine or sodium nitroprus¬
side infusion, because they do not affect plasma t-PA or PAI-1
concentrations in this forearm model.12-17-18
Data Analysis and Statistics
Plethysmography data were extracted from the chart data files, and
the last 5 linear recordings in each measurement period were
averaged. Estimated net t-PA antigen and activity release was
defined previously12 14 as the product of the infused forearm plasma
flow and the concentration difference between the infused and
noninfused forearms. Because basal t-PA concentrations were al-
Figure 1. Plasma concentrations of
TNF-a (top) and IL-6 (bottom) in the
infused (•) and noninfused (o) arms after
1 hour of intra-arterial infusion of TNF-a
at 80 ng/min (left) and 240 ng/min (right).
Pfi0.01 (ANOVA) for all responses
except IL-6 concentrations in the nonin¬
fused arm. P<0.05 (ANOVA, infused vs
noninfused arm) for all responses.












Chia ct al TNF-a, Endothelial Function, and t-PA Release 697
TABLE 1. Forearm Blood Flow (mL/100 mL/min) During
TNF-a, IL-6, LPS, and Saline Placebo Infusion
TNF-a, TNF-a, IL-6, LPS,










tered by pretreatment with TNF-a, t-PA antigen and activity release
during bradykinin infusion was calculated by subtracting the mean
t-PA release before and 15 minutes after cessation of bradykinin
infusion.
Data were examined, where appropriate, by ANOVA with re¬
peated measures and 2-tailed paired Student's / test using Statview
(SAS Institute, Inc). All results are expressed as mean+SEM.
Statistical significance was assigned at the 5% level.
Results
All subjects remained well throughout the study and reported no
adverse effects. There were no effects on hematocrit, body temper¬
ature, or white cell count throughout all studies (data on file).
Cytokine and Endotoxin Administration
Cytokine Assays
Plasma TNF-a concentrations increased from 1±0 and 2±1
pg/mL to 539±71 and 1164±41 pg/ntL in the infused arm
(/'< 0.001 for both) and to 20±2 and 62±8 pg/mL in the
noninfused arm (PC0.001 for both) during 80 and 240
ng/min of TNF-a, respectively (Figure 1). This was accom¬
panied by a gradual increase in plasma IL-6 concentrations
(Figure 1). In the infused arm, IL-6 infusion increased plasma







LPS infusion increased plasma TNF-a and IL-6 concentra¬
tions from l±3 to 7±1 pg/mL (P=().0l) and from I±0 to
6±2 pg/mL (P= 0.02), respectively.
Hemodynamic Effects
Intra-arterial saline placebo, TNF-a, IL-6, and LPS infusions
had no effect on heart rate, blood pressure, or forearm blood
flow throughout all studies (data on File; Table 1).
Fibrinolytic and Hemostatic Assays
There were no changes in plasma t-PA antigen concentrations
during IL-6, LPS, or saline placebo infusions (data on file).
Plasma t-PA antigen and activity concentrations increased in
the infused ami by up to 20-fold after both low- and
high-dose TNF-a infusions (PC0.001; Figure 2). Plasma
t-PA concentrations increased slowly, being detectable at 20
minutes and peaking at 60 minutes of infusion. Thereafter,
plasma t-PA concentrations fell but remained elevated 4
hours after initiation of the infusion, with an apparently stable
elevation between 2 and 4 hours.
Plasma PAI-1 and vWF antigen concentrations were un¬
changed throughout all studies, although plasma PAI-1 activ¬
ity was reduced in the infused ann only after high-dose
TNF-a infusion (P=0.003; Table 2).
Effect of Tumor Necrosis Factor-a on
Endothelial Function
Cytokine Assays
Intra-arterial TNF-a infusion (80 ng/min) increased plasma
TNF-a concentrations in the infused and noninfused ami
from 2±1 and 2±1 pg/mL to 561 ±108 and 15±1 pg/mL,
respectively (/'CO.001 for both).
Hemodynamic Effects
Intra-arterial TNF-a or placebo infusion had no significant
effects on heart rate, blood pressure, or basal forearm blood
flow up to 2 hours after commencement of the infusion
(P=NS for both). Forearm blood flow increased in a dose-
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Figure 2. Plasma concentrations of t-PA
antigen (solid lines) and activity (dashed
lines) in the infused (•) and noninfused
(o) arms after 1 hour of intra-arterial infu¬
sion of TNF-a at 80 ng/min (left) and 240
ng/min (right). P<0.001 (ANOVA) for all
responses except noninfused arm after
TNF-a 80 ng/min infusion. P<0.001
(ANOVA, infused vs noninfused arm) for
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TABLE 2. Plasma PAI-1 Antigen and Activity Concentrations
During TNF-a Infusion
TNF-a, i80 ng/min TNF-«,240 ng/min
Infused Noninfused Infused Noninfused
PAI-1 antigen, ng/mL
0 minutes 17±4 19±5 23±5 24±5
60 minutes 18±4 20±4 25 ±6 26±8
120 minutes 14 ± 3 16±3 18±5 24±5
240 minutes 15±4 14±3 21 ±5 36±17
PAI-1 activity, lU/mL
0 minutes 12-1:2 11±1 10±2 9±2
60 minutes 9±2 10±2 5±2* 12±3
120 minutes 11 ±1 14±3 6±1* 10±2
240 minutes 8±1 11 ±2 4±1* 12+1
Values are mean±SEM.
*P=0.003, ANOVA, infused vs noninfused arm.
dium nitroprusside infusions (Ps0.02; Figure 3). Compared
with placebo, TNF-a infusion caused impaired endothelium-
dependent vasodilatation to bradykinin (P=0.029) and ace¬
tylcholine (P=0.01) but had no effect on endothelium-
independent vasodilatation to sodium nitroprusside (jP=0.43;
Figure 3).
Fibrinolytic Assays
Plasma t-PA antigen and activity concentrations increased
from 3.5±0.6 to 8.5±1.6 ng/mL (P=0.004) and from
1.1 ±0.3 to 9.2± 1.9 IU/mL (P=0.003), respectively, after 60
minutes of TNF-a infusion. Again, this rise was sustained
with an apparently stable elevation between 2 and 3 hours, ie,
1 to 2 hours after cessation of TNF infusion (Figure 4).
Plasma t-PA antigen and activity concentrations were un¬
changed in the noninfused arm and during placebo infusion.
Plasma t-PA antigen and activity concentrations increased
in a dose-dependent manner during bradykinin infusion
(P±0.0l). Compared with placebo, pretreatment with TNF-a
resulted in higher plasma t-PA antigen and activity concen¬
trations during bradykinin infusion (11.3±0.8 versus 6.8±0.5
ng/mL and 16.5±3.9 versus 6.6±2.0 IU/mL at peak brady¬
kinin dose; P<0.002) (Figure 4) and a marked augmentation
in the estimated net release of t-PA antigen and activity
(P=0.018 and P= 0.037, respectively; Figure 5). For the
30-ntinute bradykinin dose-response infusion, pretreatment
with TNF-a resulted in 83% and 132% increases in area
under the curve for t-PA antigen and activity release, respec¬
tively (P<0.05).
Discussion
We have demonstrated for the first time that local intra-arte-
rial TNF-a administration can be used to generate an in vivo
local vascular inflammatory model in humans that is associ¬
ated with endothelial dysfunction and a unique profile of
endogenous t-PA release. In contrast to 1L-6 and LPS, TNF-a
causes a slow-onset, sustained, and selective release of t-PA
from the vascular endothelium in the absence of basal
vasomotor effects. Moreover, pretreatment with TNF-a at¬






























































Figure 3. Infused (solid line) and noninfused (dashed line) fore¬
arm blood flow responses to incremental doses of bradykinin
(a), acetylcholine (b), and sodium nitroprusside (c) in subjects
who were pretreated with TNF-a (•) or saline placebo (o).
P<0.02 (ANOVA) for all infused arm responses. *P<0.03
(ANOVA, TNF-a vs saline placebo).
acute bradykinin-induced t-PA release. These findings indi¬
cate that TNF-a and acute vascular inflammation have
complex effects on endothelial function. Although the profi-
brinolytie actions may reflect a protective mechanism in
acute inflammation, TNF-a also directly impairs endotheli-
um-dependent vasomotor responses.
Model of Local Vascular Inflammation
We have here developed a model of local vascular inflam¬
mation in vivo in humans. Using unilateral intrabrachial
infusions, we achieved high local plasma TNF-a concentra¬
tions that were comparable to the plasma concentrations seen
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Figure 4. Plasma concentrations of t-PA antigen (solid lines)
and activity (dashed lines) in infused (•) and noninfused (o) arms
after 1 hour of intra-arterial infusion of TNF-a (circles) or saline
placebo (triangles) and during bradykinin infusion. P<0.001
(ANOVA) for all infused arm responses. P<0.001 (ANOVA,
infused versus noninfused arm) for all responses. P<0.001
(ANOVA, TNF-a vs saline placebo) for infused arm responses.


















































Figure 5. Estimated net t-PA antigen (solid lines) and activity
(dashed lines) release during bradykinin infusion corrected for
baseline t-PA concentrations in subjects who were pretreated
with TNF-a (•) or saline placebo (o). P<0.001 (ANOVA) for all
responses. *P<0.05 (ANOVA, TNF-a vs saline placebo).
IPsO.05 (paired t test; TNF-a vs saline placebo).
in patients with severe heart failure.16 A direct local vascular
and endothelial inflammatory response was confirmed by the
local rise in plasma IL-6 and t-PA concentrations. However,
the fibrinolytic effects of TNF-a were not mediated through
IL-6 release, because isolated IL-6 infusion had no effect on
t-PA release. Indeed, in pilot studies, we found that high-dose
intrabrachial IL-6 infusion sufficient to increase plasma IL-6
concentrations to >100 pg/mL have also failed to produce
significant effects on forearm blood flow or t-PA release.
Effects of TNF-cr on t-PA Release
The profile of t-PA release during local intra-arterial TNF-a
administration is unique and has not been previously de¬
scribed in vivo in humans. Previous studies in healthy
volunteers have reported changes in plasma fibrinolytic15 and
coagulation20 factors during systemic TNF-a administration.
TNF-a has pleiotropic effects and may cause these effects
through actions on specific tissues or via secondary mediators
released from organs such as the liver. In the present study,
we have assessed local peripheral vascular responses to direct
intra-arterial TNF-a and have shown that it causes selective
endothelial t-PA release in the forearm without demonstrable
effects on plasma vWF or PAI-1 antigen concentrations.
Although there was a modest rise in the IL-6 and t-PA
concentrations in the noninfused arm, this may represent
overspill from the infused arm, where the concentrations
increased by up to 20-fold. In contrast to previous systemic
studies,15-20 subjects here remained asymptomatic and there
was no associated pyrexia, consistent with the absence of a
major systemic response.
We12 and others17-18 have previously reported acute rapid
t-PA release during intra-arterial substance P, bradykinin, and
methacholine infusions. Using these agents, there is a near-
instantaneous onset and offset of action with no sustained
increase in t-PA release after cessation of administration.
Moreover, there is always an associated change in vascular
tone and regional blood flow, because these agents also cause
vasodilatation. In contrast, TNF-a administration had no
effect on basal blood flow and caused a slow onset and
sustained release of t-PA that was not apparent until 20
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ABSTRACT
Hyperhomocysteinaemia is a prothrombotic condition that may cause oxidative endothelial injury
and impair endogenous fibrinolysis. Vitamin supplementation enhances endothelial function in hy-
perhomocysteinaemic patients, but responses in patients with co-existing coronary artery disease
have been variable. It is also unknown whether hyperhomocysteinaemia is associated with reduced
fibrinolytic responses in patients with coronary artery disease. The study aims were to test the
hypothesis that patients with recent myocardial infarction and hyperhomocysteinaemia have im¬
paired endothelium-dependent vasomotion and fibrinolysis that is rectified by vitamin supple¬
mentation. From a cohort of 120 patients admitted with acute myocardial infarction, 18 patients
were recruited from the upper (n = 9) and lower (n = 9) plasma homocysteine quartiles into a
randomized double-blind placebo-controlled crossover trial. Following a 4-week course of placebo
or folate/cyanocobalamin/pyridoxine supplements, FBF (forearm blood flow) was measured using
venous occlusion plethysmography during intra-arterial substance P (4-16 pmol/min), acetylcholine
(5-20 /fg/min) and sodium nitroprusside (2-8 /(g/min) infusions. All vasodilators caused dose-
dependent increases in infused FBF (P < 0.05). Patients in the upper homocysteine quartile
(16.8 ± 2.9 compared with 7.9 + 0.7 /xmol/l; P = 0.003) had reduced vasodilatation to acetylcholine
(P — 0.01) and substance P (P< 0.05), but not sodium nitroprusside. There were no differences
in substance P-induced tissue plasminogen activator release. Vitamin supplementation increased
serum folate and vitamin Bu concentrations (P < 0.05), but did not significantly lower homo¬
cysteine. or affect FBF or fibrinolytic responses. In patients with recent myocardial infarction,
hyperhomocysteinaemia is associated with impaired endothelium-dependent vasodilatation, but no
alteration in the acute fibrinolytic capacity. This endothelial vasomotor dysfunction is unaltered
by vitamin supplementation.
INTRODUCTION
Several prospective and case-control studies have shown
that elevated plasma homocysteine concentrations are an
independent risk factor for the development of athero-
thrombotic vascular disease as well as a prognostic marker
in isehaemic heart disease [1-3], Plasma homocysteine
concentrations arc consistently higher in patients with
premature peripheral and cerebrovascular diseases [4],
and almost a third of patients with premature coronary-
Key words: endothelial dysfunction, fibrinolysis, homocysteine, myocardial infarction, vasodilatation, vitamin.
Abbreviations: CI, confidence interval; FBF, forearm blood flow; NS, not significant; PAI-1, plasminogen activator inhibitor type 1;
t-PA, tissue plasminogen activator.
Correspondence: Dr David Newby (email d.e.newby@ed.ac.uk).
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artery disease are found to have hyperhomocysteinaemia
[1], In addition, apparently healthy men with plasma
homocysteine concentrations 12 % above the upper limit
of normal have a 3-fold increased risk of acutemyocardial
infarction [2], and in patients with ischaemic heart disease
there is an increased mortality associated with plasma
concentrations greater than 9 yxmol/1 [5].
The vascular endothelium plays a central role in the
control of blood flow, haemostasis and endogenous fib¬
rinolysis, and endothelial dysfunction independently pre¬
dicts cardiovascular events [6,7], Although the mechan¬
ism of vascular damage is unclear, homocysteine may
promote atherogenesis through oxidative endothelial in¬
jury that is mediated by cytotoxic reactive oxygen species
[8-10], Indeed, acute and chronic hyperhomocystein¬
aemia are associated with impaired endothelium-depen-
dent flow-mediated dilatation of the brachial artery
[10-12],
Hyperhomocysteinaemia is a prothrombotic state [3],
We [13] and others [14] have shown previously that hy¬
perhomocysteinaemia induced by oral methionine load¬
ing is associated with alterations in endogenous fibri¬
nolysis in healthy subjects and patients with premature
vascular disease. However, the influence of chronic
hyperhomocysteinaemia on the acute fibrinolytic capa¬
city is unknown and is the subject of debate [15], Inter¬
estingly, there is an association between plasma homo¬
cysteine and t-PA (tissue plasminogen activator) antigen
concentrations in stroke patients [16],
Vitamin supplementation with folate, vitamin B6 and
vitamin B12 is safe and may reduce plasma homocysteine
concentrations [17]. Although endothelial function is
enhanced following treatment with folate in patients
with hyperhomocysteinaemia [18,19] and hypercholes-
terolaemia [20], the response in patients with coronary
artery disease has been variable [21-25], Furthermore,
it is unknown whether elevated plasma homocysteine
concentrations are associated with reduced resistance
vessel vasomotor responses in patients with established
coronary artery disease.
The aim of the present study was to test the hypo¬
theses that, in patients with recent myocardial infarction,
elevated plasma homocysteine concentrations are asso¬
ciated with impaired endothelium-dependent vasodilata¬
tion and endogenous fibrinolytic capacity, and that vita¬
min supplementation (with folate, vitamin B6 and vitamin




One hundred and twenty patients admitted with an acute
myocardial infarction were recruited into the trial. Myo¬
cardial infarction was defined as typical ischaemic cardiac
pain associated with elevation of cardiac markers (greater
than twice the upper limit of normal) and electrocardi¬
ographic evidence of myocardial ischaemia. Exclusion
criteria were atrial fibrillation on warfarin therapy, im¬
paired renal function (serum creatinine >120 /xmol/1),
diabetes mcllitus, requirement for folate supplementation
or pernicious anaemia. The written informed consent of
each subject was obtained before entry into the study. All
studies were undertaken with the approval of the local
Research Ethics Committee and in accordance with the
Declaration of Helsinki (1996).
Study design
Fasting plasma homocysteine concentrations were deter¬
mined in all patients on days 5-7 following acute myo¬
cardial infarction [26], From the upper and lower plasma
homocysteine concentration quartiles, nine patients in
each quartile were recruited into a randomized double-
blind balanced-block placebo-controlled crossover trial
at least 4 months after the index event. All patients rece¬
ived two separate 4-week courses of oral sucrose placebo
or vitamin supplementation (5 mg of folate/100/xg of
cyanocobalamin/10 mg of pyridoxine), and attended at
the end of each 4-week treatment period. On each study
day, medications were withheld and subjects attended
after a 4-h fast and rested recumbent in a quiet temper¬
ature-controlled room maintained at 22-25°C. Strain
gauges and cuffs were applied, and the brachial artery
of the non-dominant arm was cannulated. After 30 min
equilibration with saline infusion, intra-arterial substance
P (4-16 pmol/min), acetylcholine (5-20 /xg/min) and
sodium nitroprusside (2-8 /xg/min) were administered
in a randomized order for 6-10 min at each dose and
separated by 20 min washout periods [27-29], Venous
samples were taken at baseline and during infusion of each
substance P dose for determination of t-PA and PAI-1
(plasminogen activator inhibitor type 1). Venous sam¬
pling was not performed during sodium nitroprusside or
acetylcholine infusion, since they do not affect t-PA or
PAI-1 release in this forearm model [13,27,30],
Intra-arterial administration and drugs
The brachial artery of the non-dominant arm was cannu¬
lated with a 27-standard wire gauge steel needle (Cooper's
Needle Works, Birmingham, U.K.) under 1 % lidocaine
(Xylocaine; Astra Pharmaceuticals, Kings Langley,
Herts., U.K.) local anaesthesia and attached to a
16-gauge epidural catheter (Portex, Hythe, Kent, U.K.).
Patency was maintained by infusion of saline (0.9%
NaCl) via a MS2000 syringe infusion pump (Graseby
Medical, Watford, Herts., U.K.). The total rate of intra¬
arterial infusions was maintained constant throughout
all studies at 1 ml/min. Pharmaceutical grade substance
P (Clinalfa, Laufelfingen, Switzerland), acetylcholine
(Cibavision Ophthalmics, Southampton, U.K.) and so¬
dium nitroprusside (David Bull Laboratories, Warwick,
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U.K.) were administered following dissolution in saline.
All solutions were freshly prepared on the day of study.
Haemodynamic measurements
Blood flow was measured in both forearms by venous
occlusion plethysmography using mercury-in-silastic
strain gauges as described previously [27,28], During
measurement periods, the hands were excluded from
the circulation by rapid inflation of the wrist cuffs to
220 mmHg using E20 rapid cuff inflators (DE Hokanson,
Bellevue, WA, U.S.A.). Upper arm cuffs were inflated
intermittently to 40 mmHg for 8 s in every 10 s to achieve
venous occlusion and obtain plethysmographic record¬
ings. Blood pressure was monitored in the non-infused
arm at intervals throughout each study with a semi-
automated non-invasive oscillometric sphygmomano¬
meter (Takeda UA 751; Takeda Medical, Tokyo, Japan).
Venous sampling and assays
Venous cannulae (17-gauge) were inserted into large
subcutaneous veins of the antecubital fossae of both arms.
Venous blood was withdrawn simultaneously from
each arm and collected into acidified buffered citrate
(Biopool® Stabilyte™, Umea, Sweden) for t-PA assays
and trisodium citrate and lithium heparin tubes
(Monovette®, Sarstedt, Niimbrecht, Germany) for PAI-1
and homocysteine assays respectively. Samples were kept
on ice before being centrifuged at 2000 g. Platelet-free
plasma was decanted and stored at — 80 °C before as¬
say. Plasma t-PA and PAI-1 antigens were determined as
described previously [27] using ELISA (Coaliza t-PA and
Coaliza PAI-1; Chromogenix, Molndal, Sweden),
and plasma t-PA activity was determined using a photo¬
metric method (Coatest t-PA; Chromogenix). Plasma
homocysteine (Axis® Homocysteine EIA; Axis-Shield,
Oslo, Norway) and serum folate and vitamin Bu con¬
centrations (Bayer Immuno 1® automated immunoassay
analyser, Bayer, Leverkusen, Germany) were determined
using enzyme immunoassay.
Data analysis and statistics
Estimated net release of t-PA antigen and activity were
defined previously [27] as the product of the infused
forearm plasma flow [based on the mean haematocrit
(Hct) and the infused FBF (forearm blood flow)] and the
concentration difference between the infused ([t-PA];nf)
and non-infused ([t-PA]Non;nf) arms using the formula:
Estimated net t-PA release
= FBF x (1 - Hct) x ([t-PA]inf - [t-PA]Noninf)
Data were examined, where appropriate, by ANOVA
with repeated measures and two-tailed paired Student's
t test (SAS Institute). All results are expressed as means
(S.E.M.) or means [95 % CI (confidence interval)]. Stat¬
istical significance was taken at the 5 % level.
Table I Patient characteristics
Values are means (S.E.M.), or numbers (percentage). ACE, angiotensin-converting
enzyme.
Patients in Patients in







Sex (male/female) 9/0 8/1
Mean arterial pressure (mmHg) 88 (5) 86 (2)
Heart rate (beats/min) 59(2) 54 (2)
Type of myocardial infarction
Anterior (n) 2 (22%) 3 (33%)
Inferior (n) 6 (67 %) 3 (33%)
Other (n) 1 (11%) 3 (33%)
Peak creatine kinase (units/I) 790 (230) 1900 (550)
Received thrombolysis (n) 6 (67 %) 6 (67%)
Medication
Antiplatelet therapy (n) 9 (100%) 9 (100%)
^-Adrenoceptor antagonists (n) 8 (89%) 6 (67%)
ACE inhibitors (n) 5 (56%) 5 (56%)
HMG CoA reductase inhibitors (n) 8 (89%) 7 (77%)
Risk factors
Smokers (n) 6 (67 %) 3 (33%)
History of hypertension (n) 3 (33%) 2 (22%)
Hypercholesterolaemia (n) 8 (89%) 7 (77 %)
Diabetes mellitus (n) 0 (0%) 0 (0%)
RESULTS
Baseline and biochemical characteristics
From the upper and lower plasma homocysteine quar-
tiles, 18 patients (nine patients in each quartile) were
recruited into the randomized controlled trial. Apart
from plasma homocysteine concentrations (P < C.01, as
determined by Student's t test), which were significantly
different by design, there were no significant differences
between the baseline clinical characteristics or medi¬
cal therapies in the two groups of patients (Tables 1
and 2).
All subjects tolerated placebo and vitamin supplemen¬
tation and no side effects were reported or noted. Serum
folate and vitamin B12 concentrations were increased
following vitamin supplementation compared with
placebo in both patient groups (P < 0.001 and P < 0.05
respectively, as determined by Student's t test; Table 2).
Plasma homocysteine concentrations appeared to be re¬
duced by «16% with active treatment in hyperhomo-
cysteinaemic patients, but this was not statistically signi¬
ficant (P= 0.3, as determined by Student's t test; Table 2).
Vitamin supplementation had no significant effects on
heart rate, blood pressure or basal FBF in either patient
group.
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Table 2 Plasma homocysteine, serum folate and vitamin
B12 concentrations following vitamin supplementation
Values are means (S.E.M.). *P < 0.01 compared with lower quartile, as determined




































| Upper limit of serum folate assay was 20 /cg/l; 13 patients had concentrations above
this after supplementation and were taken as 20 >u.g/l.
Endothelium-dependent vasomotion
Substance P, acetylcholine and sodium nitroprusside
caused dose-dependent increases in blood flow in the
infused forearm in both patient groups on each study
day (P < 0.05, as determined by ANOVA; Figure 1).
In comparison with patients in the lower quartile, hy-
perhomocysteinaemic patients had significantly reduced
FBF responses to acetylcholine and substance P (P= 0.01
and P < 0.05 respectively, as determined by ANOVA;
Figure 1), but there were no significant differences in the
blood flow responses to sodium nitroprusside [P= NS
(not significant), as determined by ANOVA].
Neither endothelium-dependent nor endothelium-
independent vasodilatation were significantly influenced
by vitamin treatment in either patient group (P = NS
for all, as determined by ANOVA). For the hyperhomo-
cysteinaemic group, the mean difference for the res¬
ponse to vitamin treatment at the peak dose was 1.1 ml •
100 ml-1 • min-1 (95% CI, —0.8 to +2.9) for substance
P, 0.3 ml • 100 ml-1 • min-1 (95 % CI, - 1.3 to + 1.8) for
acetylcholine, and — 0.3 ml • 100 ml-1 • min-1 (95% CI,
— 2.8 to +2.1) for sodium nitroprusside. For the lower
quartile group, the mean difference for the response
to vitamin treatment at the peak dose was 2.0 ml ■
100 ml-1 -min-1 (95% CI, -0.6 to +4.6) for substance
P, -0.8 ml 100 ml-1 • min-1 (95% CI, -2.9 to +1.2)
for acetylcholine, and 1.7 ml • 100 ml-1 • min-1 (95 % CI,
— 2.8 to +6.2) for sodium nitroprusside.
Fibrinolytic responses
Baseline plasma t-PA and PAI-1 antigen and t-PA activ¬
ity concentrations were similar in both groups (Table 3).
Substance P caused dose-dependent increases in plasma
t-PA antigen and activity concentrations in the infused
forearm of all patients (P < 0.05 for both, as determined
by ANOVA; Table 3). The responses were similar in











Figure I Infused (solid line) and non-infused (dashed line)
FBF responses to incremental doses of substance P (upper
panel) and acetylcholine (lower panel) in patients in
upper (closed symbols) and lower quartiles (open symbols)
following placebo (left panel) and vitamin supplementation
(right panel)
P < 0.05 for all infused arm responses, as determined by ANOVA. *P < 0.05
compared with lower quartile, as determined by ANOVA.
supplementation (P = NS, as determined by ANOVA).
The mean difference of t-PA antigen release for the res¬
ponse to vitamin supplementation at the peak substance
P dose was — 2.7 ng • 100 ml-1 • min-1 (95 % CI, — 15.5
to +10.2; P= NS, as determined by Student's t test) in
the upper quartile group and — 7.4 ng • 100 ml-1 • min-1
(95% CI, —24.3 to +9.5, P = NS, as determined by
Student's t) in the lower quartile group. Plasma PAI-1
concentrations were unaffected by substance P infusion
or vitamin treatment (P = NS, as determined by Student's
t test).
DISCUSSION
In the present study, we have demonstrated that, in pati¬
ents with a recent myocardial infarction, elevated plasma
homocysteine concentrations are associated with im¬
paired endothelium-dcpendent vasodilatationwithout af¬
fecting acute endogenous t-PA release. However, vitamin
supplementation failed to significantly reduce plasma
homocysteine concentrations or improve endothelial
vasomotor function.
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Table 3 Plasma t-PA and PAI-I concentrations and release during substance P infusion
Values are means (S.E.H.). *P < 0.05 for all responses during substance P infusion, as determined by ANOVA. AUC, area under curve; IU, international units.
Patients in the upper quartile Patients in the lower quartile
Placebo Treatment Placebo Treatment
Substance P Non-infused Non-infused Infused Non-infused Non-infused
(pmol/min) Infused arm arm Infused arm arm arm arm Infused arm arm
t-PA antigen (ng/ml) Baseline 7.7 (1.2) 8.6 (1.4) 7.5 (1.0) 8.2 (1.4) 6.6 (1.2) 6.5 (1.3) 7.2 (1.3) 7.6 (1.3)
4 9.8 (1.5) 8.3 (1.3) 9.2 (1.0) 7.7 (1.3) 7.6 (0.9) 7.0 (I.I) 8.1 (1.4) 7.6 (1.4)
8 9.4 (1.5) 8.1 (I.I) 10.3 (I.I) 7.8 (1.0) 9.3 (1.4) 7.1 (1.2) 8.9 (1.5) 7.6 (1.5)
16 12.7 (2.4)* 7.8 (0.9) ll.l (1.4)* 7.6(1.1) 10.6 (1.2)* 6.7 (1.3) 10.5 (1.6) 7.9 (1.4)
Estimated t-PA antigen release Baseline - I.I (0.7) -1.2 (I.I) 0.4 (0.7) - 0.3 (0.4)
(ng • 100 ml-1 • min-1) 4 4.0 (3.2) 5.4 (3.4) 3.4 (2.2) 1.4 (1.5)
8 4.7 (4.1) ll.l (4.2) 9.8 (3.7) 5.9 (2.4)
16 21.6 (6.7)* 18.9 (5.2)* 24.3 (8.4)* 15.6 (3.9)*
Net t-PA antigen release (AUC) 18.9 (9.3) 25.4 (9.0) 24.2 (8.5) 14.9 (4.2)
t-PA activity (lU/ml) Baseline 0.9 (0.2) 0.8 (0.2) 0.5 (0.1) 0.6 (0.1) 1.0 (0.3) 1.0 (0.3) 0.8 (0.2) 0.8 (0.3)
4 1.7 (0.6) 0.7 (0.2) 1.5 (0.3) 0.8 (0.1) 2.5 (0.8) 1.2 (0.4) 1.5 (0.6) 0.9 (0.2)
8 1.9 (0.7) 0.8 (0.3) 2.3 (0.4) 0.7 (0.2) 2.8 (0.9) 1.2 (0.4) 2.0 (0.9) 0.9 (0.2)
16 3.1 (0.8)* 1.0 (0.2) 2.9 (0.5)* 0.8 (0.2) 3.9 (I.I)* 1.5 (0.4) 2.7 (1.0)* 0.9 (0.2)
Estimated t-PA activity release Baseline 0.0 (0.1) -0.1 (0.1) 0.0 (0.1) 0.1 (0.2)
(IU • 100 ml-' - min"1) 4 2.5 (1.4) 3.1 (1.3) 6.0 (2.1) 2.2 (1.2)
8 3.6 (1.6) 7.0 (1.7) 8.4 (3.6) 4.6 (2.1)
16 9.3 (2.9)* 11.7 (3.6)* 16.4 (6.9)* 10.2 (3.4)*
Net t-PA activity release (AUC) 10.7 (4.2) 15.9 (4.7) 21.6 (8.7) 12.0 (4.9)
PAI-I antigen (ng/ml) Baseline 47 (5) 48 (4) 44 (4) 48 (5) 45 (14) 46 (14) 44 (II) 46 (13)
16 48 (4) 54 (3) 45 (4) 50 (5) 44 (15) 44 (15) 46 (12) 49 (15)
Endothelium-dependent vasodilatation
Previous studies have shown that homocysteine is asso¬
ciated with endothelial dysfunction. Lentz et al. [9] re¬
ported that, in monkeys with diet-induced hyperhomo-
cysteinaemia, endothelium-dependent vasodilatation is
impaired in carotid artery rings in vitro and hindlimb
resistance vessels in vivo. Celermajer et al. [11] documen¬
ted abnormal endothelium-dependent vasodilatation in
children with severe hyperhomocysteinaemia due to ho¬
mozygous homocystinuria. Impaired endothelium-de¬
pendent vasodilatation is detected in healthy subjects with
acute hyperhomocysteinaemia induced by oral methi¬
onine loading [10,31], as well as in patients with chronic
hyperhomocysteinaemia who are free from clinical mani¬
festations of atherosclerotic disease [12,18], In the present
study, we have extended these findings to patients with
recent myocardial infarction and demonstrated impaired
vasomotor responses in those with elevated plasma
homocysteine concentrations.
The vascular endothelium plays a critical role in the
control of vascular homoeostasis by regulating vascular
tone, platelet activity, coagulation and fibrinolysis, and
endothelial dysfunction is believed to be an early step in
the pathogenesis and pathophysiology of atherosclerosis.
Although patients with coronary artery disease typically
demonstrate endothelial dysfunction, there is consider¬
able heterogeneity in the magnitude of impairment in
individuals with similar risk factor profiles. This is of
particular interest because the extent of coronary as well
as peripheral endothelial dysfunction independently pre¬
dicts the long-term risk of acute cardiovascular events, in¬
cluding sudden cardiac death, myocardial infarction and
revascularization procedures [6,7]. Recent prospective
data have indicated that, in patients with established
coronary artery disease, homocysteine is a significant
predictor of mortality independent of other traditional
risk factors [5,32]. Our present findings therefore support
the role of homocysteine as a secondary risk marker,
suggesting that this may be mediated through its effects
on endothelial function.
Endogenous fibrinolysis
Although homocysteine impairs endothelial vasomotor
function, it does not appear to have a major effect on
endothelium-dependent fibrinolytic capacity, as both
basal and stimulated release of t-PA or PAI-1 were not
significantly different between the two patient groups.
Hyperhomocysteinaemia is a prothrombotic condition
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and may interfere with the antithrombotic and fibrino¬
lytic mechanisms of the endothelium and alter endothelial
protein secretory pathways. Although endothelial cell-
associated t-PA activity is reduced in homocysteine-
treated cells [33], our present study failed to detect
reduced fibrinolytic activity in vivo. This is consistent
with data indicating that homocysteine might perturb the
intrinsic fibrinolytic potential by reducing the functional
binding site for t-PA without altering the catalytic
capability of t-PA or affecting t-PA synthesis and
secretion [33],
Effects of vitamin supplementation
on plasma homocysteine
Previous studies have shown that treatment with folate
and B vitamins can lower plasma homocysteine concen¬
trations to a varying degree. The Homocysteine Lower¬
ing Trialists' meta-analysis predicted a 20-30 % reduction
in homocysteine in patients with plasma concentrations
above 12 /tmol/1 taking folate, and a further small addi¬
tional effect with vitamin B12 but not [17]. However, a
more modest 11-14 % reduction is seen in patients with
coronary artery disease who consumed fortified breakfast
cereals [34,35]. The limited homocysteine lowering seen
in our present study was probably related to the rela¬
tively mild hyperhomocysteinaemia and normal folate
concentrations in our study population as well as the
confounding effects of dietary folate fortification.
Effects of vitamin supplementation
on endothelial responses
We did not detect an improvement in endothelium-
depenaent vasodilatation or endogenous fibrinolytic ca¬
pacity following vitamin supplementation in the present
study. Although this may not be surprising in the absence
of significant homocysteine reduction, Doshi et al. [22]
have suggested that the acute effects of folate on en¬
dothelial function may occur by a mechanism independ¬
ent of homocysteine lowering. Moreover, the evidence
of the beneficial effects of vitamin supplementation on
endothelial function is conflicting. Chambers et al. [21]
and Title et al. [24] demonstrated improved endothelial
function in patients with coronary artery disease follo¬
wing folate treatment without or with vitamin B12. How¬
ever, our present findings are consistent with those of
other investigators who failed to detect improved endo¬
thelial function in a similar patient population, in healthy
siblings of patients with premature atherothrombotic
disease or in patients with renal impairment [23,25,36].
These contradictory findings may be related, in part, to
the presence of other cardiovascular risk factors such as
hypertension or hypercholesterolaemia, which may con¬
tribute to endothelial injury [37,38], but would not be
expected to respond to folate or B vitamins. The vascular
endothelium in patients with established coronary artery
disease may have also been subjected to chronic injury
and would therefore be less responsive to intervention.
Furthermore, although the above studies adopted flow-
mediated dilatation as a non-invasive method of assessing
conduit artery endothelial function, in the present and
other studies [28,39], we have focussed on the function of
endotheliumwithin resistance vessels. Conduit artery and
microvascular endothelial cells have distinct phenotypic
differences, and responses to mechanical rather than
pharmacological stimuli may also differ, and may contri¬
bute to the apparent disparity in the responses.
There is further controversy regarding the effects of
vitamin supplementation on cardiovascular outcomes in
patients undergoing percutaneous coronary intervention.
Contrary to earlier reports that vitamin supplementation
may reduce the rate of restenosis and adverse out¬
comes following coronary artery angioplasty [40,41],
Lange et al. [42] have recently demonstrated that folate
therapy following coronary stenting may increase the
risk of in-stent restenosis. The underlying mechanism
for these findings remains uncertain, but it is possible
that the proliferative effects of folate may promote the
growth of neointimal cells within implanted stents.
Therefore more prospective data are needed before any
recommendations can be made regarding the use of
vitamin supplementation in coronary artery disease.
Study limitations
There are several potential limitations to our present
study. First, we studied peripheral vascular function and
thus these findings may not be directly applicable to other
vascular beds. However, endothelial dysfunction is often
a generalized process, and we have shown previously con¬
sistent vasomotor and endogenous fibrinolytic responses
between the forearm and coronary circulation [27,39].
Secondly, the failure to improve endothelial function may
be related to inadequate treatment duration, although
studies have suggested that a 4-6-week treatment with
folate can improve endothelial function [20,22]. Thirdly,
the size of the study was small and, although it was
powered to detect a 15-20% difference in t-PA release
or forearm vasodilatation, it is possible that a smaller
effect may have been missed. Fourthly, we used a
placebo-controlled crossover design and there was the
possibility of a carry-over effect of the vitamin therapy on
endothelial function during placebo administration, des¬
pite a significant difference in the serum concentrations
of folate and vitamin B,2. Finally, we cannot rule out that
homocysteine may be a marker of vascular injury rather
than a mediator of endothelial dysfunction, although
experimental data support the direct role of homocysteine
in causing endothelial damage [9,33].
In conclusion, we have demonstrated that endo-
thelium-dependent vasodilatation, but not endogenous
© 2005 The Biochemical Society
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fibrinolysis, is impaired in patients with recent myocar¬
dial infarction and elevated plasma homocysteine, and
that this endothelial vasomotor dysfunction is not recti¬
fied by vitamin supplementation. These results provide
further evidence for the role of homocysteine in vas¬
cular damage, but do not support the hypothesis that
vitamin supplementation improves endothelial function
in patients with established coronary artery disease.
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Abstract
Introduction: Acute stent thrombosis and in-stent restenosis are serious complications ofpercutaneous coronary intervention (PCI) and may
be associated with vascular or platelet abnormalities. We aimed to assess endothelium-dependent vasomotion, endogenous fibrinolysis and
platelet function in patients with acute stent thrombosis or in-stent restenosis. Materials and methods: Thirty-six subjects were enrolled into
four groups: acute stent thrombosis, in-stent restenosis, uncomplicated PCI with stent implantation and healthy matched controls. Foreann
blood flow was measured using bilateral venous occlusion plethysmography during intra-brachial acetylcholine, substance P and sodium
nitroprusside infusion. Venous blood samples were withdrawn for estimation of plasma fibrinolytic variables and platelet aggregonietry.
Results: Acetylcholine, substance P and sodium nitroprusside caused dose-dependent increases in blood flow (/><0.00l) and substance P
caused a dose-dependent increase in tissue-type plasminogen activator (t-PA) release (P< 0.001) in all groups. Thrombin, collagen, adenosine
diphosphate (ADP) and the thromboxane A2 analogue, U46619, caused dose-dependent platelet aggregation (P<0.001) in all groups. There
were no significant between group differences in these responses except that, in keeping with aspirin therapy, collagen-induced platelet
aggregation was impaired in patient groups compared with healthy controls (/,<0.01). Post-hoe analysis demonstrated a significant
impairment of acute t-PA release in current smokers compared to non-smokers ( />< 0.05). Conclusions: Despite previous reports suggesting
impaired vascular function, endothelium-dependent vasomotion, endogenous fibrinolysis and platelet aggregation do not appear to play a
ma jor role in the pathogenesis of acute stent thrombosis or in-stent restenosis.
© 2003 Elsevier Ltd. All rights reserved.
Keywords: Endothelial function; Platelets; In-stent restenosis; Stent thrombosis; Fibrinolysis
Coronary artery stent implantation is a valuable adjunct to
percutaneous transluminal coronary angioplasty. It reduces
the absolute incidence of restenosis compared with balloon
angioplasty by 10-15% and improves 6-month event free
survival by 10-20% [1,2]. However, there is a small but
significant risk ofacute coronary stent thrombosis [3] and in-
stent restenosis that can have devastating consequences
Abbreviations: ADP, adenosine diphosphate; ANOVA, analysis of
variance; AUC, area under the curve; PA1-1, plasminogen activator
inhibitor type 1; PCI, percutaneous coronary intervention; t-PA. tissue-
tvpc plasminogen activator.
* Corresponding author. Tel.: +44-131-242-6422; fax: +44-131-242-
6422.
E-mail address: d.e.newby@ed.ac.uk (D.E. Newby).
including myocardial infarction and death [4], Whilst pro¬
cedure-related complications such as persistent dissection,
longer stent length and final minimal lumen diameter may be
implicated in some cases of stent thrombosis or restenosis
[3], no underlying precipitant can be identified in many
patients.
Stent thrombus formation is principally initiated by
platelet aggregation, which, in the absence of effective
endothelium-derived vasoregulation and fibrinolysis, is
then stabilised by the deposition of a fibrin mesh. The
chronology of in-stent restenosis has been described as
early thrombosis, followed by thrombus endothclialization
and infiltration by lymphocytes and monocytes, and finally
smooth muscle cell migration and proliferation within the
resolving thrombus [5-7]. The initiation, propagation and
0049-3848/$ - see front matter © 2003 Elsevier Lid. All rights reserved.
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stabilization of acute stent thrombosis and in-stent reste¬
nosis are therefore dependent on several components:
platelet aggregation, endothelial function, coagulation and
fibrinolysis.
The purpose of the present study was to identify
potential factors that may be implicated in the predisposi¬
tion to acute stent thrombosis or in-stent restenosis using a
case-control methodology. We assessed endothelium-de-
pendent vasomotion, platelet aggregation and the acute
endogenous fibrinolytic capacity in patients who have
developed thrombotic complications following percutane¬
ous coronary intervention (PCI) and stent implantation.
1. Materials and methods
1. 1. Subjects
Twenty-six patients who had undergone PCI with stent
implantation at least 6 months previously and 10 age- and
sex-matched healthy control subjects were recruited into the
study. In the patient group, 16 had developed complications
of acute stent thrombosis within 48 h of stent implantation
(n = 6) or in-stent restenosis within 6 months of intervention
(«= 10), and 10 had no clinical evidence of stent thrombosis
or restenosis at least 1 year following the procedure.
Patients with procedural complications or suboptimal stent
insertion were excluded. All patients received thienopyri-
dine therapy for 4 weeks after undergoing PCI and none
received a glycoprotein llb/IIIa receptor antagonist during
the procedure.
All subjects abstained from alcohol for 24 h, and from
food and caffeine-containing drinks for at least 4 h before the
study, and medications were withheld on the day of the
study. All studies were performed in a quiet, temperature-
controlled room maintained at 22-25 °C. The investigation
was performed with the approval of the local ethics com¬
mittee and conformed with the principles outlined in the
Declaration of Helsinki, and with the written informed
consent of each subject.
1.2. Drugs administration
Pharmaceutical-grade substance P (Clinalfa, Laufelfin-
gen. Switzerland), acetylcholine (Cibavision Ophthalmics,
Southampton, UK) and sodium nitroprusside (David Bull
Laboratories, Faulding, UK) were administered following
dissolution in saline (0.9%: Baxter Healthcare). All solutions
were freshly prepared on the day of study.
1.3. Hemodynamic measurements
Blood flow was measured in both forearms by venous
occlusion plethysmography using mercury-in-silastic
strain gauges as previously described [8,9]. Blood pres¬
sure was monitored in the non-infused arm at intervals
throughout each study with a semiautomated noninvasive
oscillometric sphygmomanometer (Takeda UA 751, Takeda
Medical).
1.4. Fibrinolytic assays
Venous blood (10 ml) was withdrawn simultaneously
from each arm and collected into acidified buffered
citrate (Biopool® Stabilyte1", IJmea, Sweden; for t-PA
assays) and trisodium citrate (Monovette®, Sarstedt,
Niimbrecht, Germany; for PA1-1 assays) tubes and centri-
fuged at 2000 x g for 30 min at 4 °C. Platelet-free
plasma was decanted and stored at — 80 °C before
assay. Plasma tissue-type plasminogen activator (t-PA)
and plasminogen activator inhibitor type 1 (PAI-1) anti¬
gens were determined as previously described [8] using
enzyme-linked immunosorbent assays (Coaliza t-PA and
Coaliza PAI-1. Chromogenix, Molndal, Sweden) and
plasma t-PA activity using a photometric method (Coatest
t-PA, Chomogenix).
1.5. Platelet aggregometry and thrombophilia screen
Fasting venous blood (30 ml) was collected into trisodium
citrate tubes (Monovette®) and immediately centrifuged at
120 x g for 10 min to obtain platelet-rich plasma, which was
aspirated, adjusted to give a platelet count of 250 x 109/1 and
pre-warmed to 37 °C. Aggregation studies were performed
Tabic I
Baseline characteristics
Acute stent In-stent Control Healthy
thrombosis restenosis patients subjects
(n-6) (n- 10) (n- 10) (n- 10)
Sex (male/female) 2:4 9:1 8:2 9:1
Age 65 ± 3 62 ±2 63 ±2 58 ±3
Current smoker, % (n) 17(1) 20 (2) 20 (2) 20 (2)
Diabetes mellitus, % (») 17(1) 30 (3) 20 (2) 0(0)
Hypertension, % (n) 50 (3) 60 (6) 30 (3) 0(0)
Three-vessel disease. % (n) 33 (2) 30 (3) 20 (2) 0(0)
Normal or mild left 84 (5) 90 (9) 80 (8) 100 (10)
ventricular impairment,
% («)
Average stent diameter, mm 3.3 ±0.2 3.0 + 0.1 3.2 ±0.2
Average stent length, mm 16 + 2 18 ± 2 20 ± 2
Medical therapy
Aspirin, % (n) 100 (6) 100 (10) 100 (10) 0(0)
p-adrcnoccptor 50 (3) 50 (5) 60 (6) 0(0)
antagonists. % («)
Angiotensin-converting 33 (2) 60 (6) 40 (4) 0(0)
enzyme inhibitors, % (n)
Statins, % (n) 100 (6) 80 18) 80 (8) 0 (0)
Calcium channel 50(3) 60 (6) 10(1) 0(0)
blockers. % (n)
Oral nitrates. % («) 50 (3) 30 (3) 20 (2) 0(0)
Mean ± S.E.M.
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Table 2
Infused forearm blood flow during substance P, acetylcholine and sodium
nitroprussidc infusion
Drug Infused forearm blood flow (ml/100 rnl/min)
infusion .
Acute stent In-stent Control Healthy
thrombosis restenosis patients subjects
(>i - 6) (n— 10) (n—10) (» = 10)
Baseline 1.7 ±0.4 2.5 ± 0.3 2.4 ± 0.2 2.8 ±0.5
Substance P (pmol/min)
4 8.6 ± 0.5 9.6 ± 1.1 9.7 ± 1.2 7.9 ± 1.0
8 9.7 + 0.7 10.6 ± 1.1 11.0± t.l 9.7 ± 1.3
16 11.6 ±1.3* 11.3 ± 1.4* 13.2 ± 1.6* 12.4 ± 1.9*
Acetylcholine (pg/min)
5 7.7 ±1.8 5.7 ± 1.2 6.2 ± 0.9 6.2 ± 1.3
10 9.7 ±2.3 6.3 ± 1.4 6.9 ± 1.0 7.3 ± 1.1
20 14.4 ±3.11' 9.2 ± 2.0* 9.0 ± 1.5* 9.4 ± 2.11
Sodium nitroprussidc (ilg/'mm)
2 9.7 ±2.9 7.3 ± 1.0 7.3 ± 0.6 8.4 ± 0.9
4 11.6 ±2.7 11.1 ± 1.2 10.1 +0.9 10.9 ± 1.3
8 13.3 ± 2.6' 13.4 ± 1.4* 12.6 ± 1.4* 14.4 + 2.1*




on the platelet-rich plasma, 30-40 min after blood sampling,
using a standard optical technique (Chronolog Ca560 aggreg-
ometer; Labmedics, Stockport, UK) as described previously
[10], using the following agonists: adenosine diphosphate
(ADP, 0.5-10 pmol/l), the thromboxane A2 analogue
U46619 (0.5-6 pmol/1), thrombin (200-1000 mU/1) and
collagen (1-5 pg/ml). Responses were for 5 min after
addition of agonists, and the peak response recorded and
adjusted for platelet count (250 x 1109/1). Platelet count
and hematocrit were measured using an automated Coulter
counter (Act. 8 Coulter Counter; Beckman-Coulter, High
Wycombe, UK).
Venous blood (12 ml) were collected in potassium F.DTA
and trisodium citrate (Monovette*) tubes and screened for
anti-thrombin, protein S and protein C deficiencies, factor V
(Leiden) and prothrombin A20210G genotypes and anti-
phospholipid antibodies.
1.6. Study design
Subjects attended following a 4-h fast and then rested
recumbent throughout the study. Strain gauges and cuffs
were applied, and the brachial artery of the non-dominant
ami was cannulated with a 27-standard wire gauge steel
needle (Cooper's Needle Works, Birmingham, UK) under
1% lidocaine (Xylocaine; Astra Pharmaceuticals) local an¬
esthesia and attached to a 16-gauge epidural catheter (Por-
tex). Patency was maintained by infusion of saline via a
MS2000 syringe infusion pump (Graesby Medical, Watford,
UK). Venous cannulae (17-gauge) were inserted into large
Table 3
Plasma t-PA and PAI-1 concentrations and release during substance P infusion
Substance P Acute stent thrombosis In-stcnt restenosis Control patients Healthy subjects
(pmol/min) 0t = 6) (71=10) (71=10) (71=10)
Infused ann Non-infused Infused arm Non-infused Infused ann Non-infused Infused ami Non-infused
aim arm ami ann
t-PA antigen (ng/ml) Baseline 4.9 ± 0.9 4.8 ±0.9 4.3 ± 0.7 4.1 ±0.6 4.7 ±0.3 4.9 ± 0.5 5.1 ±0.4 5.4 ± 0.5
4 7.2 ± 1.1 5.2 ± 1.2 5.4 ±0.8 4.2 ±0.6 5.8 ±0.5 4.7 ± 0.4 6.1 ±0.6 5.4 ± 0.5
8 7.9 ±1.1 4.9 ± 1.2 6.0 ± 0.7 4.7 ± 0.6 6.5 ± 0.6 4.7 ± 0.4 7.0 ±0.8 5.5 ± 0.5
16 10.3 ±0.8* 5.6 ± 1.3 8.8 ± 1.5* 4.7 ±0.6 7.6 ± 0.8f 4.9 ± 0.4 8.5 ± 1.3 7.6 ± 1.5
Estimated t-PA antigen Baseline 0.1 ±0.5 0.2 ± 0.4 - 0.4 ± 0.4 - 0.5 ± 0.4
release (ng/100 ml/min) 4 11.2 ± 4.1 6.8 ± 2.5 6.9 ±2.8 3.1 ± 1.3
8 18.7 ±7.7 6.9 ± 2.5 12.2 + 3.3 7.8 ± 3.3
16 34.4 ± 10.1* 25.3 ± 7.5' 19.6 ± 3.3* 5.9 ±2.1*
Net t-PA antigen release (AUC) 47.1 ± 13.9 26.4 ± 6.6 28.6 ± 8.0 13.6 ±4.1
t-PA activity (HJ/ml) Baseline 2.1 ±0.5 1.8 ±0.4 2.0 ± 0.3 2.1 ±0.5 1.2 ±0.2 1.2 ±0.2 0.8 + 0.2 1.0 ±0.2
4 5.3 ± 1.0 2.2 ±0.4 4.6 ±0.8 2.5 ± 0.6 2.4 ± 0.5 1.29 ±0.2 2.3 ±0.5 1.0 ±0.2
S 6.7 ±1.1 2.1 ± 0.4 4.7 ± 0.9 2.7 ± 0.6 3.0 + 0.6 1.88 + 0.3 3.8+ 1.2 1.4 ±0.3
16 7.6 ± 1.1* 3.8 ± 0.8 7.0 ±0.9' 3.6 ± 0.9 5.5 ± 1.0' 2.04 ± 0.4 5.9 ± 1.7 1.7 ±0.4
Estimated t-PA activity release Baseline 0.1 ±0.2 0.1 ±0.4 0.0 ±0.1 0.3 ± 0.1
(IU/100 ml/min) 4 16.8 ±4.6 11.1 ±3.6 6.6 ± 2.8 5.6 ± 1.8
8 27.9 ± 5.9 11.3 ±3.8 6.1 ± 2.3 16.1 ± 8.5
16 25.5 ± 5.5* 18.3 ± 4.2' 25.8 + 5.3' 31.5 ± 13.6*
Net t-PA activity release (AUC) 57.5 ± 10.9 31.5 ±8.2 25.6 ± 7.7 37.0 ± 16.7
PA1-I antigen (ng/ml) Baseline 33 ±4 36 ±4 28 ±7 30 ± 7 43 ±8 43 ±7 36 ± 5 36 ±5
16 28 ±2 33 ±4 32 ±7 33 ±7 42 ±7 46 ±8 36 ± 5 34 ±5
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subcutaneous veins of the antecubital fossae of both amis.
After 30 min equilibration with saline infusion, infra-arterial
substance P was administered at 4, 8, 16 pmol/min. acetyl¬
choline at 5. 10, 20 fig/min and sodium nitroprusside at 2, 4,
8 pg/min for 10 min at each dose [8,11], The drugs were
separated by 20 min of saline infusion and administered in a
randomized order. All infusions were given at a constant
infusion rate of 1 ml/min. Venous samples were taken at
baseline and during infusion of each substance P dose but
not during sodium nitroprusside or acetylcholine infusion
since they do not affect plasma t-PA or PA1-1 concentrations
in this forearm model [8.10,12J.
1.7. Data analysis and statistics
Plethysmographic and aggregometry data were extracted
from the Chart data files and forearm blood How was
calculated for individual venous occlusion cuff inflations
by use of a template spreadsheet (Excel 97, Microsoft).
Estimated net release of t-PA antigen and activity was
defined previously [8] as the product of the infused forearm
plasma flow (based on the mean hematocrit and the infused
forearm blood flow) and the concentration difference be¬
tween the infused and noninfused arms. Data was examined,
where appropriate, by analysis of variance (ANOVA) with
repeated measures and two-tailed paired Student's r-test
using Statview (SAS Institute). All results are expressed
as mean ± S.E.M. Statistical significance was taken at the
5% level.
2. Results
The baseline characteristics of all subjects are shown
in Table 1. The patient groups are matched for age,
smoking history, diabetes mellitus, hypertension and se¬
verity of coronary artery disease although there appeared
to be a greater proportion of female subjects in the acute
stent thrombosis group. No significant abnormalities were
demonstrated in the thrombophilia screen in all study
subjects.
2.1. Endothelium-dependent vasomolion
There were no significant changes in heart rate, blood
pressure and non-infused foreann blood flow during drug
infusion in all studies. Forearm blood flow increased in a
dose-dependent manner during substance P, acetylcholine
and sodium nitroprusside infusions (P<0.05, ANOVA)
(Table 2). However, there were no significant differences
between the four groups.
2.2. Endogenous fibrinolysis
Compared to the non-infused arm, substance P caused
dose-dependent increases in plasma t-PA antigen and
activity concentrations in the infused arm in all subjects
{P<0.05, Table 3), but this increase was not different
between the groups. Patients with acute stent thrombosis
had an apparently higher t-PA antigen release but this
did not achieve statistical significance nor was this seen
with t-PA activity. Post-hoc analysis demonstrated a
significant reduction of t-PA antigen and activity release
in current smokers compared to non-smokers (/'< 0.05,
Fig. 1).
2.3. Platelet aggregation
All patients were on aspirin therapy and had reduced
platelet aggregation in response to collagen (F<0.01)
compared to healthy volunteers (Fig. 2). There was no
significant difference in platelet aggregation to thrombin,











































Fig. I. Estimated net release of t-PA antigen and activity in current smokers
(black), ex-smokers (grey) and non-smokers (white). Lower panel represents
area under the curve (AUC) for the response. ANOVA for smoking status
♦P<0.01, (P<0.05.
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Fig. 2. Platelet aggregation in response to thrombin, collagen, ADP and U46619 in patients with acute stent thrombosis (open inverted triangles), in-stent
restenosis (closed triangles) and uncomplicated PCI with stent implantation (open circles), and healthy matched controls (closed circles). P<0.001 for each
dose response. *P<0.01 controls vs. patients.
However, platelet aggregation was increased in patients
with acute stent thrombosis in response to ADP compared
to in-stent restenosis (jP<0.()01), although this was
not significant when compared to the control group
(P=0.19).
3. Discussion
We have assessed three critical aspects of vascular
function in patients who have undergone PCI. We have
found no evidence to indicate that endothelial vasomotor
or fibrinolytic function plays a major role in the patho¬
genesis of acute stent thrombosis or in-stent restenosis.
Moreover, in vitro platelet function appeared to be normal
with little evidence of alterations in platelet sensitivity to a
number of agonists. In contrast, we have been able to
confirm our previous findings [9,13] of the marked inhi¬
bition of acute t-PA release in current smokers. We
conclude that endothelial and platelet function do not
appear to be major determinants of acute stent thrombosis
or in-stent restenosis.
3.1. Endothelial vasomotor function
The endothelium plays a critical role in the regulation of
vasomotor tone [14,15] and its injury or dysfunction is an
important contributing factor in atherothrombosis. There is
progressive impairment of endothelium-dependent vasodila¬
tation with the development of coronary atherosclerosis [16]
and its associated risk factors, such as hypercholesterolemia
[17], smoking [9] and diabetes mellitus [18]. In this study,
we assessed forearm blood flow following intra-arterial
infusions of the endothelium-dependent vasodilators, sub¬
stance P and acetylcholine, and the endothelium-indepen-
dent vasodilator, sodium nitroprusside. We found no
differences in the forearm blood flow responses either
between the patient groups or comparing the patient and
healthy control groups. Given the absence of risk factors and
clinically evident disease, one would have anticipated greater
endothelium-dependent vasodilatation in the healthy control
subjects. However, ageing has a marked effect on the
regulation of basal [19] and stimulated [20] endothelium-
dependent vascular tone and we studied a predominantly
elderly population with a mean age of 62 years. Moreover,
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we recognise lhat subjects who are apparently healthy in this
age group commonly have subclinical atherosclerosis that
cannot be excluded in the absence of invasive investigation
such as coronary angiography.
3.2. Endogenous fibrinolysis
The regulated release of endothelial t-PA is an important
mechanism in the defence against intravascular thrombosis
especially in the coronary circulation [21]. Several investi¬
gators have suggested that impaired endogenous fibrinolysis
is associated with restenosis after PCI [22,23], and in
particular, a rise in plasma PAI-1 antigen concentrations
[24]. In the present study, vve were unable to find any
evidence of impaired endogenous fibrinolysis in our patients
with no apparent differences in plasma PAI-1 antigen con¬
centrations or acute endothelial t-PA release. However, when
stratifying the subjects according to smoking habit, post-hoc
analysis indicated that acute t-PA release was markedly
impaired in smokers compared to non-smokers. This con¬
firms our previous findings of impaired t-PA release in
smokers [9.13] and gives support to our conclusions that,
rather than a lack of povver, there appears to be no major
impairment o f endogenous fibrinolysis in patients with acute
stent thrombosis or in-stent restenosis.
3.3. Platelet function
Platelet adherence to the arterial wall occurs within
minutes of arterial injury. Pathological studies [25] in both
porcine coronary arteries and in human saphenous vein
grafts have shown that the earliest vascular response to stent
implantation is extensive platelet deposition. However, de¬
spite important reductions in periprocedural events [26,27],
the glycoprotein llb/llla receptor antagonist abciximab does
not reduce in-stent restenosis [28]. Consistent with this
observation, platelet aggregation in response to thrombin,
ADP, the thromboxane A2 analogue U46619 or collagen was
unaffected in our study patient populations. In keeping with
long-term aspirin use, patients in all three groups demon¬
strated reduced collagen-dependent platelet aggregation in
comparison with healthy subjects. Again, this suggests that,
rather than a lack of power, there appears to be no major
difference in platelet aggregation in patients with acute stent
thrombosis or in-stent restenosis. Although assessment of
platelet function should ideally be performed after aspirin
has been withheld for at least 1 week, aspirin use was
unavoidable in our patient population.
3.4. Study limitations
There are several potential limitations to our clinical
study. First, complications from stent implantation may arise
due to procedural difficulties or suboptimal stent deploy¬
ment. However, we were careful to exclude such patients
with overt technical problems during the PCI procedure.
Second, acute stent thrombosis is a fortunately rare compli¬
cation of PCI but this makes recruitment of such patients
problematic. This is reflected in the modest number of
patients with acute stent thrombosis in our study and means
that we lack sufficient power to address the influence of all
the individual variables associated with thrombosis, partic¬
ularly given the higher proportion of female patients in this
group. The relatively low number of patients and subjects in
the whole study may also raise the potential possibility of a
type II error. Third, the assessment in our study is performed
at least 6 months following PCI and stent implantation in
order to exclude the development of late restenosis in the
control patient group. Whilst this avoids the influence of
acute confounding factors, we may have missed a transient
impairment in endothelial or platelet function. It is therefore
possible that changes in platelet behaviour, fibrinolysis or
vascular function may occur in the acute phase of stent-
thrombosis and this study does not definitely exclude that
changes in these factors contribute to the development of
acute stent thrombosis. Finally, we used a clinical diagnosis
of restenosis and cannot exclude a degree of subclinical
angiographic restenosis in the control patient group.
In conclusion, our study suggests that endothelial dys¬
function, platelet aggregation and endogenous fibrinolysis
do not appear to play a major role in the pathogenesis of
acute stent thrombosis or in-stent restenosis.
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